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ABSTRACT
Human histidyl-tRNA synthetase (HARS) is an aminoacyl-tRNA synthetase
(AARS) that catalyzes the attachment of the amino acid histidine to histidyl-tRNA
(tRNAHis) in a two-step reaction that is essential for protein translation. Currently, two
human diseases, Usher Syndrome IIIB (USH3B) and an inherited peripheral neuropathy,
Charcot Marie Tooth Syndrome (CMT), have been linked genetically to single point
mutations in the HARS gene. The recessive HARS USH3B mutation encodes an Y454S
substitution localized at the interface between the anticodon-binding domain and the
catalytic domain of the opposing subunit. Patients with Usher Syndrome IIIB lose their
sight and hearing during their second decade of life, and clinicians have observed that the
onset of deafness and blindness may be episodic and correlate with febrile illness.
Furthermore, some young USH3B patients present with a fatal form of acute respiratory
distress. In addition to the single HARS mutation linked to Usher Syndrome, eight other
mutations in the HARS gene are associated with CMT, an inherited peripheral
neuropathy. Peripheral neuropathies are associated with progressive and lengthdependent damage of the motor and sensory neurons that transmit information to the
spinal cord. The age of onset and phenotypic severity of CMT linked to HARS is highly
variable. When expressed in a yeast model system, the HARS variants are dominantly
lethal, and confer defects in axonal guidance and locomotor deficiencies when expressed
in C.elegans. Here, the biochemical characterization of the HARS USH3B and three
peripheral neuropathy variants are described. The approaches included enzyme kinetic
analysis with purified HARS enzymes to monitor catalytic deficiencies, differential
scanning fluorimetry (DSF) to evaluate structural instability, and cellular models to detect
physiological effects of axonal outgrowth by CMT variants. The results suggest that
Usher Syndrome IIIB is unlikely to be a consequence of a simple loss of aminoacylation
function, while HARS-linked peripheral neuropathy variants all share common catalytic
defects in aminoacylation. The HARS system represents a notable example in which two
different complex human diseases arise from distinct mutations in the same parent gene.
By understanding the biochemical basis of these inherited mutations and their link to
Usher Syndrome and CMT, it may be possible to develop mechanism-based therapies to
improve the quality of life of patients afflicted with them.
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CHAPTER 1: INTRODUCTION
1.1 Histidyl-tRNA synthetase as a Class II Aminoacyl-tRNA synthetase
Aminoacyl-tRNA synthetases (aaRS) are essential for protein synthesis, providing
aminoacylated-tRNA for incorporation of amino acids into a growing polypeptide chain
by the ribosome. Aminoacyl-tRNA synthetases are classified as ligases and use high energy
ATP to catalyze the attachment of amino acids to cognate tRNA, a key reaction that
contributes to the accuracy of protein synthesis. A typical animal cell contains 37
cytoplasmic and mitochondrial synthetase genes, all of which are encoded on nuclear
chromosomes. Mitochondrial synthetases are given the same name as cytosolic
synthetases, appended with the numeral 2 (e.g. HARS and HARS2). Collectively, they
ensure accurate and efficient protein synthesis under a broad range of conditions, in
multiple cellular compartments.
This family of enzymes has been partitioned into two classes, containing 10
members, on the basis of sequence comparisons [1-3] [4]. Class I and class II enzymes
differ mainly with respect to the topology of the catalytic fold and site of esterification on
cognate tRNA [1]. Class I enzymes are, with the exception of TyrRS and TrpRS,
principally monomeric, contain a Rossman fold catalytic domain, and aminoacylate the 2´
hydroxyl of the A76 of their cognate tRNAs during catalysis. Class II aaRSs typically form
dimers or tetramers and have a catalytic domain composed of anti-parallel β-sheets and
flanked by α-helices (residues 1-325). The class II enzymes couple the amino acid moiety
to the 3´ hydroxyl of the tRNA’s terminal adenosine. The anticodon binding domain further
divides the aaRS enzymes into three sub-classes a, b and c. Class IIa, distinguished by an
N-terminal catalytic domain and C-terminal accessory domain (later shown to be the
1

anticodon binding domain); class IIb, whose anticodon binding domain is located in the Nterminal region; and class IIc, encompassing the tetrameric PheRS and GlyRS class II
synthetases [5].
In higher eukaryotes from flies to humans nine of the synthetases from both class I
and class II assemble in to the Multi-synthetase complex (MSC). The MSC includes
AspRS, ArgRS, MetRS, Glu-ProRS, GlnRS, IleRS, LeuRS, LysRS, and three auxiliary
proteins p43, p38, and p18 to aid in assembly of the MSC [6].

1.2 Structure of human Histidyl-tRNA Synthetase

Figure 1.1 Human histidyl-tRNA synthetase APO dimer.
HARS is a homodimer aaRS consisting of two 57 kDa monomers shown as blue and
yellow.

2

Histidyl tRNA Synthetase (HARS) is a 114 kDa homodimer (Figure 1.1) that
belongs to the class II group of aaRS. The overall secondary structure of a HARS monomer
consists of 20% beta strands/37% 𝛼 helices and is structurally classified as an α-β layered
sandwich. Each 57 kDa monomer contains a N-terminal catalytic domain, an insertion
domain, and a C-terminal anticodon binding domain (Figure 1.1). HARS also contains
three class II conserved motifs (I, II, and III).
The C-terminal anti-codon binding domain of HARS is shared with GARS, TARS,
and PARS [7]. Eukaryotic HARS enzymes contain an additional 50 amino acid helix-turnhelix domain called the WHEP domain. The WHEP domain is named after the first three
aaRS enzymes that contain at least one or more copies of the domain within their structure
tryptophanyl, histidyl, and glutamyl-prolyl tRNA synthetases (W, H, and EP) (Figure 1.2).
Additionally, glycyl and methionyl-tRNA synthetase enzyme structures also contain a
WHEP domain.

Figure 1.2. NMR structure of human Histidyl-tRNA synthease WHEP domain.
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MNN...IQSIKRYHIAKVYRRDQPAMTKGRMREFYQCDFDVAGTFESMVPDSECLSILVEGLTSLGIKDFK.IKLN
EHGLLYNQEQRLWYIGPMFRHERP..QKGRYRQFHQLGCEVFGLQGPDID.AELIMLTARWWRALGISEHVTLELN

Insertion Domain
α5

PDB 4PHC
HUMAN
MOUSE
WORM
YEAST
BACTERIA

η2

220

α6

η3

230

α7

240

α8

250

260

β7
270

α9
280

DRRILDGMFAICGVSDSKFRTICSSVDKLDKVSWEEVKNEMVGEKGLAPEVADRIGDYVQQ......HGGVSLVEQ
DRRILDGMFAVCGVPDSKFRTICSSVDKLDKVSWEEVKNEMVGEKGLAPEVADRIGDYVQQ......HGGVSLVEQ
HRLILEGMFAVSGIPAKDFKTICSSVDKLDKTPWEDVEQEMINEKFLTKEQTGKLGELVRFRELNSDLNNLELLEK
HRKILDGIFQIAGVKDEDVRKISSAVDKLDKSPWEAVKKEMTEEKGQSEETADKIGEYVKLNGSLK.....EIHAV
SIGSLEA...RANYRDALVAFLEQHKEKLD....EDCKRRMYTNPLR.................VLDSKNPEVQAL

His A motif
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HUMAN
MOUSE
WORM
YEAST
BACTERIA

α10

290

η5

300

310

β8
320

TT

HUMAN
MOUSE
WORM
YEAST
BACTERIA

340

LLQDPKLSQNKQALEGLGDLKLLFEYLTLFGIDDKISFDLSLARGLDYYTGVIYEAVLLQ..............TP
LLQDPKLSQNKQAVEGLGDLKLLFEYLILFGIDDKISFDLSLARGLDYYTGVIYEAVLLQ..............MP
MSQLPDLGQNDKFKKGAEELKVLIEYLNVDGVT.TVRYEPSLARGLDYYTGAIYEAVAPKALEGT......AVENS
LSADANITSNEKAKQGLDDIATLMKYTEAFDIDSFISFDLSLARGLDYYTGLIYEVVTSASAPPENASELKKKAKS
LNDAPALGDYL.DEESREHFAGLCKLLESAGIA..YTVNQRLVRGLDYYNRTVFEWVTNS................

His B motif
PDB 4PHC

β9

TT

330

β10
350

Motif 3
α11

360

β11

370

380

α12
390

β12
400

410

AQAGEEPLGVGSVAAGGRYDGLVGMFDP....KGRKVPCVGLSIGVERIFSIVEQRLEALEEKIRTTETQVLVASA
TQAGEEPLGVGSIAAGGRYDGLVGMFDP....KGRKVPCVGLSIGVERIFSIVEQRLEASEEKVRTTETQVLVASA
EDTAGQPVGVGSVAAGGRYDGLVKMFDS....KA.NVPCCGVSFGIERLFAIMEARQK...VAIRTTQTEVYVASA
AEDASEFVGVGSIAAGGRYDNLVNMFSEASGKKSTQIPCVGISFGVERIFSLIKQRINSS.TTIKPTATQVFVMAF
......LGSQGTVCAGGRYDGLVEQLG......GRATPAVGFAMGLERLVLLVQAVNPEF..KADP.VVDIYLVAS

tRNA binding domain
α13

PDB 4PHC
HUMAN
MOUSE
WORM
YEAST
BACTERIA

420

430

β13
440

α14
450

β14
460

α15
470

β15
480

TTT

.....QKKLLEERLKLVSELWDAGIK.AELLYKKNPKLLNQLQYCEEAGIPLVAIIGEQELKDGVIKLRSVTSREE
.....QKKLLEERLKLVSELWDAGIK.AELLYKKNPKLLNQLQYCEEAGIPLVAIIGEQELKDGVIKLRSVASREE
.....QKNLVRDRKKLVKMLRSAGIK.TEMALKANPKLLTQFQYAEERRIPLAIVIGEQELKDGVVKLRNVVTRDE
GGGKDWTGYLPERMKVTKQLWDAGIE.AEYVYKAKANPRKQFDAAEKAGCHIAVILGKEEYLEGKLRVKRLGQEFA
GADT.QSA....AMALAERLRDELPGVKLMTNHGGGNFKKQFARADKWGARVAVVLGESEVANGTAVVKDLRSGEQ

PDB 4PHC

β16
....

α16

HUMAN
MOUSE
WORM
YEAST
BACTERIA

....VDVRREDLVEEIKRRTGQPLCIC...........
....VDVRREDLVEEIRRRTNQPLSTC...........
....QTIKLDQLITAVRDTLAAL...............
DDDGELVSAADIVPIVQEKLSQIHEDGLNEVTRLIKGL
TAVAQ....DSVAAHLRTLLG.................

490

500

Figure 1.3. Multiple species alignment of histidly-tRNA synthese with family
conserved domains and motifs annotated.
Stricly conserved residues are white highlighted in red, semi-conserved residues are red.
4

Human HARS has three unique structural elements that are found across all species of
HARS enzymes: HisA, HisB motifs, and the insertion domain (Figure 1.3). These motifs
and domains play a role in catalytic activity of HARS and will be discussed in detail
throughout this introduction.
The first crystal structures of E.coli HARS complexed with ATP, AMP, histidine,
histidinol, histidyladenylate (HAM), and 5’-O-[(L-histidinylamino)sulfonyl] adenosine
provided structural insight of active site residues involved in substrate specificity and
catalysis. Most recently tRNAHis bound to bacterial Thermus thermophilus HARS was
crystallized [8].
The first crystal structures for eukaryotic Trypanosomal brucei and Trypanosomal
cruzi HARS highlighted a key difference between eukaryotic and prokaryotic HARS [9]
in the insertion domain. In eukaryotes the insertion domain is much larger than what is
observed in the bacterial HARS structures [9]. To date there are four deposited crystal
structures of human HARS in the Protein Data Bank (PDB) not including two NMR
structures of the isolated WHEP domain and HARS splice variant. However, the only
substrate bound to the human HARS enzyme to date is histidine [10]. While, not as many
human HARS:substrate complexes have been resolved, many of the key residues
previously identified for bacterial HARS enzymes are conserved in human (Table 1.1).
Therefore some basic aspects and chemistry in the HARS active site can be inferred from
what is known about E.coli HARS. These structural elements and residues are essential in
assisting the two step mechanism carried out to aminoacylate tRNAHis with high fidelity.

5

Table 1.1: Amino acid residues involved in substrate specificity and
binding
E.coli
Phe125
Tyr122
Thr281
Arg113
Arg121
Glu115

Human
Phe171
Tyr168
Ser356
Arg157
Arg167
Glu159

Substrate Binding

Glu131
Tyr264
Arg259
Gln127
Glu83
Arg112

Asp177
Tyr331
Arg326
Gln173
Asp127
Arg157

Histidine

Arg9
Arg116
Arg123
Q118

Lys60
Asn160
Arg169
Thr145

tRNAHis

ATP

1.2.1 Histidine Binding Pocket
Histidine binding prepares HARS for catalysis via an induced-fit model [11]. These
conformational changes in the active site of HARS are initiated by the histidine binding
pocket composed of highly conserved residues found in distinct sequences motifs. First,
the LV/AAGGGLDYY loop (or HisA Loop) forms one wall of the binding pocket. This
HisA loop is highly conserved and extends over a part of the active site [12]. Second, the
glycine-rich β-strand (sequence AGGRYDGL preceding motif III) comprises the histidine
binding pocket floor and wall.
Histidine forms hydrogen bonds (H-bonds) with eight amino acids residues within
the binding pocket (Figure 1.4) of the human HARS enzyme. The Asp 177 and Tyr331
residues form H-bonds with the Nδ and Nε of the imidazole ring, respectively [10]. The
nature of these interactions are conserved in E.coli HARS as Glu131 (motif II) and Tyr264
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[12]. The α-amino functional group of histidine forms H-bonds with the side chains of
Asp130, Thr132, and Tyr330 while the α-carbonyl functional group forms hydrogen bonds
with Arg157, Gln173 and Arg326. In the E.coli structure conserved side chains that make
direct contact with histidine are Glu83 and Gln127 (motif II), which contact the α-amino
and α-carbonyl functional groups [12].

Figure 1.4. Human HARS histidine binding.
Active site residues that are essential for histidine binding are shown as yellow sticks
while the substrate histidine is shown as gray sticks. Hydrogen bond and electrostatic
interactions are shown as black dotted lines.
1.2.2. ATP Cofactor Binding
Many interactions are required to prepare adenosine triphosphate (ATP) for attack
by a bound histidine molecule and encourage the magnesium pyrophosphate moiety to act
as a leaving group. Bound ATP in the active site of E.coli HARS forms a “fishhook”
conformation that is evidently unique to class II aaRS [13]. Interestingly, these residues
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are seemingly pre-positioned upon large structural rearrangements made by histidine
binding [9]. Residues in the β strands and the loop portion of motif 2 are important in ATP
contacts for HARS [14]. Generally, residues involved in ATP binding are among the most
highly conserved in the HARS family and for the most part shared by all members in class
II. In the E.coli HARS structure the π-stacking interaction between the adenine ring of ATP
and Phe125 provides specificity in the binding of ATP. The recognition of the N6 amino
group of ATP involves the main chain carbonyl of Tyr122. The ATP ribose 2’ OH forms
an additional contact with HARS by hydrogen bonding with the main chain carbonyl of
Thr281. There are four arginine residues that mediate interactions with the triphosphate
group of ATP. First, the conserved Arg113 forms a bridging interaction with the α and β
phosphates of ATP in the crystal structure of E.coli HARS complexed with histidinol [14].
Also, the γ phosphate forms salt bridges with conserved Arg121 and Arg311 in a complex
with ATP. However, when HARS is complexed with the adenylate, the Arg121 and
Arg311 interactions are absent and adopt different conformations [14, 15]. Furthermore,
Glu115 also assists in the stabilization of the triphosphate group of ATP in a position such
that it points back towards the adenine base. The α phosphate of ATP interacts with
conserved residue Arg113. The β and γ phosphates are neutralized by two coordinated
magnesium ions that are positioned by water molecules and conserved Glu115 [12]. The γ
phosphate also forms interactions with conserved Arg121 and Arg311.
While to date there is currently no human HARS structure bound to ATP, key
residues are highly conserved (Figure 1.3 and Table 1.1). Modeling the structural alignment
of human HARS bound to histidine with the E.coli ATP bound structure reveals that many
of these interactions are preserved (Figure 1.5).
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Figure 1.5. Alignment of E.coli and human amino acid active site residues involved
in histidyl-adenylate binding.
Modeling human residues critical for ATP and adenylate binding. Residues identified as
essential for adenylation recognition from the E.coli structure are shown as green sticks
while identical residues in human are shown as blue sticks. Histidyl-adenylate from the
E.coli structure is shown as gray sticks.
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1.2.3 Histidyl-tRNA Recognition
Accuracy of protein synthesis is dependent upon the ability of aaRS enzymes to
specifically recognize identity elements of cognate tRNA molecules. These nucleotides are
primarily concentrated in the anticodon region and acceptor stems and provide functional
groups that can be recognized by specific amino acid side chains of the aaRS enzymes [16,
17]. tRNA identity and recognition can emerge from the presence of modified bases such
as those commonly seen in the dihydrourdine (D-arm) of tRNA molecules, or from less
common modifications such as C5-methylation of uracil [18]. Key identity elements for
E.coli HARS recognition of histidyl-tRNA (tRNAHis), primarily concentrated in the
acceptor stem, include an additional 5’ guanosine residue at the -1 position (G-1) and its
monophosphate, the G-1:C73 base pair, and the GUG anticodon. Mutations of these E.coli
tRNAHis identity elements diminishe aminoacylation in vitro [19-21] while inclusion of
these acceptor stem identity elements on micro helices confer recognition by E.coli and
yeast HARS [22-24]. The G-1 base is unique to tRNAHis and a critical identity element that
is present in Bacteria, Eukarya, and Archaea, with few exceptions. The G-1 base can be
either encoded in the tRNAHis gene for most Bacteria and Archea [25, 26] but in Eukarya
is added post-transcriptionally upon 5’ end processing by the enzyme, tRNAHis
guanylyltransferase (Thg1)[27]. Additionally, the 5’ monophosphate of E.coli tRNAHis G1 is also important in recognition and aminoacylation by HARS [19, 20].
The prokaryotic discriminator base C73 diverges in eukaryotes to form a nonWatson-Crick base pair G-1:A73 (Figure 1.6). Substitutions of this base pair impaired
recognition by eukaryotic yeast HARS, although the base requirements at this position
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were less stringent for yeast compared with E.coli [28]. Additionally, a RNA
methyltransferase Bicoid-interacting protein 3 (BCDIN3) was shown to specifically bind
cytoplasmic tRNAHis and monomethylate the G-1 monophosphate in vivo and in vitro [29].
The 5’G -1 monomethylation of cytoplasmic tRNAHis by BCDIN3 molecules was shown
to increase stability while not disrupting aminoacylation.
Previously, E.coli family conserved HARS residues involved in discriminator base
G-1:C73 tRNAHis recognition included motif loop 2 residues Arg123, Arg116, and Gln118.
A substitution of Arg123 as a putative contact to the 5’phosphate produced a 200-fold
decrease in aminoacyl-transfer [30]. Similar kinetic defects in aminoacyl-transfer were also
observed for Arg116 and Gln118 [30]. Consistent with their role in selectivity of tRNAHis
residues, these are moderately conserved in the human HARS structure (Table 1.1).
Interestingly, eukaryotic A73 tRNAHis recognition by yeast HARS relies on a specific tripeptide sequence (Ala-Thr-Met) located in motif loop 2 [31].

Figure 1.6: Cloverleaf representation of E.coli and human tRNAHis molecules.
Clover leaf structure of E.coli and human histidyl tRNA. Key recognition elements are
shown in red.
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Recent crystal structures of Thermus thermophilus HARS-tRNA complexes have
illuminated the conformational changes necessary to accommodate tRNAHis upon binding
[8]. Only slight structural changes occur throughout the protein with tRNAHis binding
(Figure 1.7) and are primarily limited to the insertion domain [8]. Interestingly, the
anticodon of the tRNA molecule becomes more flexible upon HARS binding.

Figure 1.7. Structural model of tRNAHis binding of HARS.
Thermus thermophilus HARS-tRNAHis complex is aligned to human HARS-histidine
bound complex. Human HARS is shown as a yellow cartoon with histidine in green
spheres. T. Thermophilus cartoon structure is shown in purple with tRNAHis as gray
sticks.
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1.2.4 A Role for Coordinated Metal Ions
HisRS requires two magnesium ions to carry out catalysis. Arnez et al. defined the
locations of magnesium ions by taking a crystal of HisRS:histidinol:ATP complex and
soaking it in manganese(II) chloride (MnCl2). These data showed that two Mn2+ ions
coordinate the β and γ phosphates of ATP. The β and γ phosphates of ATP are neutralized
by two coordinated magnesium ions that are positioned by water molecules and conserved
Glu115. Weak electron density, consistent with a bound Mg2+ ion, was observed in an
electron density map for the HisRS:histidinol:ATP complex [14]. This particular Mg2+ ion
coordinates the β and γ phosphates of ATP. Furthermore, interatomic distances between
the Mn2+ principal ion and the β phosphate oxygen is approximately 0.5 Å, which would
be expected to contribute to catalysis by weakening the bond between the α and β
phosphates of ATP. In similar manganese soaking experiments with class IIa, Seryl-tRNA
synthetase (SerRS), the principal metal ion was shown to coordinate the α and β phosphates
[32]. The functional role for the metal ion coordination between the α and β phosphates for
SerRS is a metal-catalyzed mechanism for the adenylation reaction. Arg259 in the
HisRS:ATP complex resides in the position occupied by the metal catalyst Mg2+ in class
IIa SerRS. However, Arg259 and Arg113 serving in place of a Mg2+ ion is unique to HisRS
compared to other class II aaRS. Other class II aaRS enzymes have conserved carboxylate
groups to assist coordination of metal ions to carry out catalysis, while HisRS has in place
residues Glu270 and Thr281 that have poor geometry for metal coordination but participate
in the arginine salt bridge switch [14].

13

1.3 Function of Histidyl-tRNA Synthetase
As HARS is a class II aaRS enzyme it attaches the amino acid histidine to the 3’OH
of the terminal ribose of tRNAHis [12]. HARS catalyzes the transfer of histidine to a
histidine transfer RNA molecule (tRNAHis) in a two-step reaction:
𝐻𝐴𝑅𝑆 + 𝐴𝑇𝑃 + 𝐻𝑖𝑠 ⇌ 𝐻𝐴𝑅𝑆 ∙ 𝐴𝑀𝑃 − 𝐻𝑖𝑠 + 𝑃𝑃𝑖

(1)

𝐻𝐴𝑅𝑆 ∙ 𝐴𝑀𝑃~𝐻𝑖𝑠 + 𝑡𝑅𝑁𝐴345 ⇌ 𝐻𝑖𝑠~𝑡𝑅𝑁𝐴345 + 𝐴𝑀𝑃

(2)

This two-step mechanism is facilitated by critical residues in the active site of
HARS, many of which are also involved in substrate binding as described above. However,
the mechanistic role of active site residues was judiciously evaluated by our group and is
described below.
1.3.1 Electrophilic Catalysis is Required to Facilitate HARS Amino Acid
Activation Reaction
The adenylation reaction requires both histidine and ATP binding to the HARS
active site and involves a highly conserved residue Arg259. This HARS family arginine is
not present in other aaRS class II enzymes and takes part in the adenylation reaction.
Utilizing Arg259 for catalysis is unique to HARS, as other class II aaRS enzymes
AspRS[33] and SerRS[32] use a divalent magnesium metal ion to coordinate the αphosphate of ATP and serve as an electrophilic catalyst. Arg259 is positioned on the HisA
loop to fix the α-carboxylate group of the histidine substrate as the attacking nucleophile
by supporting amino acid residues within the active site [34]. The ηN of the guanidinium
group of Arg259 is positioned approximately 3Å from the α-phosphate of ATP while the
ηN hydrogen bonds with phenolic group of Tyr264. Thus, stabilization by Tyr264 enhances
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substrate binding allowing for the formation of a hydrogen bond to the δN of the histidine
[12]. In the HARS:histidinol complex a water-mediated interaction exists between Glu270
and εN of Arg259. However, in the HARS:adenylate complex Glu270 moves to form a salt
bridge with the guanidinium group excluding the water molecule. This movement serves
as a salt bridge switch that weakens the ionic interaction between Arg259 and the αphosphate [14] and stabilizes adenylate formation in the active site. Arg113 as well as
Arg259 are arranged to interact with α-phosphate of the histidyl-adenylate intermediate
which stabilizes negative charge developed on the non-bridging oxygens α-phosphate
during the transition state [12]. Evidence for Arg259 as a critical residue in catalysis is
further supported by mutational studies where a two or three log decrease in activity is
observed when Arg259 is substituted with histidine [14] or other amino acids [35].

1.3.2 HARS Aminoacylation Reaction involves Substrate Assisted Catalysis
Once the histidyl-adenylate is formed, the second reaction carried out by HARS,
aminoacylation, requires the decomposition of a mixed anhydride (the histidyl-adenylate)
to form an aminoacyl ester on the 3’OH of tRNAHis. While Glu83 in the active site is in a
favorable location to function as a base it is also poised to neutralize the α-amino group of
the histidine substrate. Mutational analysis of Glu83 [36] suggests that it does not act as a
base but forms a salt bridge with the α-amino group of histidine, neutralizing the charge,
and satisfying a critical electrostatic interaction.
The HARS mechanism for transfer of the aminoacyl-adenylate intermediate onto
its cognate tRNAHis is described as substrate assisted catalysis (SAC). During the substrate
assisted catalysis bond formation between the 3’OH of tRNAHis and the α-carboxylate
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carbon of the aminoacyl-adenylate occurs prior to the cleavage of the bond joining the αcarboxylate carbon to the axial oxygen of the α-phosphate. In the SAC mechanism the proS non-bridging oxygen acts as the base to abstract a proton from the 3' hydroxyl of the A76
ribose on the histidyl-tRNA [36]. Then the A76 3’oxygen facilitates a nucleophilic attack
on the carboxyl carbon of the histidyl-adenylate and breaks the mixed anhydride to release
AMP.
1.3.3 Alternating Site Catalysis Model
As E.coli HARS is a dimer the active site of one monomer has the potential to affect
catalytic events in the second. A model to explain the coordination of catalysis between
the two active sites of the HARS dimer has been described by Guth and Francklyn in 2007
as “Alternating Site Catalysis”[30]. In this model histidine and ATP bind to one active site
of the dimer to form the histidyl-adenylate intermediate. Following adenylate formation,
tRNAHis will then bind to this same subunit. A single round of aminoacyl transfer takes
place in this active site, producing a “primed complex” with one aminoacylated tRNAHis
per dimer. Instead of disassociating from the HARS dimer the aminoacylated tRNAHis
molecule remains bound while histidine and cofactor ATP are recruited into the second
active site. The second active site will form the histidyl-adenylate and recruit another
tRNAHis molecule. Finally, the aminoacylated tRNAHis from site one is released while the
catalytic transfer of histidine onto tRNAHis occurs in the second site. Evidence for this
model include single turnover and stoichiometry studies that have indicated that one mole
of adenylate is formed per active site and adenylate production is influenced by the
presence of tRNAHis [30, 36]. Generating a fluorescent version of E.coli HARS enabled
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detection of the adenylation reaction in real time [37]. These assays demonstrated that the
rates in the active sites are also different and defined by a double exponential [37].
1.3.4 Evolutionary Conservation and Structural Homology
During the course of evolution, the catalytic domain is the most preserved between
prokaryotic and eukaryotic HARS enzymes. Overall the sequence homology shared
between prokaryotic, E.coli, HARS and eukaryotic, S.cerevisiae, HARS is only 28.5% in
the catalytic domain, encompassing 235 residues [14]. However, overall sequence
homology shared between eukaryotic and prokaryotic C-terminal anticodon binding
domain is minimal but they share a conserved GExExxxG motif in the C-terminal domain.
The eukaryotic HARS enzymes share much greater overall sequence homology, for
example S.cerevisiae and H.sapiens HARS have 43.5% shared sequence homology.
However, while both the human and trypanosomal HARS sequences are part of the same
eukaryotic branch on the phylogenetic tree [38] there is less than 30% sequence identity
shared between them. Similarly, the sequence identity between trypanosomal HARS and
bacterial HARS is less than 30% [9].
The evolutionary addition of the appended WHEP domain occurred at the time of
insects. This helix-turn helix structure is found in five other aaRS enzymes. The WHEP
domain facilitates noncanonical function of glutamyl-prolyl-tRNA synthetase (EPRS) [39]
and mediates protein complex formation for other aaRS enzymes [40]. For HARS the
WHEP domain supports aminoacylation function [41]. Additionally, a short sequence of
the WHEP domain is an epitope for Jo-1 anti-synthetase antibodies [42]. While the WHEP
domain mediates noncanonical activities of the EPRS complex, a similar role for HARS is
not known.
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1.4 Non-canonical function of aminoacyl-tRNA synthetases
It is now appreciated that many of the aaRS enzymes have evolved to perform
secondary non-canonical functions (Table 1.2). Known “moonlighting” activities of aaRS
enzymes include; cytokine activity, regulation of inflammatory response, cell migration,
pro and anti-angiogenic activity, and even transcriptional regulation [43]. aaRS enzymes
that have moonlighting activities include EPRS, Tyrosyl-tRNA synthetase (YARS),
tryptophanyl-tRNA synthetase (WARS), SARS and TARS [43, 44].
Table 1.2: Non-canonical functions of aminoacyl-tRNA synthetases
AminoacyltRNA
synthetase

Location of noncanonical activity

EPRS
MARS

Intracellular

SARS
LARS
YARS
GARS

Extracellular

TARS
WARS
Intracellular/Extracellular
KARS

Description of noncanonical activity
Translational inhibition
of inflammatory mRNAs
Tumor suppression and
global translational
repression
Repress translation and
inhibits angiogenesis
Lysosomal mTORC1
activation
Stimulates angiogenesis
and immune cell
migration
Anti-tumorigenic
Stimulates endothelial
cell migration
Anti-proliferative and
antiangiogenic
Transcriptional control
and pro-migratory

References
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]

Methionyl-tRNA synthetase (MARS) after UV exposure can globally reduce
translation[54]. This noncanonical function is mediated by a phosphorylation on MARS
that reduces the affinity for tRNAiMet, thereby reducing available initiator methionyltRNA (itRNAMet) suppressing translation[54]. A similar mechanism for reduced translation
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is observed by EPRS[55]. EPRS is a bifunctional enzyme with the two aaRS active sites
linked in function by a WHEP domain and attaches both glutamate and proline to the
respective tRNA molecules (linked by a WHEP domain). As a resident MSC protein, EPRS
is released by phosphorylation to form the GAIT (gamma interferon activated inhibition of
translation) complex after stimulation with interferon (IFN)-g in myeloid cells [56]. It
subsequently binds the 3’-UTRs of select mRNAs to repress translation and production of
toxic proteins during the immune response, after acute inflammation[57].
Furthermore, SARS, YARS, WARS, and TARS all have secondary functions that
are thought to regulate blood vessel growth and development[58]. SARS is capable of
regulating transcription of VEGF-A during vascular development by translocating into the
nucleus [47]. There is published evidence to indicate that the non-canonical functions of
YARS, WARS and TARS in regulating blood vascular biology are mediated
extracellularly. YARS is secreted and cleaved by extracellular polymorphonuclear
leukocyte (PMN) elastase to form two fragments that have cytokine activity and proangiogenic properties [49] [59]. Extracellular fragments of WARS have an anti-angiogenic
effect inhibiting both proliferation and migration of endothelial cells [52]. TARS proangiogenic properties are also mediated extracellularly and its catalytic activity is likely
necessary for this activity [51, 60].
Glycyl-tRNA synthetase (GARS) is yet another example of another synthetase that
when secreted has non-canonical functions. GARS can reduce tumor growth in a mouse
model in vivo via inhibition of ERK and induction of apoptosis [50]. This non-canonical
function of GARS is thought to be mediated by intracellular ERK signaling.
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To date the only identified non-canonical function of HARS is its cytokine activity
associated with the autoimmune disease idiopathic inflammatory myositis. The WHEP
domain of HARS serves as the epitope for the auto antibody anti-Jo-1 as the precipitating
factor of the disease. Interestingly, transcript analysis from skeletal muscle biopsies have
revealed evidence for two splice variants [61, 62]. One splice variant completely lacks the
core catalytic domain linking the WHEP and C-terminal anticodon binding domain[61],
while the second splice variant entails only the WHEP domain (Figure 1.8) [62].
Consequently, anti-Jo-1 antibodies cross react with both HARS splice variants. Of note, a
pharmaceutical company ATyr currently utilizes HARS as a therapeutic for limb griddle
muscular dystrophy [63]. However, the mechanism of secretion from skeletal muscle tissue
and biological function of extracellular HARS splice variants remain unknown.

Figure 1.8. Human HARS splice variant.
HARS splice variant shown as cartoon model completely lacks the core catalytic domain.
A disordered linker connects the WHEP domain to the anti-codon binding domain.
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1.5 Link between aminoacyl-tRNA synthetases and neurobiological disease
Currently, pathological mutations associated with human diseases have been
identified in genes that encode both cytoplasmic and mitochondrial aaRS enzymes. The
first of these was mitochondrial DARS2 gene, which encodes mitochondrial aspartyltRNA synthetase [64] while the first cytoplasmic ARS mutation associated with a human
disease, Charcot Marie Tooth (CMT), was discovered in GARS [65].
Interestingly mutations in GARS and other aaRS genes can specifically affect the
central, sensorineural, and peripheral nervous system (Table 1.3). To date, pathological
mutations in ten of the genes encoding mt-ARSs [66] have been identified. Of the known
pathological aaRS mutations, many have shared characteristics but some also lead to tissue
specific phenotypes (Table 1.3).
1.5.1 Aminoacyl-tRNA synthetases and central nervous system diseases
There are few reports linking aaRSs to central nervous system diseases, which often
affect specific brain regions. The autosomal recessive monogenetic disease
Leukoencephalopathy with Brain stem and Spinal cord involvement and elevated Lactate
(LBSL) represents the first well-characterized CNS disease associated with an aaRS.
Genetic analysis of some 30 different families helped link the disease to mutations in the
DARS2 gene encoding mitochondrial AspRS [64]. Hallmarks of the disease defined by
MRI imaging include abnormalities of the white matter in the cerebellum, spinal cord, and
brainstem. While the mutant substitutions in LBSL are predicted to impair dimer formation
and decrease DARS2 catalytic function, mitochondrial respiratory chain complex activity
in these LBSL patients was normal [64].
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Table 1.3: Aminoacyl-tRNA Synthetases associated with neurological
diseases
aaRS_Protein
OMIM #

Phenotype
OMIM #

Location of Mutation(s)
in Protein Structure

Phenotype

Reference

KARS_601421

613641

Anti-codon binding domain
Active site

CMTRIB

(McLaughlin, Sakaguchi
et al. 2010)

GARS_600287

601472
600794

Dimer interface

CMT2D
DHMN5A

(Antonellis, Ellsworth et
al. 2003)

AARS_601065

613287

Editing domain

CMT2N

YARS_603623

608323

Catalytic domain

DI-CMTC

HARS_142810

NC*

Dimer interface

CMT

HARS2_600783

614926

Catalytic domain

Perrault Syndrome

LARS2_604544

615300

Catalytic domain
C-terminal domain

Perrault Syndrome

HARS_142810

614504

Anti-codon binding domain

Usher Syndrome IIIB

KARS_601421

613916

Anti-codon binding domain

NSHL

DARS_603084

615281

Catalytic domain

HBSL

DARS2_610956

611105

Multiple

LBSL

RARS2_611524

611523

Lacking exon 2

PCH

QARS_603727

ONA*

MARS_156560

NC*

EARS2_612799

614924

Multiple

LTBL

AIMP2_600859

168600

na

Parkinson’s Disease

Catalytic domain
N-terminal domain
C-terminal domain
N-terminal domain

MCPH
HSP

(Latour, Thauvin-Robinet
et al. 2010)
(Jordanova, Irobi et al.
2006)
(Vester, Velez-Ruiz et al.
2013)
(Pierce, Chisholm et al.
2011)
(Pierce, Gersak et al.
2013)
(Puffenberger, Jinks et al.
2012)
(Santos-Cortez, Lee et al.
2013)
(Taft, Vanderver et al.
2013)
(Scheper, van der Klok et
al. 2007)
(Edvardson, Shaag et al.
2007)
(Zhang, Ling et al. 2014)
(Novarino, Fenstermaker
et al. 2014)
(Steenweg, Ghezzi et al.
2012)
(Lee, Karuppagounder et
al. 2013)

Table abbreviations: NC- not confirmed ONA-OMIM not assigned Na-not applicable Charcot-MarieTooth disease (CMT), distal spinal muscular atrophy type V (dSMA-V), autosomal recessive nonsyndromic hearing impairment (ARNHI), Brain stem and Spinal cord involvement and elevated Lactate
(LBSL), leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL),
hypomyelination with brain stem and spinal cord involvement and leg spasticity (HBSL), pontocerebellar
hypoplasia (PCH), hereditary spastic paraplegias (HSP), autosomal-recessive primary microcephaly
(MCPH

Mutations in the DARS gene encoding cytoplasmic AspRS were also identified in
patients with hypomyelination with brain stem and spinal cord involvement and leg
spasticity (HBSL), an inherited white matter disease [67]. These DARS coding changes
may affect enzyme activity by either disrupting tRNA binding or reducing protein
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expression [68, 69]. Interestingly, patients with the DARS-linked white matter disease
exhibited the same types of white matter abnormalities in brain stem and spinal cord
regions by MRI imaging that were observed in patients with the DARS2 mutations linked
to LBSL. Cases of white matter disease associated with aaRSs are not exclusively restricted
to AspRS. A recent report described a disease called leukoencephalopathy with thalamus
and brainstem involvement and high lactate (LTBL) linked to mutations encoding
mitochondrial glutamyl-tRNA synthetase (EARS2) [70]. In an attempt to generate a HBSL
mouse model, halpoinsufficiency was not sufficient enough to explain the tissue specific
phenotype observed in patients [71]. Heterozygous mice had normal CNS morphology and
myelination suggesting that pathological mechanisms of DARS2 mutations are likely due
to be a gain of toxic function and not simple loss of aminoacylation function. The
pathological role of aaRS proteins in these diseases is at an early stage, and it is too soon
to conclude that they are entirely explained by the sensitivity of neurons to decreased
output in translation.
Several other reports highlight the potential association of mutations in aaRS genes
with neurodegenerative diseases. For example, the lethal heterogeneous neurodegenerative
disease pontocerebellar hypoplasia (PCH6) was linked to the RARS2 (mitochondrial
arginyl-tRNA synthetase) gene in a patient with a homozygous frameshift mutation
predicted to generate a truncated protein [72]. Other case studies of PCH6 subjects
subsequently identified additional RARS2 mutations [73]. In the zebrafish model, RARS2
is highly expressed in the brain 24 hours post fertilization. Of further interest, zebrafish
knockdown models of TSEN54 (subunit associated with RNA splicing previously
described) and RARS2 produce comparable phenotypes characterized by brain hypoplasia
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and increased cell death, but little effect on brain patterning. These interesting results
suggest there may be a common pathological PCH phenotype associated with loss of
function of the TSEN and RARS2 alleles, as well as a demand for specific spliced tRNA
products at specified times during neuronal development [74]. Recently, whole-exome
sequencing identified that QARS is a causative gene in affected individuals of the two
families with children affected by autosomal-recessive primary microcephaly (MCPH)
[75]. Symptoms of this disease are associated with intellectual disability, seizures during
infancy, and atrophying in brain regions of the cerebellar vermis and cerebral cortex. This
disease phenotype is similar to the PCH caused by mutations in RARS and TSEN complex
previously described. However, specific brain regions are differentially affected for each
disease. Four variants were identified, two of which were localized to the catalytic domain
and the remaining two to the tRNA binding N-terminal domain. Activity studies showed
that all mutations caused a loss of functional protein.
MARS was identified by an exome sequencing study as one of 15 genes linked to
hereditary spastic paraplegias (HSP) [76]. HSP is characterized by the degeneration and
progressive loss of corticospinal motor neuron tract function; patients typically present
with lower limb spasticity, seizures, ataxia, peripheral neuropathy, intellectual disability,
skin, and visual defects. The potential roles of many of the genes reported in this study in
HSP were validated in the zebrafish model; the MARS mutation was too severe to be fully
evaluated.
Another important connection between aaRS function and neurodegenerative
disease is the linkage between the aminoacyl-tRNA synthetase complex interacting
multifunctional protein-2 (AIMP2, also referred to as p38) and familial Parkinson’s
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disease. Initially, AIMP2 was reported to be deposited in Lewy bodies, and its
accumulation had been noted in some familial cases of Parkinson’s disease [77, 78]. Later,
AIMP2 was determined to be a substrate of the E3 ligase PARKIN. Multiple loss of
function mutations in the gene encoding PARKIN are a common cause of familial
Parkinson’s disease. While the complete basis of AIMP2-linked neurological
pathophysiology is not yet clear, it is possible that an important secondary role of AIMP2
is modulating neuronal protein turnover; when this process is dysfunctional, particular cell
death pathways may become activated.
1.5.2 Aminoacyl-tRNA synthetases and sensorineural diseases
Sensorineural deafness is characterized by defects in either the inner ear or the
connecting auditory neural circuitry. Perrault Syndrome is described clinically as an
ovarian dysgenesis with sensory hearing loss. Genetic studies indicate that mutations in
mitochondrial HARS2 and mitochondrial (leucyl-tRNA synthetase) LARS2 are both
linked to Perrault Syndrome [79, 80]. Similarly, the LARS2 mutation associated with
Perrault Syndrome, T522N, also targets a highly conserved residue located in the catalytic
domain. By contrast, the frame shift mutation at codon 360 (c.1077delT) and T629M
compound heterozygous mutations found in another Perrault syndrome patient localizes to
the poorly conserved leucine-specific C-terminal domain. Yeast complementation assays
showed that T522N LARS2 did not support growth, while T629M LARS2 did. Notably,
C. elegans models carrying the mutations were completely sterile, recapitulating at least
one component of the disease phenotype.
Hearing loss phenotypes have been linked to a number of aaRSs in addition to
HARS. Patients in three unrelated consanguineous Pakistani families suffered from an
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autosomal recessive non-syndromic hearing impairment (ARNHI) linked to mutations in
the known ARNHI-associated locus in (lysyl-tRNA synthease) KARS, DFNB89 [81]. One
of the mutations is predicted to encode an Y173H substitution in a residue located in the
oligomer-binding (OB) fold motif of the KARS anticodon binding domain. In this location,
the substitution could negatively affect tRNA binding and/or catalysis. Significantly, the
mouse organ of Corti and vestibular system features many cell types, including inner/outer
hair cells spiral ligament, and sulcus and spiral limbus cells of the vestibular membrane
epithelium where KARS is prominently expressed.
1.5.3 Aminoacyl-tRNA synthetases and inherited peripheral neuropathies
Charcot-Marie-Tooth disease (CMT) is a hereditary peripheral neuropathy that
manifests as progressive degeneration of distal motor and sensory neurons, leading
ultimately to muscle weakness and atrophy of the legs and hands/arms. The various forms
of CMT can be further categorized into either demyelinating type 1, which features defects
in the myelin sheath surrounding peripheral nerves, and axonal type 2, which results in
abnormalities in the axon of the peripheral nerve. Nerve conduction studies and
electromyography (EMG) examination of patients with CMT are typically abnormal.
While more than 80 genes have been linked to CMT [82], 30 gene mutations in aaRS genes
are associated with the intermediate and axonal autosomal dominant and intermediate
autosomal recessive forms of the disease [43]. The first cytoplasmic aaRS to be linked to
CMT was glycyl-tRNA synthetase (GARS) [65]. Since that initial report, mutations in the
genes encoding four additional aminoacyl-tRNA synthetases have been linked to CMT
[83]. The cytoplasmic YARS, bifunctional (cytoplasmic and mitochondrial) KARS, and
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cytosolic alanyl-tRNA synthetase ARS and HARS have all been implicated in CMT.
Mutations in aaRS genes have also been linked to non-CMT peripheral neuropathies.
1.6 HARS mutations associated with disease
1.6.1 Association of HARS with idiopathic inflammatory myopathy AntiSynthetase Syndrome
Idiopathic inflammatory myopathy (IIM) is a heterogeneous connective tissue
disease characterized by inflammation of skeletal muscle [84]. While clinically muscle
weakness, wasting, and elevated serum creatine kinase (CK) are helpful in diagnosis the
hallmark of this disease is revealed in muscle biopsy samples in which immune cell
invasion is apparent. The inflammatory response in IIM can also include extramuscular
organs and these characteristic patterns of organ involvement help define the clinical
subtypes dermatomyositis (DM), polymyositis (PM), necrotizing autoimmune myopathy
(NAM) and sporadic inclusion body myositis (sIBM) [85]. Frequently, autoantibodies
directed against intracellular proteins can be detected in IIM patients. Among these,
autoantibodies generated against aaRS enzymes are common. Autoantibodies against eight
aaRS enzymes have been identified and associated with a distinct clinical IIM phenotype
known as anti-Synthetase Syndrome (aSS). aSS clinical features include myositis
(polymyositis or dermatomyositis), polyarthritis (non-destructive polyarthritis of knees,
wrists, elbows and finger joints), Mechanic’s hands (cracked thin skin over tips and sides
of fingers, interstitial lung disease, and Raynauld phenomenon, a symptom that causes
areas of your body such as your fingers or toes to numb or cold in response to colder
temperature or stress.
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Patients with Jo-1 antibodies [86] were the first known aaRS antibody with
immunoreactivity to HARS. Jo-1 antibodies are also the most commonly in patients with
polymyositis or dermatomyositis, present in 20-25% of patients. Furthermore, HARS was
shown to be have cytokine activity and causes immune cells to become activated [87]. Jo1 antibodies selectively target amino acid residues 60-90 of the HARS enzyme [88].
Additionally, mice immunizied with the HARS Jo-1 antibodies recapitulate all the
symptoms of aSS as HARS can trigger both innate and adaptive immune responses[88].
Currently, autoantibodies against eight aaRS enzymes histidyl (Jo-1), threonyl (PL7), alanyl (PL-12), isoleucyl (OJ), glycyl (EJ), asparaginyl (KS), phenylalanyl (Zo) and
tyrosyl (Ha) have been identified in aSS patients.

1.6.2 Mitochondrial HARS2 mutations associated with Perrault Syndrome
Perrault Syndrome is described clinically as an ovarian dysgenesis with sensory
hearing loss. Genetic studies indicate that mutations in mitochondrial HARS2 and LARS2
are both linked to Perrault Syndrome [79, 80]. In the HARS2 gene, a compound
heterozygous mutation encoding both L200V and V368L is linked to Perrault Syndrome,
and these substitutions alter highly conserved residues in the catalytic domain1.
Pyrophosphate exchange assays demonstrated that the resulting mutant proteins exhibit
decreased activity, implying that the phenotype is a straightforward loss of function effect
likely arising from reduced respiratory chain complex activity. Given the limitations of this
single assay, the mutant substitutions may have other structural and functional
consequences.
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1.6.3 Heterozygous mutations in HARS gene are associated with peripheral
neuropathy.
The first HARS mutation found in a patient with peripheral neuropathy was
R137Q[89]. Recently, a genetic screening of patients suffering from peripheral neuropathy
identified mutations in the HRS gene [89]. One of these mutations, R137Q, demonstrated
a complete loss of function in a yeast complementation assay but in a C.elegans was shown
to be neurotoxic. An analysis of the recently crystallized human histidyl-tRNA synthetase
structure[61] shows this highly conserved arginine residue is involved in electrostatic
interaction with Asp64 at the dimer interface. Other aaRS enzymes are related to CharcotMarie-Tooth (CMT) disease that also clinically presents as a peripheral neuropathy[90].
Glycyl-tRNA synthetase (GlyRS) is a well-studied aaRS related to CMT for which eight
different mutations have been identified. To date, no correlations between aaRS
aminoacylation activity and CMT have been clearly made.
1.6.4 The first recessive HARS mutation associated with Usher Syndrome IIIB
Cytoplasmic HARS has also been associated with a heterogeneous sensorineural
disease that causes deaf-blindness, Usher Syndrome Type IIIB. Usher Syndrome is a
polygenetic disease with at least 11 different loci identified. Most of the genes associated
with Usher Syndrome are typically involved in inner ear hair cell morphology and
development [91]. The three clinical subtypes are divided up by severity of the symptoms
and age of onset that the phenotype presents. A homozygous mutation in HARS, Y454S,
was discovered in patients with Usher Syndrome IIIB [92] and is the first cytoplasmic
HARS mutation associated with disease. In these patients hearing and vision are severely
impaired early in childhood, and fever induced hallucinations can occur. While peripheral
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nerve function seems to be normal, there is some mild trunk ataxia. The Y454S mutation,
which is localized specifically on the surface of the anticodon-binding domain (ABD),
juxtaposes the catalytic domain of the second monomer. Y454 hydrogen-bonds with
residue E439 within the anticodon binding domain, and E439 is positioned to interact with
K148 from the catalytic domain of the second monomer to form a salt-bridge interaction
[61]. Initial aminoacylation data employing wild type and mutant versions of the mouse
enzyme demonstrates that the Y454S substitution is unlikely to be a simple loss of function.
1.7 Questions remaining for Histidyl-tRNA synthetase
To date there is no fundamental kinetic evaluation of the human HARS enzyme.
Currently, there are few kinetic studies of other human AARS enzymes that have been fully
characterized by multiple turnover kinetics and pre-steady state kinetics alongside
associated disease mutations. We sought to rectify the lack of basic enzyme kinetics of the
human enzyme to determine the functional consequences of these single point mutations
linked to disease. Active site residues constitute the principal sequence elements conserved
between E.coli and human HARS enzymes which only share 27% sequence identity.
However, structural differences such as the larger insertion domain found in eukaryotes
may contribute to subtle differences in catalytic activity. We have developed a purification
protocol to isolate human WT and Usher-like syndrome Y454S HARS enzymes from a
human cell line to eliminate cross species dimers for tRNAHis binding studies, there by
permitting enzyme kinetic analysis, and thermal stability evaluation.
As HARS is an essential component of the translation machinery, mutations that
are associated with disease are unlikely to lead to a complete loss of function, as this would
be embryonic lethal. However, understanding subtle defects in activity might provide
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insights about disease progression. Furthermore, while a biochemical characterization of
HARS disease variants is important, exploring how these mutations affect the intracellular
environment must also be addressed. With this work I have advanced our understanding of
how disease-associated HARS variants contribute to the pathophysiology of human
disease.
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CHAPTER 2: METHODS FOR EVALUATING AMINOACYL-TRNA
SYNTHETASE STRUCTURE, FUNCTION, AND CELLULAR
ENVIRONMENT
2.1 Introduction
As the discovery of HARS mutations associated with disease increases, methods to
accurately determine the biochemical effects of single amino acid substitutions of the
human enzyme should be readily available. This requires revisiting the current techniques
and applications that are available for the study of aminoacyl-tRNA synthetases [1] while
also developing new approaches. The goal of this thesis is to understand if disease
associated mutations of the human HARS enzyme perturb primary aminoacylation
function, substrate binding, thermal stability, dimerization, cellular morphology, or cellular
stress. Techniques described here will aid in the execution of human HARS enzyme steadystate amionacylation assays, determination of rate constants for amino acid activation and
transfer, and evaluation of enzyme stability and substrate binding. Furthermore, we have
developed methods to evaluate axonal outgrowth and cellular responses to endoplasmic
reticulum (ER stress) of cells expressing HARS disease associated variants. Application of
these methods will enable the comparison of disease-associated HARS mutations to the
WT enzyme and further our understanding of aaRS pathophysiology in the context of the
cell.
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2.2 Expression of human HARS enzyme in mammalian cell culture (HEK293 cells)
Previously, expression and purification of human HARS enzymes were described
and carried out using E.coli as an expression system [2]. Interestingly, human HARS
purified from this system is susceptible to aggregation, in the absence of reducing agent.
Additionally, our experience in purifying TARS from E.coli required multiple liters of
media with special attention to induction and growth conditions to yield protein that had
reduced activity [3].
Therefore, in an effort to purify human HARS as a folded and active enzyme we
sought to use a mammalian cell line, human embryonic kidney cells (HEK293). HEK293
cells were an ideal expression system because 1) they contain appropriate protein folding
machinery, 2) can yield post-translational modifications that may be relevant, and 3) the
relative ease and transfection efficiency is favorable for yielding target protein expression.
2.2.1 Plasmid constructs, cell culture conditions and transfection
For expression of human HARS in HEK293 cells we used plasmids
(pCAG/FLAG/RFC/A) that contained a CAG promotor and N-terminal FLAG-tagged
HARS from GateWay vector Reading Frame Cassette A. These plasmids bicistronically
express green fluorescent protein (GFP) and provide a reliable check for transfection
efficiency. HEK293 cells are typically grown in Dulbecco’s Modified Eagle Medium
(DMEM) (Thermo) supplemented with 10% fetal bovine growth serum (FBS) (Gibco), 1%
penicillin/streptomycin (Gibco), and 1% L-glutamine (Gibco) and maintained at 37 °C in
a humidified incubator containing 5% CO2. Plasmids (pCAG/FLAG/RFC/A) containing
the genes for WT N-terminal FLAG-tagged human HARS were a generous gift from Dr.
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Robert Jinks (Franklin and Marshall College). This plasmid bicistronically expressed green
fluorescent protein, to monitor transfection efficiency. Cells were transfected when 50%
confluent using polyethyleneimine (PEI) at a 3:1 (µg) ratio of PEI:DNA diluted in serumfree media, and incubated for 48h post transfection.
Neuropathy-associated HARS R137Q, S356N, Y330C and V155G HARS
containing plasmids were generated by QuickChange II Site-Directed Mutagensis (Qiagen)
using the WT (pCAG/FLAG/RFC/A) plasmid as a template. The following forward and
reverse primers were used in the mutagenesis reactions for S356N, forward 5’CCAGCAGCCACATTGCCC

ACACCCAGG-3’

CCTGGGTGTGGGCAATGTGGCTGCTGG-3’,

for

and
Y330C

TCACCCCAGTGTAGCAATCCAGCCCTCGAG-3’and
CTCGAGGGCTGGATTG

CTACACTGGGGTGA-3’

GGTTATCCCGCCGATATCC

reverse
forward

reverse
reverse,

CTTTGCTATGTGGTAG-3’

for
and

5’5’5’

V155G
reverse

55’-

CTACCACATAGCAAAGGGATATCGG CGGGATAACC-3’. Successful mutagenesis
of the HARS gene was analyzed by Advanced Genome Technology Core sequencing
facility at the University of Vermont and results were validated using Sequencher.
2.2.2 Affinity purification and ion exchange – purity of final product
To obtain purified human HARS enzyme, HEK293 cells that were transiently
transfected with HARS-expressing plasmids were harvested and lysed in CelLytic M buffer
(Sigma-Aldrich) containing mammalian protease inhibitor cocktail (Sigma-Aldrich) for 20
min at 4 °C. The FLAG-tagged HARS was purified by binding to an anti-DYDDDDK resin
per manufacturer protocol (GenScript) and eluted by competition with 3X-DYKDDDDK
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peptide in buffer containing 50 mM Tris-HCl pH 7.4, and 150 mM NaCl. Isolated FLAGHARS is then further purified by HiTrapQ HP column (GE Healthcare) and eluted by a
NaCl gradient to 150-500 mM. Individual fractions containing HARS are typically
identified by SDS-PAGE, pooled, and dialyzed at 4 °C into a storage buffer containing 50
mM HEPES pH 7.5, 150 mM KCl, 10 mM MgCl2, 5 mM b-mercaptoethanol (b-ME). After
dialysis, samples are concentrated using Amicon Ultra-4 centrifugal filters (Millipore),
then diluted by the addition of 80% glycerol for a final glycerol concentration of 40%.
Protein concentrations are determined by A280 utilizing an extinction coefficient.
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Figure 2.1. Purification and detection of human HARS from HEK293 cells.
(A) Ion exchange chromatogram of affinity FLAG-tagged HARS purification. (B) SDSPAGE of fractions pooled for dialysis post ion exchange purification. (C) Western blot of
two column purified HARS. Blots were probed with anti-FLAG antibody (left blot) and
anti-HARS antibody (right blot)
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2.2.3 Western blot analysis of purified HARS proteins
A method to semi-quantitatively determine the amount of endogenous WT HARS
dimerization with purified FLAG-tagged HARS proteins is by western blot. Purified
FLAG-tagged HARS proteins from HEK293 cells were separated by a 12% SDS-PAGE
and subjected to Western blot analysis. As our constructs are FLAG-tagged transfected
HARS was visualized with anti-FLAG antibody (1:3000, Sigma), while both endogenously
produced HARS and FLAG-tagged transfected HARS were visualized with anti-HARS
antibody (1:3000 dilution, Abcam). The signal was developed by secondary antibody
conjugated to horseradish peroxidase (HRP) (1:10000, Santa Cruz) and Super Signal West
Femto (Thermo). Blots are then visualized by Versadoc and quantified by Quantity One
(Bio-Rad) software. Endogenous HARS runs lower on an SDS-PAGE gel than FLAGtagged HARS, but less than 10% endogenous is typically detected in FLAG-tagged HARS
preparations (Figure 2.1).
2.3 Synthesis, purification, radioactively labeling of in vitro transcribed human
tRNAHis
2.3.2 In vitro tRNA transcription and purification
An essential component to successfully monitoring aminoacylation activity is the
ability to obtain reasonable yields of tRNAHis molecules. Human tRNAHis used for kinetic
studies and gel shift assays were generated by enzymatic synthesis with T7 polymerase. In
vitro translation is a commonly used method that enables the generation of high amounts
of unmodified tRNAHis.
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First, the human tRNAHis gene was constructed by overlap PCR incorporating
EcoRI and BamHI sites cloned into a pUC19 derivative, pJA15 [1, 4]. The plasmid DNA
was purified by giga prep (Qiagen) and subsequently restricted with FokI (New England
Biolabs) to produce a linearized tRNAHis sequence with a T7 polymerase binding site.
In vitro transcription reactions were performed as previously described [1, 5, 6].
After overnight incubation the tRNAHis transcripts were precipitated with ethanol and
sodium acetate. The tRNAHis was then re-suspended in 1:1 mixture of 10 mM HEPES (pH
6.0): formamide, and purified on 12% acrylamide (19:1 acrylamide:bis-acrylamide), 6M
urea, Tris-borate-EDTA gel. Following gel purification tRNAHis molecules are
electroeluted from gel slices with an Elutrap apparatus (Whatman/Schleicher & Schuell).
After electroelution tRNA samples are precipitated with 1.5 times of the volume of 100%
ethoanol and 1/10th the volume of sodium acetate. The purified tRNAHis pellet was
resuspended in either 10 mM HEPES pH 7.0 or TE6 (Tris EDTA pH 6.0) buffer, and was
then stored at −80 °C to avoid degradation.
2.3.3 Generating 3’-[32P]-labeled human tRNAHis
Approaches to detect aminoacylation activity can include the use of radioactive
substrates, such as 3H or

14

C-labled amino acids[1]. While this approach is relatively

straightforward, limitations include low specific activity of the radioactive labeled amino
acids at low concentrations (50 𝜇M). For these reasons it might be particularly challenging
to determine elevated amino acid KM values. One assay that is helpful in remediating these
issues is radio labeling 3’-tRNA with 32P-ATP. This reaction is catalyzed in two steps by
the E.coli CCA adding enzyme (Figure 2.2) [7].
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Briefly, purified tRNAHis is labelled at the A76 nucleotide with [32P]-α-ATP as
previously described [8] with some modifications. These modifications included
phenol:cholorform extraction to remove CCA adding enzyme, a Urea PAGE purification
step to remove residual α-ATP [32P], and an overnight to 24 hr. soaking of gel pieces at
37°C in TE6 buffer to extract α-ATP [32P]-labeled A76 tRNAHis, opposed to purification
by spin columns.

Figure 2.2. Radio labeling human 3’-tRNAHis with E.coli CCA adding enzyme.

2.4 Electrophoretic mobility shift assay (EMSA) to monitor tRNAHis binding tRNA
and data analysis
These experiments employed radiolabeled tRNA, either 32P-tRNAHis transcripts
prepared as above, or total RNA purified from human placental tissue [9]. The tRNAs, at
concentrations (30 nM) much below enzyme concentration, was incubated with various
concentrations (0.1-30 µM) of WT or Y454S HARS at room temperature. The binding
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buffer for HARS enzymes includes 50 mM HEPES pH 7.5, 150 mM KCl, 10 mM MgCl2,
5 mM b-ME, 0.0001% Triton-X. Binding reactions typically included 5 mM histidine and
5 mM AMP to mimic adenylate while precluding aminoacylation of tRNAHis. Prior to its
addition in binding reactions, tRNAHis can be folded by heating to 95 °C for two minutes
in a water bath, adding MgCl2 to 5 mM, and cooling to room temperature. Following a tenminute incubation period, samples were brought to 25% glycerol with loading dye, and
then loaded onto a native polyacrylamide gel (10% polyacrylamide, 50 mM Tris borate, 5
mM MgCl2, 0.0001% Triton X-100). Gels were electrophoresed at 10 mA per gel for 3-4
hours, dried, exposed to a phosphorimaging screen, and then scanned using a Pharos BioRad Molecular Imager FXä.
Phosphor imaging data was analyzed using Prism from GraphPad Software,
employing a one-site heterologous model with depletion for the competition assay, as
described in [10]. Modelling of the competition assay determined that less than 1.25% of
the binding sites were non-specific, so we used a one site-specific binding equation to
measure binding of the transcribed tRNAHis to enzyme.
2.5 Evaluating activity of human HARS enzyme and active tRNA preparations
Protein purification methods may lead to misfolded or oxidized proteins that are
inactive. Therefore, it is important to evaluate and determine the concentration of active
enzyme from HEK293 purifications. By measuring the amount of AMP converted in the
first step of catalysis by rapid chemical quench we can determine the number of active site
residues from human HARS enzymes purified from HEK293 cells.
Additionally, in vitro transcription reactions to generate tRNAHis can lead to
incomplete transcripts or misfolded tRNA that can reduce the active tRNA population.
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Therefore, it is equally important that we also evaluate the effective concentration of active
tRNAHis by plateau charging experiments.
2.5.1 Determination of active protein from HEK293 cells
The activity of each enzyme preparation was determined by monitoring the
appearance of a-labeled

32

P-AMP in the presence of histidine under pre-steady state

conditions with rapid chemical quench [1, 11]. Enzyme at 10 µM was incubated in one
syringe with saturating histidine, 5 mM MgCl2 and 8 U/mL of PPiase in standard buffer
conditions, while the second syringe contains 200 µM ATP. The reactions were quenched
with 400 mM NaOAc, pH 4.5, 0.1% SDS. Then the products were analyzed by thin-layer
chromatography in a mobile phase of 750 mM monobasic phosphate buffer. Radioactive
products were detected by radioisotopic imaging on a phosphor screen (Bio-Rad Molecular
Imager FXä) (Figure 2.3)

Figure 2.3: Thin layer chromatography to monitor AMP formation in
determination of HARS active sites.
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2.6 Monitoring aminoacylation with radio labeled tRNAHis with 3’-32P-ATP
We monitored tRNAHis aminoacylation with a slightly modified version of the
Uhlenbeck-Wolfson assay [8] (Figure 2.2). After 3’labling and gel extraction trace amounts
of 3’labeled [32P]-tRNAHis are diluted to a final 1:10 of the total reaction volume
(sufficient for detection) is combined with saturating histidine and ATP. Plateau charging
reactions to determine the fraction of active tRNA typically includes excess enzyme
combined with low enzyme concentrations and the reaction is allowed to proceed for an
extended period of time, on the order of minutes. After completion of aminoacylation time
courses, quenched time points with tRNAHis are subsequently digested for 40-60 minutes
with 0.1 µg P1 nuclease (Thermo), that cleaves at the 5’-monophosphate, at ambient
temperature. Radiolabeled aminoacylated A76 is separated from non-aminoacylated A76
by thin layer chromatography on PEI cellulose plates (Scientific Adsorbents) using a
mobile phase of 0.1M ammonium acetate and 5% acetic acid (Figure 2.4).
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Figure 2.4. P1 nuclease digest of human tRNAHis.
Separation of 32P-tRNAHis by thin layer chromatography. (A) Comparison of P1 nuclease
digested reaction products with no HARS enzyme control and no P1 control. (B) A and B
were digested with P1 prepared in standard buffer with lane C as a no P1 control, D and
E were digested with P1 prepared in water and resolution of different preparations of
RNase contaminated 32P-tRNAHis preparations (F-J). Samples were quenched in quench
buffer of pH 7.0 to test P1 digestion.
Initial protocols indicate that S1 and P1 nucleases are interchangeable, however
little experimental evidence comparing the two nucleases has been shown. Under our
experimental conditions we have noticed differences in digestion efficiency of tRNAHis
when comparing P1 and S1 nuclease (Figure 2.5). There is also a clear difference in 32P tRNAHis labeling preparation and digestion (Figure 2.5).
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Figure 2.5. Quantification and validation of aminoacylated of 32P-tRNAHis
aminoacylation assay.
Aminoacylation time course data (A) Comparison of P1 nuclease digestion with S1
digestion with E.coli HARS using just labeled 32P-tRNAHis and digested with S1 (red
squares), labeled 32P-tRNAHis and gel purified, digested S1 nuclease (blue circles) and
labeled 32P-tRNAHis and gel purified digested P1 nuclease (black circles) (B) Human
HARS aminoacylation with 10 nM enzyme and 1 uM tRNAHis with increasing glycerol
concentrations- reactions were allowed to proceed for 2 min (black circles) or 1 min (
black x’s). (C) Plateau charging experiment of WT E.coli HARS with 100 nM enzyme
and 2 uM tRNAHis. (D) Plateau charging experiment of WT human HARS with 1 uM
enzyme and 100nM tRNAHis.
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2.6.1 Aminoacylated tRNAHis product data analysis
After imaging of radioactive products on a phosphor screen the concentration of
aminoacylated tRNAHis was quantified by comparing the ratio of the relative amount of
aminoacylated A76 (aa) (determined as counts * mm2) to total radiolabeled product (aa +
A76) according to equation (1).

[AA − tRNA His ] =

€

(AAcounts × mm 2 )
× [tRNA His ]
(AAcounts × mm 2 ) + (A76 counts × mm 2 )

Plateau charging assays of human tRNAHis by human HARS enzyme reveal that

each tRNAHis preparation contains approximately 50-60% of active tRNA molecules
relative to the total tRNAHis concentration by A260 readings.
2.6.2 Application of multiple turnover and rapid chemical quench kinetics to
monitor human HARS activity.
Extensive multiple turnover (steady state) kinetics for aminoacylation and tRNA
recognition functions of the E.coli HARS enzyme have been reported [4, 12, 13] but there
have been relatively few studies focusing on the function of the human enzyme [14].
Multiple turnover kinetics have been reported for a number of other human AARS
enzymes,

including

those

associated

with

disease

causing

mutations

[15]

[16],[17],[18],[19], but few have been characterized by rapid state kinetics. In light of the
lack in knowledge of human HARS enzymatic mechanism we chose to use MechalisMenten kinetics to evaluate basic aminoacylation function and rapid chemical quench to
monitor half-reactions.
50

The aminoacylation assays were carried out at 37 °C in a final reaction volume of
20 µL with reaction buffer containing 50 mM HEPES pH 7.5, 150 mM KCl, 10 mM
MgCl2, 5 mM (b-ME), and approximately 0.5 pM

32

P-labeled tRNAHis [7]. Steady-state

kinetic constants were determined by titrating a range of substrate concentrations from 1
µM to 5 mM in histidine, 100 nM to 15 µM in tRNAHis and 5µM- 0.5 mM ATP for WT
HARS. Reactions were initiated with the addition of 2 nM to 20 nM HARS enzyme, and
are terminated by introducing 2 µL of the reaction mixture into 8 µL of a quenching buffer
of (400 mM NaOAc pH 4.5, 0.1% SDS). These reaction conditions were suitable for
monitoring WT HARS enzyme activity however, some HARS variants require higher
concentrations of enzyme and or higher substrate titration ranges.
2.7 Determing independent rate constants for adenylation/amino acid activation
and transfer of histidine to tRNAHis by rapid chemical quench
Rapid chemical quench assays have been previously applied in the study of
prokaryote HARS aminoacylation half-reactions [4, 12, 13]. These experiments can be
performed with the KinTek RQF-3 (KinTek, College Park, PA) instrument. The instrument
contains three drive syringes and two ports for sample injections for samples and quench
solution. With internal loops of varying lengths this machine can be programmed to sample
reactions on a millisecond time scale.
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Figure 2.6. Schematic of rapid chemical quench.
Experimental set up to determine rate constants for adenylation (top reaction) and the
contents of each syringe (top boxes with red text) and single turnover experiments for
monitoring aminoacyl-transfer reaction (bottom reaction) and the contents of each
syringe (bottom boxes with blue text).
2.7.1 Pre-steady state kinetics to monitor the amino acid activation reaction
Pre-steady state amino acid activation assays using a KinTek RQF-3 were set up
and conducted essentially as described previously [4, 12] for E.coli HARS. A typical
experimental set up (Figure 2.6), includes one syringe containing HARS enzyme, 8 U/mL
inorganic pyrophosphatase (PPiase), a saturating concentration of histidine, and +/tRNAHis in reaction buffer, while the second syringe contained 200 µM [a-32P] ATP in
reaction buffer. The fractional conversion of ATP to AMP on the TLC plates was analyzed
by radioisotopic imaging using K-screen and Bio-Rad Molecular Imager FXä. The presteady state rate of amino acid activation was determined by fitting the first turnover to a
single or double exponential equation [1].
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2.7.2 Single turnover aminoacyl transfer kinetics by rapid chemical quench
Single turnover aminoacylation (aminoacyl transfer) kinetics of HARS enzymes
were also be determined with the KinTek RQF-3 chemical quench. In all single turnover
reactions, the enzyme:histidyl-adenylate complex was generated in situ prior to the reaction
by the incubation of HARS (2 µM), ATP (2.5 mM), histidine (10 mM), and PPiase (2
U/mL) at 37 °C for 10 min. The enzyme adenylate reaction was loaded into one syringe,
and then challenged with varying concentrations of tRNAHis in the opposing syringe
(Figure 2.6). The reactions were quenched as described above. After P1 nuclease digestion,
aminoacylated tRNAHis product was detected and quantified as described above.
The single turnover aminoacyl transfer rate data were fit to a single exponential
equation from which rate and amplitude parameters were extracted, as described previously
[1]. The amount of aminoacylated tRNAHis product was plotted as a function of time and
the single turnover aminoacyl transfer rate data was determined by use of equation (2):

Y = A1 × (1 − e ktrans t +C ) )
Where A1 represents the amplitude, C is the y offset, and ktrans is the rate of histidine transfer.

€

2.8 Determining thermal stability by differential scanning fluorimetry
Introduction: Development of Differential Scanning Fluorimetry Assay
Traditionally, biophysical techniques to measure aaRS enzyme stability and
unfolding have included spectroscopic methods such as intrinsic tryptophan fluorescence
in the presence of a denaturant like urea or guanidine-HCl, monitoring fluorescence with
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1-anilino-8-naphthalene-sulfonic (ANS) dye, and circular dichroism [20-23]. For example,
a classic method for determining a protein melting point without the use of exterior dyes is
differential scanning calorimetry [24] [25]. Differential scanning calorimetry (DSC)
calculates the amount of heat required to raise the temperature of a sample by a given
number of degrees, computing the difference between the sample and a buffer reference
cell. This approach has been employed to study protein stability in several aminoacyltRNA synthetases systems [26, 27]. Isothermal titration calorimetry (ITC) has also proven
useful for studying the interactions of small molecule ligands with aaRSs is [28-30]. In
addition to providing binding constants and stoichiometry, ITC is a direct process that does
not involve chemical alteration of either the enzyme or the substrate, can provide detailed
thermodynamic parameters for a given interaction. The chief disadvantage of ITC is that it
requires expensive instrumentation and, depending on the specific heat of a particular
interaction, may require relatively high concentrations of the target protein in order derive
adequate signal. Accordingly, both calorimetric approaches can provide valuable
information, but typically require large quantities of protein, extensive analysis, and are
low throughput.
Differential Scanning Fluorimetry (DSF) is a method that enables researchers to
monitor thermal denaturation of purified proteins with a fluorescent reporter. The DSF
assay relies on the interactions of the fluorophore dye SYPRO Orange with the exposed
regions of partially unfolded proteins rich in hydrophobic amino acids (Figure 2.7). The
native folded structure of proteins sequesters these hydrophobic amino acid residues from
water, burying them in the highly folded regions of the protein’s core domains. As the
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solution temperature is increased incrementally, denaturation of the protein exposes
increasing numbers of hydrophobic residues. This creates an opportunity for SYPRO
Orange dye binding, which gives rise to an increase in fluorescence (excitation and
emission of 490 and 575 nm, respectively).

Figure 2.7. Differential scanning fluorimetery schematic.
(1) Folded native protein is incubated in solution with SYPRO Orange dye. (2)
Temperature increases and causes protein to unfold and SYPRO orange dye to bind
exposed hydrophobic residues and increase in fluorescence signal is observed. (3) Protein
is denatured and maximum SYPRO Orange dye binding is achieved. (4) Denatured
protein begins to aggregate and SYPRO orange dye binding decreases.

DSF was first developed as a drug screen for small molecule studies, but is also
applicable as a screen to optimize stabilizing buffer conditions for aaRS crystallization [31]
[32, 33] and ligand binding studies to obtain binding parameters [34]. Many examples of
DSF have been reported for proteins such as Carbonic Anhydrase-II [35], cytoplasmic
sulfotransferase 1C1 [36], cAMP-dependent protein kinase (PKA) [37], MAPK13 [38],
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and pregnane xenobiotic receptor (PXR) [39] to name a few[40]. A particular advantage of
the methods is that the experimental set up can be implemented in a high-throughput mode
by use of a 96-well microtiter plate [41]. The measurements can be performed in a realtime PCR instrument that is standard equipment for most molecular biology core facilities
[42]. Fluorescence output is plotted against temperature to determine the melting
temperature (Tm), by fitting fluorescent data to the Boltzmann equation [43].
2.8.1 Differential scanning fluorimetry method
All reagents used in the DSF assays are listed in Table 2.1. All buffers were premade in sterile 0.22µM filtered deionized water. The dilution buffer used in our thermal
shift experiments is identical to the standard reaction buffer typically used for
aminoacylation assays: 20 mM HEPES pH 7.5, and 150 mM KCl. Final glycerol
concentrations in our preparations varied between 1% to 10%, as this is a stabilizing agent
for HisRS [44] glycerol was excluded by dialysis from the enzyme preparation to examine
its effects on Tm.
Table 2.1: Reagents for DSF experimental set up
Reagent or supply

Supplier

Cat. number

CalBioChem

391338

KCl

Fisher

138149

SYPROrange Dye 5,000 X

Molecular probes

S6651

MillexGV 0.22uM filter

MerkMillipore

309603

Sterile syringe 5mL

BD Biosciences

309603

Siliconized low retention

Fisherbrand

02-681-311

96 well PCR Plate non-warping

Phenix Research

MPS-3580-NW

ThermalSeal RT2 Fi

Phenix Research

LMT-RT2-RR

Ultrol grade HEPES buffer

micocentrifuge tubes
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A 10X stock of enzyme at a concentration of 100 µM was prepared and usually a
useful starting point with respect to final aaRS concentration in an individual DSF reaction
well was 10 µM. In our assay to determine Tm and the effect of bound ligand on protein
Tm, approximately 0.5 mg of protein distributed over 48 wells was used. Based on the
requirement of 10 µg of sample for each well, approximately 1 mg of enzyme would be
needed to fill a 96 well microtiter plate.
Typically, substrates to be evaluated for binding and stability are made as 10X
concentrated stocks (ie. amino acid, nucleotide (ATP or AMP), and tRNA. In our
experiments, typical 10X concentrated substrate stocks were 50 mM amino acid and 100
µM for tRNA. These were diluted to final concentrations of 5 mM and 10 µM, respectively.
SYPRO Orange (Molecular Probes #S6651- 5,000X concentrated solution) was diluted to
a 20X stock in a dark Eppendorf tube (Sigma SIAL311AA2C). Typical reactions for
determination of melting temperature and the effect of ligands on aaRS stability features
25 µL reaction volumes. The final enzyme concentration that we routinely use was 10 µM.
The sample mix is prepared by combining enzyme, ligand, buffer, and SYPRO Orange in
an Eppendorf tube.
Once samples are prepared, 20 µL of the sample mix is immediately transfered per
well of a 96 well plate either individually or using a multichannel pipette. Air bubbles in
the sample well(s) should be avoided during this process. Following transfer to the
microtiter plate, reactions containing SYPRO Orange should not be allowed to stand for
longer than 15-20 min before reading in PCR instrument. Plates were covered with
ThermalSeal as listed in Table1 and placed in a swinging bucket centrifuge configured with
adapters for 96-well plates and subjected to centrifugation at 700-1000 x g to ensure that
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the entire sample volume resides the bottom of the well before placing the plate in a PCR
instrument.
2.8.2 Melting temperature determination by use of qPCR device
These studies used an Applied Biosystems 7500 fast real-time qPCR device and the
basic program for dye-binding temperature scans is designated in the instructions for the
ABI instrument as the “Protein Thermal Shift Solution” and has been described previously
[32, 43]. Briefly, the ROX (carboxy-X-rhodamine) detector for the ABI 7500 fast
instrument is selected with no passive dye reference to monitor SYPRO orange
fluorescence emission. In a typical run, the scan is programmed to initiate at 26°C, followed
by a temperature gradient in which the samples are heated at a scan rate of 1°C per minute
until a final temperature of 95 °C is reached. During the heating process, fluorescence
intensity is measured every 1 °C. Under these conditions, a complete scan of a 96 well
plate can typically be completed in 1.5 hours.
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Figure 2.8. DSF data analysis of Lysozyme.
(A) Arbitrary fluorescence units for 6 well run with Lysozyme (empty circles) and buffer
control incubated with SYPRO Orange (filled squares) obtained from ABI real-Fast PCR
instrument plotted against temperature. (B) Data shown as relative fluorescence units
plotted against temperature. (C and D) Both arbitrary and relative fluorescence data
truncated and fit to Boltzmann equation to determine melting temperature (Tm).
2.8.3 Data analysis
Fluorescent data can be exported as component data from the ABI 7500 Fast
instrument and annotated Excel sheet for Graphpad Prism 6 for Tm analysis. Fluorescent
values are typically plotted on the Y-axis, while temperature is plotted on the X-axis
(Figure 2.8A). The thermal shift data is typically truncated by excluding fluorescent values
after maximum fluorescence intensity is achieved (before fluorescent values begin to
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decrease as a result of protein aggregation) (Figure 2.8A). Relative fluorescence is
calculated by dividing all fluorescence data in a given well by the maximum fluorescence
value achieved during the run within the same well (Figure 2.8B and 2.8D). To determine
the melting temperature (Tm) the the fluorescent data is fit to the Boltzmann equation:

where F(T) is the fluorescence at a particular temperature, F(pre) is the fluorescence before
the transition or melting at the start of the region of analysis (ROA), F(post) is the
fluorescence after the transition or melting at the end of the ROA, Tm is the melting
temperature, and C is a slope factor that corresponds to the enthalpy of the reaction. If the
data is a monophasic curve Boltzmann will be an appropriate fit to determine Tm (Figure
3C). ΔTm is substrate dependent and can be determined by the equation shown below:

ΔTm = Tm − T0
Here Tm represents the protein in the presence of ligand while T0 is the unbound

€
protein. This will yield a positive
ΔTm if binding ligand increases in stability (Tm>T0). A
negative ΔTm values would imply a decrease in stability as a function of ligand binding.
For samples that may have more then one transition of unfolding or bi-phasic melt curves,
the Boltzmann equation cannot be used to reliably fit the data and determine Tm (Figure
2.8C). However, the derivative method can be used to determine the Tm. By plotting the
first derivative of fluorescence emission as a function of temperature (−dF/dT) each
unfolding transition can be easily evaluated as the peak values Tm (TmD) [32].
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2.8.4 Replicates and controls
Technical Replicates for each condition (sample mix) should minimally be done in
triplicate within one 96-well plate run. The reactions shown in this protocol can be prepared
in a single Eppendorf tube and are sufficient for a triplicate analysis based on three wells
of a microtiter plate. A single set of technical replicates provides an indication of the
variability between wells for the PCR instrumentation being used. We suggest repeating
this step an additional one or two times for a total of 6-9 wells of three technical replicates.
A 60 µL reaction containing 0.1 mg/mL lysozyme in 50mM HEPES pH 7.0, 100 mM KCl
serves as a simple test experiment. In this standard DSF reaction, lysozyme exhibits an
apparent published melting temperature transition (Tm) of 70.9 ± 0.7 °C [45]. In our
apparatus and using these conditions, we determined a Tm of 69.4 ± 0.1 °C for lysozyme
(Figure 2.3). Additionally, we have determined that SYPRO Orange does not bind tRNA
and therefore tRNA substrates can be tested for binding with aminoacyl-tRNA synthetases.
DSF was shown to reliably and reproducibly determine Tm values for two different
HisRS preparations only varying by approximately 1°C. Similar studies examining the
effects of disease related aaRS substitutions have been investigated by DSF for
mitochondrial AspRS [46]. The experimental conditions described here to determine Tm
represent useful initial conditions to initiate analysis of an AARS with an unknown
apparent melting temperature. These conditions have been successfully used in the
characterization of purified human AARS enzymes. Additionally, a negative Tm can be
indicative of a positive hit for binding [43]. One possible explanation for a lower ΔTm value
relative to Tm is that ligands or substrates bind the unfolded protein much more tightly [47].
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As DSF was originally designed for small molecules studies, it can easily be applied
to evaluate amino acid binding by aaRS enzymes, assuming a significant shift in Tm occurs
upon binding [48]. By titrating increasing amounts of histidine while holding HARS
enzyme concentration constant, the change in Tm (ΔTm) can be recorded as a function of
amino acid concentration. In some cases, ligand dependent changes in Tm values
determined by DSF have been shown to correlate with activity and calorimetrically
determined binding measurements [49]. However, it appears that the concentration of
histidine required to produce 50% of the ligand dependent increase in melting temperature
is higher than the Kd determined by spectrofluorometric methods. In other systems, Tm
shifts greater then 4°C have been shown to correlate to IC50 values less then 1µM [36]. In
our experiments, a maximal apparent Tm increase of 4.4°C was observed upon titration of
histidine to E.coli HARS; this required several orders of magnitude higher concentrations
than the 35.4 µM KM determined kinetically [6].
2.9 Determine dimerization of HARS in solution by analytical ultracentrifugation
(AUC)
There are a number of methods that can be used to rapidly evaluate the molecular
weight of proteins including, size exclusion chromatography (SEC) and native gel
electrophoresis [50]. However, SEC requires calibration while limitations of native gel
electrophoresis hinge on the homogeneity of protein preparations.
AUC is an accurate method for the characterization of protein molecular weight
and oligomeric state in a biologically relevant solution[51]. The theory of AUC is centered
on laws of gravitation and therefore sedimentation of proteins in solution allow for the
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determination of mass, buoyancy, and shape. Protein oligomerization by AUC is
determined in the absence of interactions with a solid support or acrylamide gel matrix.
Furthermore, AUC can accurately and quantitatively determine not only molecular weight
but also sample heterogeneity [52], purity, degree of aggregation, and hydrodynamic shape
at a wide range of concentrations [53].
There are two classical AUC experiments sedimentation velocity (SV) and
sedimentation equilibrium. SV experiments of HARS enzymes characterize the solution
behavior of macromolecules and observe the sedimentation and diffusion behavior of all
species in a mixture, and report their partial concentrations, buoyant molar masses, and
anisotropies. Sedimentation and diffusion transport in the ultracentrifugation cell are
described by the Lamm equation, which can be solved using adaptive finite element
methods [54, 55]. Therefore, we conducted the SV experiments at 230 nm where the
extinction coefficient is significantly higher compared to the standard 280 nm absorbance,
and allows us to monitor at lower concentration. Data quality at 230 nm is also higher due
to the high light emission intensity of the Xenon lamp used in the ultracentrifuge. Whole
boundary data obtained in SV experiments are fitted by linear combinations of such
solutions using advanced optimization routines [56-58] that are typically implemented on
a supercomputer [59].
Analytical centrifugation experiments were performed with purified HARS
enzymes that were typically dialyzed into a buffer containing 10 mM potassium phosphate
buffer, 50 mM KCl, and no reducing agents. All protein samples were concentrated to 0.3
OD units/mL at 230 nm (0.7 µM). Sedimentation velocity experiments were performed by
the Center for Analytical Ultracentrifugation of Macromolecular Assemblies at the
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University of Texas Health Science Center at San Antonio, and conducted at 20 ºC, 35 K
rpm, in a Beckman Optima XLI analytical ultracentrifuge using an An60Ti rotor and
standard 2-channel epon centerpieces (Beckman-Coulter) and measured by UV intensity.
All data were examined with UltraScan-III ver. 3.5, release 2170 [54, 55] and
hydrodynamic corrections for buffer density and viscosity was estimated to be 1.0019 g/ml
and 0.998 cP, respectively. The partial specific volume of HARS (0.745 ml/g) was
estimated by UltraScan from protein sequence analysis using methods outlined in Laue et
al. [60]. Experimental sedimentation data were pre-processed by 2-dimensional spectrum
analysis (2DSA) [56, 58, 61] and fitted by the parametrically constrained spectrum analysis
(PCSA), using a straight-line parameterization coupled with a Monte Carlo approach[59,
62]. The calculations [63] were performed on the Lonestar cluster at the Texas Advanced
Computing Center at the University of Texas at Austin and on Comet and Gordon at San
Diego Supercomputing Center.
Experimental SV data were pre-processed by 2-dimensional spectrum analysis
(2DSA) [56] with simultaneously removal of time- and radially-invariant noise
contributions [64], and to fit the meniscus position as described in [64]. The resulting data
were fitted by the parametrically constrained spectrum analysis (PCSA), using a straightline parameterization coupled with a Monte Carlo approach [59, 63]. The calculations are
computationally intensive and are carried out on high-performance computing platforms
[63]. All calculations were performed on the Lonestar cluster at the Texas Advanced
Computing Center at the University of Texas at Austin and on Comet and Gordon at San
Diego Supercomputing Center.
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2.10 Evaluating cellular effects of HARS disease associated mutations in model cell
systems
The assays described thus far can provide essential information about the functional
and structural biochemical consequences of HARS disease associated variants. However,
a critical gap in knowledge as to what cellular consequences these mutations may have in
neuronal cells, is still unknown. Notably, expression of various CMT mutations in animal
models have presented with axonal phenotypes [65]. Additionally, intracellular
perturbations by expression of disease associated mutant aaRS enzymes may involve
activation of amino acid starvation response, accumulation of misfolded proteins, or noncanonical functions yet to be discovered.
2.10.1 Immunoprecipitation from HEK293 cells for HARS-protein interaction
studies and identification of post-translational modifications.
Immunoprecipitation experiments in preliminary studies to identify aaRS proteinprotein interactions as well as post-translation modifications are readily achieved using
HEK293 cells. Immunoprecipitation reactions for human HARS enzymes were readily
achieved with anti-FLAG (or anti-DYDDDK) resin used for the first step in protein
purification. Briefly, transfected HEK293 cell lysates were incubated with agarose resin
conjugated with anti-DYKDDDK antibody for 2 hours. After incubation with the resin
samples were spun down at 6,000 x g for 30 seconds. After the initial spin supernatant was
collected from the resin pellet and the resin was re-suspended and washed 3 times with
TBS. The final elution of bound HARS-protein complexes was achieved with an acidic
buffer, opposed to the peptide elution used for the purification. The eluted sample was
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combined with 4X SDS PAGE loading dye and boiled for 10 min. at 95℃. The samples
were then resolved by SDS PAGE and specific bands or whole lanes was cut from the gels
after gel code blue staining. Gel pieces were then soaked and digested with Trypsin. Tryptic
digested samples were then submitted for mass spectrometry analysis for either protein ID
or post-translational modification.
2.11 Cell models to evaluate axonal phenotypes of HARS disease associated
variants
While HEK293 cells are a useful line for generating active recombinant HARS
protein, they are not particularly useful for evaluating defects HARS mutations may have
in neuronal cells. While primary cell lines derived from a mouse model containing the
HARS mutations would be the gold standard, these options are expensive and challenging
to obtain. Previous studies have utilized an immortalized embryonic mouse motor neuron,
neuroblastoma fusion cell line, known as MN-1, to identify GARS CMT mutations that
lead to aberrant localization within the cell [66]. An alternative cell line that can exhibit
neuronal morphology and properties upon nerve growth factor (NGF) treatment are known
as pheochromocytoma (PC12) cells. We have utilized the latter of these two immortalized
cells lines to evaluate phenotype, toxicity, and basic cellular biology of HARS disease
mutations. Here we describe the methods and protocols for use of this cell line to evaluate
axonal defects aaRS disease variants may elicit.
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2.11.1 Pheocytochromotoma (PC12) cells for axonal phenotype
PC12 cells are a tumor-derived cell line originally isolated from rat adrenal medulla
pheochromocytoma [67]. A valuable property of these cells is their response to nerve
growth factor (NGF) [68]. When PC12 cells are maintained in normal growth medium they
exhibit a small round morphology that is slightly bi-polar and upon NGF treatment the cells
begin to differentiate and form long processes [69]. Treatment of PC12 cells with NGF
halts proliferation, promoting differentiation to non-dividing sympathetic neuron-like cells
[70]. During this differentiation process the cells will extend processes reminiscent of
axons and dendrites, collectively termed neurites. Differentiation is coupled to the
increased expression of neurofilament (NF-L) [71] and GAP43 that aids in cytoskeletal
rearrangement and growth cone formation, respectively. As PC12 cells have the cellular
organization to synthesize and store neurotransmitters, NGF differentiation has been
shown to prompt PC12 cells to become electrically active [72].
PC12 cells are a valuable system to study axonal outgrowth. Differentiated PC12
cells can then be used to evaluate normal neuronal homeostasis such as trafficking, effects
of mitochondrial function, and receptor localization[73-75]. PC12 cells have been useful
for disease research in Parkinson’s [76], Alzheimer’s [77], diabetic neuropathy [78] and
even CMT [79]. Many pharmacology studies [80, 81] have also utilized PC12 cells to
evaluate how compounds perturb axonal morophology. Our goal is to utilize these cells for
evaluating HARS CMT variants cellular localization and perturbations to axonal outgrowth
as previously observed in animal models.
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2.12.2 PC12 cell maintenance and transfection.
PC12 cells were typically maintained in a growth media of RPMI-1640 (Thermo)
supplemented with 10% horse serum, 5% FBS, 1% penicillin/streptomycin, and 1% Lglutamine and maintained at 37 °C in a humidified incubator containing 5% CO2. Cells
were passaged as a ratio of 1:3 or 1:4. For successful transfection PC12 cells require a
minimum confluence of 60-70% on poly-lysine coated plates. Prior to transfer of PC12
cells for transfection, plates were coated for a minimum of 30 minutes with 0.5 mg/mL of
poly-lysine and then thoroughly rinsed. Once PC12 cells reach optimal confluence (at least
50-75% confluency) on poly-lysine treated plates they were pre-treated with OPTI-MEM
media (Thermo) for 30 mins at 37 °C in a humidified incubator containing 5% CO2. While
the cells were pre-treated with OPTI-MEM, 5 𝜇g of plasmid was added to 100 𝜇L OPTIMEM and separately 15 𝜇L of lipofectamine 2000 was combined with 200 𝜇L OPTI-MEM
for 5 mins at room temperature. After a 5 min incubation the DNA:OPTI-MEM and
Lipfectamine:OPTI-MEM mixtures were combined and incubated at room temperature for
25-30 mins. After appropriate incubations the transfection mixture were added to the cells
that have been incubating with OPTI-MEM media and placed back in the incubator for 5
to 6 hours. After the 5 to 6-hour transfection the OPTI-MEM media was replaced with
warm normal PC12 growth media.
Plasmid (pCAG/FLAG/RFC/A) containing the genes for human N-terminal FLAGtagged HARS bicistronically expresses GFP, to identify transfected cells and effectively
observe neurite outgrowth.
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2.12.3 PC12 cell differentiation
For evaluating neurite outgrowth 24 well plates were used to evaluate multiple
CMT mutations or different treatments on PC12 cells. For NGF differentiation PC12 cells
require both poly-lysine and laminin coated surfaces. First, poly-lysine was diluted to 0.5
mg/mL from a 1 mg/mL stock in Dulbecco’s Phosphate Buffered Saline (DPBS) and
incubated in wells (200-300 𝜇L/well) for 1 hour. After washing the wells with DPBS two
times or sterile ddH2O, laminin (1mg/mL) diluted with DPBS to 0.02 mg/mL is added to
the wells with (150 uL/well) for 1 hour. Again plates and/or coverslips are washed 2X with
DPBS and once with media. After 24 hours that PC12 cells have been transfected they can
be transferred into a 24 well plate at a desired density in differentiation media of RPMI1640 with 1% horse serum, 1% penicillin/streptomycin, and 1% L-glutamine, and B27
supplement (Thermo). Three hours after transfected cells were plated they can be treated
with NGF (50 ng/mL) for 1 to 4 days.
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Figure 2.9. PC12 cell differentiation after NGF treatment and neurite tracing
following image collection.

2.12.4 Imaging, neurite quantification and data analysis
Images of transfected PC12 cells fixed on 24 well plates can be collected at 20X
with an inverted fluorescence microscope such as Olympus IX71 and quantified with a
simple measuring and tracing using SPOT microcopy imaging software (Figure 2.9). To
evaluate localization of HARS in neurites images of transfected PC12 cells fixed onto
coverslips were taken with a 40x objective on a Nikon Eclipse Ti inverted microscope.
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Useful co-localization markers included were cytoskeletal proteins such as TUJIII (to stain
microtubules) and phalloidin to mark actin filaments.
To alleviate bias in the image processing multiple images are taken of each well
and multiple wells of transfected PC12 cells for each variant per experiment are collected.
From these images, parameters that can be measured include cell number, cell body width,
number of neurites per cell [82], and neurite length. Experimental parameters to evaluate
from this data include percent of differentiated cells as defined by cells that have at least
one neurite twice the length of the cell diameter (approximately 10 to 20 microns) [83] .
2.13 Conclusion
Many researchers have contributed to our understanding of aaRS substrate binding,
specificity, and editing catalytic activity over the past few years. However, as many
different diseases have been linked to aaRS mutations it is essential to create new methods
to evaluate different aspects of aaRS biology. Here, we describe kinetic assays to critically
evaluate aminoacylation function of human HARS enzymes. Additionally, the application
of DSF and AUC in structural studies are also described here. Finally, both HEK293 and
PC12 cell methods were established in hopes to explore perturbations of the cellular
environment and potential axonal phenotypes.
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CHAPTER 3: CHARACTERIZATION OF HUMAN HARS MUTATIONS
ASSOCIATED WITH INHERITED PERIPHERAL NEUROPATHY
3.1 Introduction
Peripheral neuropathy is a disease that describes damage or disease of the
peripheral nervous system. Peripheral neuropathy can be either acquired or inherited [1]
and symptoms include pain, weakness and or numbness of the hands and feet. Acquired
peripheral neuropathies are associated with physical injury and disease related damage by
diabetes [2], autoimmune disease, and infections. Acquired peripheral neuropathies can
also result from exposure to toxins such as chemotherapeutics [3] and alcohol. Peripheral
neuropathies can also be caused by inherited or de novo mutations as Charcot-Marie-Tooth
(CMT) is a hereditary peripheral neuropathy that involves damage to both sensory and
motor neurons.
CMT manifests as progressive degeneration of distal motor and sensory neurons,
leading ultimately to muscle weakness and atrophy of the legs and hands/arms. CMT
typically presents in an axon-length dependent manner with the structures innervated by
longer axons affected first [4]. CMT specifically affects the peripheral nerves of the
extremities, causing a progressive muscle weakening and wasting, decreased sensation,
and skeletal deformities. The onset and penetrance of CMT is quite variable, with many
patients experiencing symptoms in the first two decades of life that become progressively
worse over time. Subtypes of CMT can be further categorized into either demyelinating
type 1 (CMT1), which features defects in the myelin sheath surrounding peripheral nerves,
and axonal type 2 (CMT2), which results in abnormalities in the axon of the peripheral
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nerve. Nerve conduction studies and electromyography (EMG) examination of patients
with CMT are characteristically abnormal. Patients with CMT1, demyelination of Schwann
cells, typically have decreased motor nerve conduction velocities (MNCVs). While
patients with (CMT2) may have normal MNCVs but reduced muscle action potentials
arising from axonal degeneration. There also exists an intermediate form that has
characteristics of both CMT1 and CMT2 [5-8].
3.1.1 Aminoacyl-tRNA synthetase mutations are associated with CMT
Over 80 genes have been linked to CMT, distributed among diverse functional
categories [9]. Four genes account for 96% of all CMT cases, consisting of peripheral
myelin protein 22 (PMP22), myelin protein zero (MPZ), and gap junction beta-1 (GJB1),
which are linked to CMT1, and mitofusin 2 (MFN2), which is linked to CMT2. In addition
to myelin assembly, the diverse cellular processes affected by CMT include
cytoskeleton/axonal transport, protein synthesis and quality control, endosomal sorting,
mitochondrial functions, channel abnormalities, and mRNA/processing transcription.
While the end result of genetic changes in these processes is likely to involve a degradation
of Schwann cell function or axonal dysfunction, the precise mechanisms by which
alterations of individual genes bring about these phenotypes are, for many genes, not well
understood. At the current time, there are no effective treatments for CMT. Among the
elements of the protein synthesis and protein quality control apparatus that are linked to
CMT are the aminoacyl-tRNA synthetases (ARSs)[10].
To date 30 gene mutations in aaRS genes are associated with the intermediate and
axonal autosomal dominant and intermediate autosomal recessive forms of the disease
[11]. In contrast to the relatively rare neurological diseases where a mutation or mutations
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in a single aaRS gene is linked to the disease pathophysiology, at least six different aaRS
genes are linked to inherited peripheral neuropathies, typically CMT [12, 13].
The first aaRS associated with CMT was GARS, where mutations in the gene
encoding GARS were implicated in axonal CMT disease via positional cloning in families
with an atypical disease presentation [14, 15]. Notably, the majority of patients presented
with an upper limb predominant neuropathy that affected the intrinsic muscles of the hand
(i.e., the thenar eminence and first dorsal interosseous) [14, 15]. Mutations in the GARS
gene can cause both CMT2D and distal spinal muscular atrophy type V (DHMN5A) [14].
It is likely significant that the synthetase enzyme encoded by the GARS gene is obliged to
function in both the cytoplasmic and mitochondrial compartments. Similar to other class II
enzymes, GARS is an obligate dimer, and several of the mutant substitutions linked to
CMT alter residues located at the dimer interface [16]. Some of these have been shown to
either weaken or strengthen dimer formation [16]. Additionally, it may also be relevant
that wild type protein forms punctate structures (granules) in neurite projections, a property
lost in some of the GARS CMT mutants [17]. Other in vitro models of CMT GARS
mutations also demonstrate a defect in localization to neurite-like projections in a
transfected neuroblastoma cell line [18]. It is not clear whether the phenotype is related
solely to the cytoplasmic or mitochondrial distribution of GARS, or both. However,
cytoplasmic aaRS gene mutations associated with peripheral neuropathies [12] indicate
that dysfunctional mitochondrial protein translation is not the primary cause of these
phenotypes.
A Drosophila model was created to examine the effects of the GARS CMT2D
mutation on two different types of neurons, olfactory projection neurons and mushroom
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body γ neurons [19] representing two CNS neuron populations that differ in development,
morphology, and circuitry. The olfactory projection neurons showed severe defects in
dendritic morphology but few axonal defects. However, mushroom body γ neurons had
defects in both axon and dendritic morphology. Interestingly, as GARS is cytoplasmic and
mitochondrial, individual disruption of cytoplasmic protein synthesis caused large defects
in axonal and dendritic nerve end branching, while disruption of mitochondrial protein
synthesis led to more dendritic nerve end branching than axonal. The Drosophila GARS
mutations could be rescued by expression of human WT GARS. However, CMT2D
mutations E71G and L129P could not rescue the defective neuronal projections and hence
are loss of function mutations.
Mouse models of GARS CMT mutations have shed some light on the possible
pathological mechanism for which aaRSs can cause peripheral neuropathy. Interestingly,
there did not appear to be significant mislocalization of GARS protein or change in GARS
granule formation in the CMT2D mouse model, GARSNmf294/+ [20]. The GARSNmf294/+
mouse model of CMT2D also showed defects in the neuromuscular junction (NMJ),
reduced axon diameter, and sensory and peripheral axonal loss but no myelination defects.
Importantly, this mutation does not cause a substantial loss of primary aminoacylation
function [21]. More recent studies of GARSNmf294/+ mice have shown that peripheral
neuropathy is not caused by reduced neuronal connectivity to distal muscle fibers but that
defects and denervation commonly observed at NMJs corresponds to inappropriate
maturation process at distal muscle fibers [22].
Subsequently, mutations in tyrosyl- (YARS) and alanyl-tRNA synthetase (AARS)
genes were identified via linkage analysis of families with a more typical presentation of
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CMT disease [23, 24]. In particular, the mutant YARS substitutions G41R and E196K, and
deletion Δ153-156, are associated with dominant intermediate Charcot-Marie-Tooth C
(DI-CMTC) (Jordanova et al., 2006). While the G41R and Δ153-156 mutations
demonstrated severe catalytic defects, the E196 mutant was more active, suggesting that
canonical activity defects are not responsible for the disease phenotype [25]. Furthermore,
mutations are not found in domains responsible for previously reported non-canonical
functions such as the cytokine activity of YARS [26], suggesting that the CMT pathogenic
substitutions may not be associated with YARS non-canonical activities. The mutated
YARS enzyme exhibits stability in vivo that is comparable to the wild type enzyme [25],
but may be subject to a similar tendency to cellular mislocalization in neuroblastoma cells
lines that was seen with GARS [23].
Following these reports, a screen of a large cohort of CMT patients led to the
identification of three variants of the KARS gene that are associated with a recessive
intermediate form of CMT that exhibit additional neurological and non-neurological
sequelae [27]. The bifunctional (cytoplasmic and mitochondrial) lysyl-tRNA synthetase
(KARS) represents another targeted gene in CMT. One interesting CMT patient was found
to be a compound heterozygote with mutations encoding both a L133H missense and a
Y173SX7-frame shift mutation [27]. Both mutations localize to the anticodon-binding
domain, however the Y173SX7-frame shift likely results in complete loss of the catalytic
domain. The L113H catalytic analysis results showed a reduction in aminoacylation to
levels below 25% of wild type. In addition to peripheral neuropathy, a behavioral pathology
was observed in this subject. KARS is also part of the multi-synthetase complex (MSC)
and can exist as either a dimer or tetramer. KARS has additional non-canonical functions
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involved in signaling, cell migration, and viral HIV infection, some of which are activated
by

post-translational

modification

[28].

Mitogen-activated

kinase

(MAPK)

phosphorylation induces release of one dimer from the MSC for translocation into the
nucleus, while the other dimer remains with the MSC to continue protein synthesis [29].
Another well characterized tRNA synthetase associated with hereditary motor
neuropathy is the cytosolic AARS. In an earlier study, characterization of the mouse strain
AARSsti (or “sticky” mouse) with uncharacteristic CMT phenotype, a progressive
neurogeneration and a coat defect, suggested a link between these properties and an editing
defect in AARS[24] [30]. Phenotypically, the AARSsti mice have significant Purkinje cell
loss and ubiquitin inclusions suggestive of protein misfolding that are absent in
GARSNmf294/+ mice [20]. Investigations of AARS CMT2N subjects in an Australian family
showed additional symptoms that included sensorineural deafness [31]. An attractive
hypothesis is that the protein misfolding is a direct consequence of mistranslation
originating from the misacylation of tRNAAla with serine instead of alanine [32].
Additionally, patients with late-onset CMT2 were identified to carry mutations in
methionyl-tRNA synthetase (MARS) gene [33]. The mutation affects a highly conserved
arginine residue, R618C, that forms a salt-bridge interaction at the catalytic and anticodonbinding domain interface. The R618C MARS mutation phenotypically has a late-onset and
does not show complete penetrance as a loss of function mutation in yeast models.
However, additional studies are required to link MARS mutations to CMT disease.
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3.1.2 HARS variants associated with inherited peripheral neuropathy CMT
Definitive evidence linking HARS mutations to CMT disease was developed by
identification of multi-generational pedigrees with inherited peripheral neuropathies that
segregated with missense mutations in HARS coding for substitutions in active site residues
(e.g., T132I, P134H, D175E, and D364Y) [34]. All four missense mutations affected
HARS protein function in a yeast complementation assay and over-expression of two of
these mutations (R137Q and D364Y) in worm resulted in dominant toxicity to neurons[34]
caused aberrant motor neuron axonal growth and a progressive loss of motor coordination.
These data confirmed HARS as the fourth ARS locus implicated in CMT disease, but also
demonstrate that different HARS mutations lead to distinct diseases, suggesting different
pathophysiological mechanisms.
Here, we report detailed functional analyses of three previously unreported HARS
missense mutations derived from three distinct families. Each mutant protein was
expressed, purified, and characterized biochemically. The mutations were also studied in
yeast complementation assays to assess the ability of the mutants to support growth in
yeast. The results of these analyses show that this set of HARS mutations lead to a clear
reduction in HARS catalytic activity, typically manifesting as an increase in the Km for
histidine, ATP, or both. None of the mutants exhibited an altered KM for the transfer RNA
substrate, and none of the mutants led to a weakening of the HARS dimer stability. These
data represent the first detailed biochemical analyses of HARS mutations associated with
CMT, and our results are discussed in light of current models linking altered ARS activity
to CMT pathophysiology.
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3.2 Results and discussion
3.2.1 Clinical and genetic analysis of patients with peripheral neuropathy
Family 1. A three-generation family of Persian-Jewish descent (living in Israel) was
identified with peripheral neuropathy (Figure 3.1A). Five affected individuals are present
and the family displays an autosomal dominant inheritance pattern; please note the maleto-male transmission. Age of onset is in the second decade of life for the two youngest
individuals; age of onset is less clear for the older individuals but the affected status was
clear upon examination. All individuals display a motor predominant to pure motor
phenotype with clear pyramidal features as assessed by brisk reflexes and ankle
clonus/Babinski signs. All patients—except for one—have normal sensory exams. At least
two of the elder individuals have severe weakness necessitating the use of a cane or a
wheelchair; however, the younger individuals are ambulatory. Nerve conduction studies
are consistent with a motor predominant axonal neuropathy. There is some co-morbidity:
the female patient from the second generation has systemic lupus and one of the males in
the third generation has uveitis, hematuria, and proteinuria.
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Figure 3.1. Histidyl-tRNA synthetase mutations identified in three pedigrees with
peripheral neuropathy.
(A-C) Genotyping was performed to determine if HARS variants segregate with disease
status. The pedigree structures of Family 1 (A), Family 2 (B), and Family 3 (C) are
shown. Circles represent female individuals and squares represent male individuals.
Shaded symbols represent affected individuals and non-shaded symbols represent
unaffected individuals. Diagonal lines indicate deceased individuals. Genotypes are
indicated under each individual where DNA was available.
Whole-exome sequencing was performed on one affected individual, which
revealed common or non-segregating SLC5A7, SETX, and LAMA2 variants (the variant in
LAMA2 was not consistent with a dominant neuropathy). This analysis also revealed
V155G HARS, which fully segregated with the disease phenotype upon PCR and Sanger
sequencing of additional individuals; however, DNA is not available for the unaffected
individual in the third generation. V155G HARS affects an amino-acid residue that resides
in the catalytic core of the HARS enzyme (Figure 3.2A and Figure 3.2B) and that is
conserved from human to yeast (Figure 3.2A) V155G HARS has not been previously
reported nor has it been detected in the gnomAD database (Table 3.1) [35].
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Table 3.1. HARS variants identified in patients with peripheral neuropathy
Amino acid
changea

Detection in
gnomADb

Position in
yeast HTS1c

Reference

Not detected

dbSNP
accession
no.
None

T132I

T131I

(Safka Brozkova et al. 2015)

P134H

Not detected

None

P133H

(Safka Brozkova et al. 2015)

R137Q

20 / 246,154

rs191391414

R136Q

(Vester et al. 2013)

V155G

Not detected

None

V154G

This study

D175E

Not detected

None

D174E

(Safka Brozkova et al. 2015)

Y330C

Not detected

None

Y330C

This study

S356N

5 / 277,222

rs144322728

S370N

This study

D364Y

Not detected

None

D378Y

(Safka Brozkova et al. 2015)

a

Human amino acid positions are relative to GenBank Accession number NP_002100.2
http://gnomad.broadinstitute.org
c
Yeast amino acid coordinates correspond to GenBank accession number EDN61168.1
b

Family 2. A two-generation pedigree was identified with peripheral neuropathy
(Figure 3.1B).The age of neuropathy onset for both patients was during childhood. Both
individuals show a motor predominant phenotype, with distal motor deficit and atrophy,
hammer toes, and pes cavus. Both affected patients have mild sensory symptoms in the
toes, with reduced vibration sense at the knees. Tendon reflexes were brisk in both patients.
The mother (patient 1) is restricted to a wheelchair while her son (patient 2) walks with
difficulty but without aid. The CMT Neuropathy Score (CMTNS) for patient 1 is 22 and 9
for patient 2. It has to be considered that phenotype of patient 1 is probably exacerbated by
concomitant diseases (diabetes, chemotherapy for melanoma, radiculitis secondary to
herpes zoster and Parkinson’s disease). Nerve conduction studies show axonal motorpredominant neuropathy in both patients.
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Targeted gene panel screening in Family 2 (Figure 3.1B) revealed two missense
HARS variants in cis: S227A and Y330C; these variants were previously reported as part
of a larger study on CMT disease [36] but the functional consequences of the mutations
were not assessed. Both mutations segregate with the disease phenotype; however, S227A
was deprioritized due to the number of alleles detected in gnomAD (37 alleles in 282,464
alleles total) and the lack of conservation of the affected residue (see Figure 3.2A). Y330C
HARS affects an amino-acid residue that resides in the catalytic core of the HARS enzyme
(Figure 3.2A and Figure 3.2B) and that is conserved from human to bacteria (Figure 3.2A).
Y330C has not been previously reported nor has it been detected in the gnomAD database
(Table 3.1) [35].
Family 3. A simplex pedigree was identified with two unaffected parents and a
single daughter affected with peripheral neuropathy (Figure 3.1C). The affected daughter,
at 15 years of age, was seen in consultation for difficulty with walking. Her early
milestones were normal including walking with a normal gait at 12 months. She was
physically active as a child and able to keep up with her peers until the age of 10. At 12
years of age she noticed she could no longer walk on her heels. At ~13 years of age she
developed difficulties with walking. This progressed and she had problems with other
activities such as jumping and running by the age of 15. She had ankle weakness, a foot
drop, and right knee pain. She began to wear foot orthotics bilaterally. No problems with
hand function were reported, but a slight hand tremor was reported and observed. Her
sensory exam was normal to pinprick, light touch, and joint position sense in all four
extremities. Vibration sensation was also normal with the exception of a slight reduction
at her toes. Her feet turned in bilaterally but could be brought to a neutral position. She had
87

high arches and atrophy noted in her hands and distal forearms. Her CMT Neuropathy
Score (CMTNS) was a 10, which is in the high end of the mild range. Her CMT Pediatric
Score (CMTPeds) was a 33, which is in the moderately impaired range.
Whole-exome sequencing was performed on the affected daughter in Family 3
(Figure 3.1C), which revealed S356N HARS as the only candidate disease-associated
variant. Sanger sequencing revealed that this variant was inherited from the unaffected
mother suggesting decreased penetrance or that this is a non-pathogenic variant. S356N
HARS affects an amino-acid residue that resides in the catalytic core of the HARS enzyme
(Figure 3.2B and C) and that is conserved from human to yeast (Figure 3.2A). S356N
HARS has not been previously reported; however, it has been detected in the gnomAD
database (5 alleles in 277,222 chromosomes; Table 3.1) [35].
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Figure 3.2. Neuropathy-associated HARS mutations are found in the active site of
the dimeric enzyme.
(A) Histidyl-tRNA synthetase forms a homodimer (first monomer yellow and second
monomer blue). The neuropathy-associated HARS residues are shown in the 3D structure
as red sticks of the HARS dimer bound to histidine (green spheres) (PDB 4PHC). (B) A
close up of the HARS active site pocket (yellow) reveals that neuropathy-associated
mutations face into the active site (shown as red sticks and spheres). (C) Modeling in
HARS neuropathy-associated substitutions indicates that interference with substrate
binding (histidine green sticks and ATP gray sticks) can occur. ATP was modeled into
the active site of the human HisRS bound to histidine (PDB 4PHC) by aligning the
HisRS E. coli structure bound to ATP (PDB 1KMN). (D) Complete amino acid sequence
alignment of human, mouse, worm, yeast, and bacterial HARS enzymes annotated with
domains and motifs localizes mutations in or near active site motifs critical for substrate
binding.
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3.2.2 Identified HARS mutations affect viability in yeast complementation studies
To test the functional consequences of the HARS missense variants described above
(V155G, Y330C, and S356N), each variant was introduced into the yeast ortholog HTS1
to model the effect of the mutation in the context of a eukaryotic cell (Table 3.1). Yeast
complementation assays were then performed to independently test all three missense
changes for the ability to support yeast cell growth as compared to wild-type HTS1 or an
empty vector. A haploid yeast strain (with the endogenous HTS1 locus deleted and a
maintenance vector to express wild-type HTS1 and URA3) was transformed with either a
pRS315 vector with no insert (‘Empty’) or a pRS315 vector harboring wild-type HTS1, or
a mutant version encoding one of the three missense mutations (V155G, Y330C, or
S356N). Yeast cells were then selected on media containing 5-FOA, which is toxic to yeast
carrying the URA3-bearing maintenance vector [37]. Thus, only yeast cells expressing a
functional HTS1 allele from the pRS315 vector will grow in this assay.
Yeast transformed with a wild-type HTS1 expression vector demonstrated
significant growth, while those transformed with an empty vector did not (Figure 3.3A),
consistent with HTS1 being an essential gene [38]. Yeast expressing Y330C or S356N
HTS1 displayed severely depleted, but not ablated, yeast cell growth (Figure 3.3A),
indicating that these are hypomorphic alleles. In contrast, V155G HTS1 supported yeast
cell growth, but at levels less than wild-type HTS1 (Figure 3.3A). Growth at 37OC did not
affect the cellular phenotype associated with above mutations, and over-expression of
tRNAHIS or supplementation of histidine in the media did not improve the growth
phenotypes associated with S365N or Y330C HTS1 (data not shown). In summary, our
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previously employed in vivo yeast complementation assay demonstrated that V155G HTS1
supports growth similar to wild-type HTS1, and that S365N and Y330C HTS1 are
hypomorphic alleles in this assay.
The lack of a cellular growth defect associated with V155G HTS1 was surprising
given that this mutation segregates with disease in a three-generation family. One possible
explanation for this discrepancy may be differential effects of V155G of the function of
yeast HTS1 compared to human HARS. To explore this possibility, we attempted to rescue
deletion of yeast HTS1 with the full-length human HARS protein. In yeast
complementation assays similar to those described above, expressing human HARS
rescued yeast cell growth while a vector with no HARS insert did not (Figure 3.3B); this is
the first report that human HARS is functional in yeast cells. We next mutated the HARS
expression construct to harbor the three missense mutations described here (V155G,
Y330C, or S356N) and found that, consistent with our studies in HTS1, Y330C and S356N
HARS did not support any yeast cell growth indicating that they are functional null alleles
(Figure 3.3B). Interestingly, V155G HARS supported growth, but in a manner that is
severely reduced compared to wild-type HARS (Figure 3.3B); these data indicate that
V155G HARS is a hypomorphic allele. Combined, our in vivo functional analyses indicate
that V155G, Y330C, and S356N HARS are loss-of-function alleles.
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Figure 3.3. Neuropathy-associated HARS mutations result in loss-of-function in
vivo.
(A) Yeast complementation analysis of HARS variants. Haploid DHTS1 yeast strains were
transformed with a vector containing no insert (‘Empty’) or an insert to express wildtype, V155G, Y330C, or S356N HTS1. Two colonies (indicated by ‘A’ and ‘B’) from
transformations with V155G, Y330C, or S356N HTS1 are shown. Resulting colonies
(undiluted, diluted 1:10, or diluted 1:100) were grown on agar plates containing complete
media with 0.1% 5-FOA. Note the severe depletion of growth associated with Y330C and
S356N HTS1 in the 1:10 and 1:100 dilutions. (B) Similar yeast complementation assays
as described in A using the human HARS open-reading frame. Haploid DHTS1 yeast
strains were transformed with a vector containing no insert (‘Empty’) or an insert to
express wild-type, V155G, Y330C, or S356N HARS. After transformations, colonies
(undiluted, diluted 1:10, or diluted 1:100) were grown on agar plates containing complete
media with 0.1% 5-FOA. Note the severe depletion of growth associated with V155G
HARS in the undiluted sample and the lack of growth in the 1:10 and 1:100 dilutions.
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3.2.3 Multiple-turnover kinetics identify specific catalytic defects of HARS
mutations
The results of the yeast complementation assays and the location of these
neuropathy-associated mutations in the catalytic domain raised the possibility that these
substitutions compromise catalytic function. As an initial characterization of catalytic
function, the production of histidyl-tRNA by each mutant and a wild type control was
monitored over a ten-minute time course in the presence of saturating concentrations of all
three cognate substrates. In excellent agreement with the yeast complementation results,
the two non-complementing mutants (S356N and V330C HARS) generated about 20% of
the amount of charged tRNAHis generated by WT and V155G in ten minutes (Figure 3.4).
Despite its near wild type level of product accumulation, the initial rate of product
formation by the V155G mutant was approximately 50% of the wild type protein,
indicating that this mutant is at least partially compromised for aminoacylation (Figure 3.4,
inset).
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Figure 3.4. Catalytic defects are apparent for neuropathy-associated HARS
mutations.
Aminoacylation of tRNAHis with histidine by wild-type or mutant HARS enzymes [5
nM]. Reaction conditions utlizing saturating substrates (10 mM ATP, 10 mM histidine,
and 10 µM tRNAHis) by wild-type or mutant HARS enzymes was monitored with
radioactive 32P-labled 3’-tRNAHis as a function of time (seconds) for the wild-type HARS
enzyme (black diamonds) and the mutants V155G (green triangles), Y330C (red circles),
and S356N (blue squares). Values represent the average of 3 independent experiments,
and error bars indicate the standard error.
In order to assess the effect of the mutant substitutions on the recognition of
individual substrates, the

32

P-tRNA aminoacylation experiments were repeated under

multiple turnover conditions employing fixed nanomolar concentrations of enzyme and
varying substrate concentrations. In the first set of kinetic experiments, aminoacylation was
monitored in presence of varying concentrations of tRNA and saturating concentrations of
histidine and ATP. This set of experiments showed that, while none of the mutants
exhibited an elevated KM for tRNAHis, Y330C and S356N HARS exhibited 9-fold and 18fold reductions (0.6 s-1 and 0.3 s-1, versus 5.4 s-1 for WT) in the steady state kcat for
aminoacylation, relative to wild type HARS (Figure 3.5A, Table 3.2). By comparison, the
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V155G HARS mutant exhibited a modest two-fold reduction in kcat (Figure 3.5A, Table
3.2). These results confirm and extend the previous yeast complementation and product
formation assays.
When histidine was the variable substrate and tRNA and ATP were the fixed
concentration substrates, the turnover numbers for each of the mutants were similar to the
values obtained in experiments where tRNA was the variable substrate (Figure 3.5B and
Table 3.2). The most significant kinetic differences were seen with the Y330C and V155G
HARS mutants. The KM for histidine was elevated 25-fold for Y330C HARS, and at least
86-fold V155G HARS (Figure 3.5B and Table 3.2). These results illustrate that, despite
the fact that Y330C and V155G HARS both exhibit deficits in histidine binding, the V155G
HARS mutant alone is catalytically “rescuable” by elevated concentrations of histidine.
Additionally, these results suggest that the diminished kcat associated with S356N HARS
appears not be linked to a decrease in binding to histidine.
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Figure 3.5. Multiple turnover (steady state) kinetics pinpoint catalytic deficiencies
of neuropathy-associated HARS mutations.
Steady-state kinetics by wild-type or mutant HARS enzymes were monitored for each
substrate. Initial velocity of product formed vs. varying substrate concentrations are
shown for (A) tRNAHis, (B) Histidine and (C) ATP. Plots in (A), (B) and for WT (black
diamonds in C) were fit to Michaelis-Menten equation to determine kcat, KM, and VMax.
Mutant HARS enzymes saturation was not achieved at 5mM ATP and were fit linearly to
determine an estimate for kcat/KM. Values represent the average of 3 independent
experiments, and error bars indicate the standard error.

Table 3.2A: Steady state kinetics of tRNAHis aminoacylation for human
neuropathy-associated mutations of HARS with tRNAHis as the variable substrate
tRNAHis

kcat (s-1)

Km (µM)

kcat/Km
(µM-1 s-1)

WT
0.782 ± 0.101
5.4 ± 0.2
6.9
HARS
S356N
0.199 ± 0.059 0.30 ± 0.02
1.5
HARS
Y330C 0.330 ±0.072 0.56 ± 0.03
1.7
HARS
V155G
0.979±0.159 3.05 ± 0.14
3.1
HARS
E. coli
0.34 ±0.05
1.71 ± 0.06
5.0
HisRS
Values reported are the mean ± standard error of three independent experiments.
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Table 3.2B. Steady state kinetics of tRNAHis aminoacylation for human
neuropathy-associated mutations of HARS with histidine as the variable substrate
Histidine
kcat (s-1)

Km (µM)

kcat/Km
(µM-1 s-1)

WT
8.0 ± 4.0
4.1 ± 0.4
0.5 ± 0.4
HARS
S356N
10.8 ± 9.1
0.39 ± 0.04
0.04
HARS
Y330C
202.9 ± 83.23
0.74 ± 0.10
0.004
HARS
V155G
687.2 ± 200.0
2.08 ± 0.16
0.003
HARS
E. coli
35.4 ± 3.7§
3.8§
133 ± 2.2§
HisRS
Values reported are the mean ± standard error of three independent experiments.
Table 3.2C. Steady state kinetics of tRNAHis aminoacylation for human
neuropathy-associated mutations of HARS with ATP as the variable substrate
ATP

WT
HARS
S356N
HARS
Y330C
HARS
V155G
HARS
E. coli
HisRS

Km (µM)

kcat (s-1)

kcat/Km (µM-1 s-1)

44.2 ± 5.5

5.8 ± 0.2

0.13

ND

ND

1.5x10-4 ± 1.2x10-5

1,763 ± 544

0.48

0.000272

ND

ND

3.8x10-4 ± 2.7x10-5

380 [39]

ND

ND

The final set of steady state kinetic experiments investigated the kinetics of
aminoacylation under conditions of variable ATP concentrations and saturating histidine
(10 mM) and tRNAHis (5 µM). Kinetic experiments for the wild type enzyme indicate that,
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under these substrate conditions, the KM value for ATP in the aminoacylation reaction is
44.2 µM (Table 3.2C). This is comparable to the value of 140 µM determined for the
S.typhiumurium WT HisRS catalyzed aminoacylation reaction [40]. Initial pilot
experiments conducted with the mutants indicated that substantially higher titration ranges
had to be to employed in order to accurately determine parameters. Even under these
conditions, saturating velocities were not obtained with any of the mutants. However,
plotting the velocities to the concentration of [ATP] yielded straight lines from which
estimates of the second order rate constant Vmax/ KM could be estimated (Figure 3.5C).
Relative to wild type HARS, all three mutants showed significant decreases in Vmax/ KM
for ATP, corresponding to 342-fold for V155G HARS, 866-fold for S356N HARS, and
2549-fold for Y330C HARS (Table 3.2). Based on these results, we conclude that, for all
three mutants, a major component of the attenuated catalytic activity originates from a
significant increase in KM, for ATP. It is noteworthy that while we were unable to achieve
saturation at 5mM ATP we were able to reproduce kcat results with 10 mM ATP in both the
tRNA and histidine titration (Figure 3.5A and Figure 3.5B). In summary, we conclude that
the HARS neuropathy-associated mutations lead to significant decreases in catalytic
activity. Similar defects in kcat and ATP binding are observed for all three HARS
neuropathy mutations and minor issues with tRNA and histidine binding.
3.2.4 Differential scanning fluorimetery reveals only one out of three mutations
are unstable and two have apparent substrate binding defects
Differential scanning fluorimetry (DSF) is a useful technique that can be used to
assess the melting temperature stabilizing effect of a substrate with respect to an enzyme,
as well as aid in the evaluation of the effect of a potential pathogenic amino acid on protein
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structure [41]. Previously, incubation of HARS with saturating concentrations of the
histidine amino acid ligand raised the thermal shift transition temperature by seven degrees
[42]. On the basis of the kinetic results indicating weaker binding of both histidine and
ATP, we predicted that one or more the mutants would show altered thermal shift behavior.
Thermal shift assays were performed for each combination of mutant enzyme and
substrate. Consistent with the previous kinetic data, there was an inverse relationship
between the KM for histidine of a given mutant protein and the extent of temperature
stability provided by incubation with histidine in the assay. As seen in Figure 3.6 and Table
3.3, S356N HARS exhibited the same extent of stabilization by histidine (8.3 vs 7.03°) as
WT HARS, consistent with its essentially equivalent KM in aminoacylation. By contrast,
Y330C HARS and V155G HARS exhibited smaller histidine mediated temperature shift
(4.23 and 1.3°, respectively) closely tracking their substantially increased histidine
Michaelis constants (202.9 µM and 687.2 µM fold, respectively).
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Table 3.3. Thermal stability of neuropathy-associated HARS variants and
substrate complexes
Tm °C

Δ Tm °C #

Δ Tm °C ##

51.72 ± 0.44***

-

-

WT + histidine

58.75 ± 0.41

7.03

-

WT + ATP

53.76 ± 0.21

2.04

-

WT + tRNAHis

53.43 ± 0.41

1.71

-

S356N

50.87 ± 0.33

-

-0.85

S356N + histidine

59.17 ± 0.31

8.30

0.42

S356N + ATP

53.12 ± 0.11

2.25

0.64

S356N + tRNAHis

55.16 ± 0.20

4.29

NA

Y330C

51.72 ± 0.36

-

0

Y330C + histidine

55.95 ± 0.32

4.23

-2.8

Y330C + ATP

53.85 ± 0.12

2.13

0.09

Y330C + tRNAHis

55.88 ± 0.29

4.16

NA

48.05 ± 0.39***

-

-3.67

V155G + histidine

49.35 ± 0.67

1.30

-9.4

V155G + ATP

51.09 ± 0.16

3.04

-2.67

V155G + tRNAHis

53.91 ± 0.26

5.86

NA

Enzyme
WT

V155G

Bold values were previously determined [42]. # Relative to the apo form of the same enzyme. ## Relative
to the same form of WT HARS enzyme. Values reported are the mean ± standard error of 2 independent
experiments in triplicate. Values that are significantly different WT to V155G are indicated as ***
p<0.0001 (extra sum-of-squares F test).
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For wild type HARS, the ATP and tRNA mediated temperature shifts are much
smaller (2.04 and 1.7°, respectively) than that provided by histidine (Figure 3.6 and Table
3.3). In the presence of saturating ATP (5 mM) all three neuropathy-associated mutations
had slightly increased ∆Tm values, corresponding to least 2 ºC for Y330C and S356N, and
3 ºC for V155G (Table 3.3). In the presence of 20 µM tRNAHis, all three mutants exhibited
1 ºC in ∆Tm increases in stability (Table 3.3). Notably, none of the three mutants showed a
significantly altered melting temperature in the presence of either ATP or tRNA, despite
the fact that all three show substantially reduced apparent second order rate constants
associated with ATP binding (Table 3.3).
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Figure 3.6. Differential scanning fluorimetry reveals melting temperatures of
neuropathy-associated HARS enzymes and indicate issues in substrate binding.
Melting temperature of apo wild-type or mutant HARS enzymes were determined at a
concentration of 10 µM enzyme (A-C) WT (black diamonds), S356N (blue squares),
V155G (green triangles), and Y330C (red circles). Stabilization by histidine was
monitored by incubation of mutant HARS enzymes with 5 mM histidine (D-F) Empty
symbols represent APO enzymes while filled symbols represent histidine bound enzymes
(D) S356N, (E) V155G and (F) Y330C. Thermal shift curves are representations of
neuropathy-associated HARS mutants measured in duplicate and WT once.
3.2.5 Analytical ultra-centrifugation confirms that HARS neuropathy-associated
mutations do not disrupt enzyme dimerization.
Previous studies investigating mutations in the GARS gene linked to CMT have
reported that for a subset of these mutants the mutant substitutions lead to weaker tertiary
interactions and thus reduced dimer stability [18]. Given the location of the HARS mutants
in the active site, we considered the possibility that the decreased activity of these mutants
might be a consequence of reduced dimer stability. To address this hypothesis, we
subjected highly purified preparations of each of the mutant proteins and a wild type
control to sedimentation velocity experiments at various loading concentrations. In these
experiments, we monitored protein absorbance at 230 nm, allowing the experiments to be
performed at concentrations that would be in the range of the equilibrium dissociation
constant (Kd) for the dimer. As shown in Figure 3.7, the molar mass distributions of the
wild type and mutant proteins were similar. For each mutant, a major species was observed
that had a molar mass that was in excellent agreement with the dimer form of HARS (Table
3.4). In none of the mutants was there a detectable amount of material corresponding to the
monomeric form of the enzyme. On the basis of these results, we conclude that the
pathophysiology of these mutants is unlikely to be the result of a weakened dimer. This is
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a key result as the lower melting temperature of the V155G mutation is not a consequence
of increased monomers in solution.
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Figure 3.7. Dimerization of HARS enzyme is not disrupted by neuropathyassociated mutations.
A. Molar mass distributions determined by sedimentation velocity, showing the PCSAMonte Carlo distributions for HARS WT (black), HARS V155G (red), HARS Y330C
(blue), and S356N (green). A minor contaminant (< 2%) of unknown identity is visible in
the Y330C preparation. Molar masses are in excellent agreement with a dimer of each
species. B. Frictional ratio anisotropies for HARS WT (black), HARS V155G (red),
HARS Y330C (blue), and S356N (green), as a function of the sedimentation coefficient
(WT (black) is congruent with HARS Y330C and therefore hardly visible). Pseudo-3D
plots derived from PCSA-Monte Carlo analyses of sedimentation velocity experiments.
The right vertical axis indicates the partial concentration in terms of color density. All
four samples show remarkable similarity.
Table 3.4. PCSA – Monte Carlo results (straight-line parameterization) from the SV
experiment.
Species

Molar mass D(x 10-7 cm/sec2) s (x 10-13 sec)
(kDa)

f/f0

RMSD

WT

118.5
(111.6, 125.5)

4.54
(4.43, 4.66)

5.67
(5.48, 5.85)

1.44
0.002484
(1.43, 1.45)

V155G

122.0
(110.6, 133.5)

4.43
(4.20, 4.65)

5.68
(5.42, 5.94)

1.46
0.003170
(1.44, 1.49)

Y330C

120.6
(116.3, 124.9)

4.52
(4.50, 4.55)

5.74
(5.51, 5.97)

1.44
0.002818
(1.42, 1.46)

S356N

120.0
(110.3, 129.6)

4.41
(4.34, 4.49)

5.57
(5.21, 5.93)

1.48
0.003418
(1.46, 1.49)

Values in parenthesis are 95% confidence intervals from the Monte Carlo analysis. The
theoretical molar mass of HARS WT dimer is 114.9 kDa, indicating the observed species
is a dimer. The residual mean square deviation (RMSD) of the fit is shown in units of
absorbance at 230 nm.
3.2.6 Results and discussion for Y330C, S356N, and V155G HARS CMT
variants
All three of the amino acid substitutions analyzed here alter amino acids located in
the catalytic domain, consistent with their pronounced effect on aminoacylation.
Visualization of these substitutions in the context of available X-ray structure of human
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HARS provides insights into potential structural and functional consequences. S356 does
not appear to be involved directly in substrate binding interactions. Ser356 may be
important for positioning other amino acid residues within the active site that are critical
for binding of the ATP substrate. ATP binding in the active site of HARS requires
coordinated interactions from conserved arginines in motif 2 and motif 3, as well as
interactions from conserved magnesium ions coordinated to one or more coordinated
glutamates. In the human HARS histidine complex (no ATP), Ser356 is within 2.5 Å of
Arg 388 (Figure 3.8A), the conserved motif 3 arginine that (based on the E. coli complex)
is predicted to interact with the gamma phosphate of ATP (Figure 3.8B). Important caveats
regarding the likely effects of S356N are that, firstly, a complex with ATP is not available,
and secondly, that much of the loop between strands B9 and B10 in which the Ser356
residue resides is disordered in the various human HARS structures, and has different
conformations in the different subunits of the asymmetric unit. Hence, it is difficult to make
definitive conclusions about the potential role of Ser356 in stabilizing interactions in the
bound complex, and about the consequences of substitution with asparagine. However, the
elevated KM for ATP for S356N could be interpreted as a likely outcome of a local
disruption of contacts to the gamma phosphate.
The one HARS mutant that is predicted to have the most dire consequence for
function is Y330C, which substitutes a highly conserved tyrosine, in the His A motif,
constitutes part of the binding site for histidine (Figure 3.2A). Notably, this residue has
different conformations in the apo versus histidine bound complex. In the apo complex
without substrates (4X5O), Y330 adopts a conformation directed away from the active site,
pointing towards solvent and donating a hydrogen bond to the main chain carbonyl of
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Gly108 (Figure 3.8C). In the complex of HARS with its amino acid substrate, Y330 moves
some 8 Å to approach within 3.1Å of the alpha-carbon of histidine (Figure 3.8D). In this
bound conformation, Y330 may further stabilize the histidine binding pocket by engaging
in a stacking interaction with the neighboring tyrosine in position 331.
A similar effect may underlie the effect of V155G on HARS function. Analysis of
the human HARS-histidine complex and comparison to the E. coli HisRS-histidinol ATP
complex suggests that V155G is unlikely to substitute a residue that interacts directly with
ATP (Figure 3.8E). However, Val155 is in the region of the active site near where ATP
binds, and the valine can potentially make a CH-p interaction with the neighboring
hydrophobic Phe171 in the active site (Figure 3.8E). Phe171 in human HARS corresponds
to Phe125 in the E. coli enzyme[43], which makes a critical stacking interaction with the
adenine ring (Figure 3.8F). The substitution of glycine for valine at position 155 may allow
greater conformational flexibility on the part of Phe 171, reducing its ability to generate
stable binding pocket for ATP. The effects of this disruption are apparent in the elevated
KM value for ATP observed for V155G. Additionally, a glycine substitution would permit
greater conformational freedom in the accessible phi si angles within the peptide backbone
of the beta sheet, potentially accounting for the lower melting temperature in the absence
of substrate. Furthermore, a “loose” beta sheet created by the glycine substitution could
directly impact helix 3, which contains the ‘TXE’ motif for histidine binding. This provides
a structural rationale for the decreased Tm of the V155G apo enzyme, the dramatically
reduced Tm in the presence of histidine (Table 3.3), and the elevated KM for histidine (Table
3.2).
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Figure 3.8. Structural analysis of HARS enzyme reveal how substitutions
compromise enzyme structure and substrate binding.
Molecular interactions of HARS neuropathy-associated amino acid residues in the active
site. (A) S356 is positioned in the active cite to coordinate a critical arginine residue
R388 in motif III. (B) R388 is highly conserved and corresponds to R311 in E.coli HisRS
structure (cyan) that is responsible for positioning the gamma phosphate of ATP with
R121. (C) Y330 faces 2.5 Å from the alpha carbon of histidine and no immidate
interactions with modeled ATP (gray sticks and spheres). (D) Y330 and Y331 facilitate
hydrogen bonding interactions with histidine. Y330 in the apo enzyme (shown as purple
sticks) can flip away from the active site and swing 8 Å upon histidine binding (shown as
red sticks) to facilitate hydrogen bonding interactions. (E) V155G is buried in the active
site and does not mediate any direction interactions with either substrate histidine or ATP
but in the apo enzyme forms a CH-Pi interaction with the aromatic ring of Phe 171 within
the active site. (F) Phe 171 forms a stacking interaction with the ribose ring of ATP (as
modelled in to active site as grey sticks and spheres).
3.2.7 R137Q HARS as a periphearal neuropathy variant at the dimer interface
A candidate gene screen on 363 patients with CMT disease and no known diseasecausing mutations had previously identified the first HARS missense mutation (R137Q) in
a 65 year old patient with a 15 year history of motor and sensory peripheral neuropathy
[38]. While functional studies suggested that R137Q HARS was pathogenic, the genetic
data was not sufficient to implicate HARS as a bona fide CMT disease gene [38].
In a fashion reminiscent of the some of the GARS-linked CMT mutants, the R137Q
substitution eliminates a salt bridge at the dimer interface with D64 of the opposite
monomer [44] (Figure 3.9). This provides one scenario by which the R137Q substitution
could bring about a loss of function, and promote the peripheral neuropathy phenotype.
However, the existence of a heterozygous asymptomatic carrier with the same mutation
suggests that the genetics of the system are not straightforward, and may be confounded
by incomplete penetrance effects. To determine if R137Q shares similar catalytic or
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structural defects with S346N, V155G, and Y330C we used similar kinetic, DSF, and AUC
studies to make comparisons.

A

B

Figure 3.9. R137Q mutation disrupts an essential electrostatic interaction at the
dimer interface.
R137Q substitution alters a highly conserved dimer stabilizing interaction at the dimer
interface and opposed to the USH3B Y454S HARS mutation in the anti-codon binding
domain-catalytic domain interface. R137 forms a salt-bridge with D64 at the dimer
interface near the catalytic domain.
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3.2.8 R137Q CMT variant is catalytically compromised for the adenylation
reaction but can still aminoacylate
Initial experiments were carried out to evaluate if the R137Q HARS variant had
catalytic activity by monitoring AMP formation. While AMP production by R137Q
relative to WT was not extensive, the requirement for histidine confirms that any AMP
formed was the result of catalysis by R137Q HARS and was not produced by a
contaminating protein (Figure 3.10).

Figure 3.10. TLC analysis of AMP formation by WT and R137Q HARS enzymes.
(A)WT and (B) R137Q HARS were evaluated for activity as a function of AMP
formation. Enzyme concentrations evaluated were (1𝜇M for WT and R137Q
respectively).
Notably, turnover of ATP to AMP was improved in the presence of tRNA (Figure
3.11). As these initial experiments were done using relatively low concentrations of ATP
(10𝜇M) we sought to evaluate the adenylation reaction of R137Q by rapid chemical
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quench. Under these conditions much higher ATP concentrations (100𝜇M) are used to
evaluate amino acid activation (Figure 3. 11).
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Figure 3.11. Quantification of WT and R137Q AMP production as a function of
time.
Formation of AMP was quantified from TLC time course results. (A) AMP production of
WT 1 uM and R137Q 1uM in the presence and absence of tRNAHis 2uM) evaluated for
30 mins. with 10 uM ATP 5 mM histidine (B) Data from the first 5 mins of the reaction
time course.
Pre-steady state adenylation revealed as that R137Q is defective in the adenylation
reaction and has a significantly slower rate, 0.014 ± 0.02 s-1. Interestingly, the rate
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improves with the addition of tRNAHis and this improvement is apparent in the first 5
second of the amino acid activation reaction, 0.4 ± 0.01 s-1 (Figure 3.12). As a comparison
to the first test for activity (Figure 3.11) the rapid quench pre-steady state assay seems to
provide a more accurate analysis for activity of R137Q with the presence of tRNAHis. This
is likely the result of the increased ATP concentration and the presence of tRNAHis. These
results are very interesting and potentially indicate issues with ATP binding. This data
would be further supported by a complete Michaelis menten kinetic analysis titrating ATP
as the variable substrate. Without a complete histidine titration, it is also unclear if R137Q
also has catalytic defects when histidine is the variable substrate.

Figure 3.12. Pre-steady state amino acid activation reaction for WT and R137Q in
the presence and absence of tRNAHis.
Rapid quench was utilized to measure rate of adenylation in the presence of tRNAHis.
Conditions of the reactions were as follows: 5µM hHARS and 25µM of in vitro generated
tRNAHis transcript. Data was fit to a single exponential to determine the rate of
adenylation.
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As the R137Q variant had severely compromised rate for the adenylation reaction
we sought to determine how this affects aminoacylation. Surprisingly, in the presence of
saturating histidine (10 mM) and ATP (5mM) R137Q seems to have comparable
aminoacylation activity similar to WT for low and high concentrations of tRNA (Figure
3.13). This data suggests that under conditions of saturating ATP and histidine R137Q is
very active and may not be defective in tRNAHis binding. However, to be certain, a
complete titration with tRNAHis as the variable substrate would be required to make this
observation complete.

Figure 3.13. R137Q HARS aminoacylation of tRNAHis.
(A)Aminoacylation with 1µM tRNA with10nM enzyme (WT black filled circles)
(R137Q purple filled squares) and 100nM tRNAHis and 0.9µM enzyme (WT empty black
squares)(R137Q purple empty squares). (B) Thin layer chromatography plates of R137Q
and WT aminoacylation time courses.
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3.2.8 R137Q is thermally unstable and slight formation of monomer is apparent
by AUC
R137Q is the only known HARS CMT variant that forms a direct dimer interface
contact. As this substitution may disrupt a critical salt bridge at the dimer interface we
evaluated its DSF profile in the presence of substrates and its ability to form dimers by
AUC. DSF data indicated that R137Q is indeed thermally unstable (Figure 3.14) with a Tm
values of 46.1 ºC. R137Q is not readily stabilized by the addition of histidine or ATP,
yielding ΔTm values of 0.8 ºC and 1.2 ºC respectively. Notably, the most stabilizing
substrate was tRNA, and this data corresponds with the apparent improvement of
adenylation activity upon the addition of tRNA with a ΔTm value of 4.7 ºC. Furthermore,
as histidine did not have a stabalizing effect for R137Q, this may support evidence for
histidine binding defects. As mentioned previously, these findings might become more
apparent by multiple turnoever kinetic analysis titrating in histidine as the variable
substrate (Table 3.5).
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Figure 3.14. Thermal shift data of R137Q HARS.
Comparison of WT HARS thermal shift data with WT (black) (A). Tm as a function of
R137Q substrate binding to histidine (B), ATP (C), and tRNAHis (D).
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Table 3.5. Differential Scanning Fluorimetery Tm values for CMT Variant
R137Q HARS
Enzyme

R137Q

WT

Substrate

Tm

S.E.

ΔTm

NA

46.12

0.70

-----

5mM Histidine

46.88

0.60

0.76

5mM ATP

47.35

1.04

1.23

10uM tRNA

50.86

0.603

4.74

NA

50.37

0.64

------

5mM Histidine

58.95

0.58

8.58

5mM ATP

52.91

0.33

2.54

ATP + Histidine

59.65

0.44

9.28

While R137Q is also thermally unstable it can form stable dimers in solution
(Figure 15). This particular construct is the first example where the appearance of monomer
in solution is observed, otherwise, R137Q is comparable with WT with respect to
dimerization.
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Figure 3.15. Analytical ultra centrifugation analysis of R137Q HARS
dimerization.
(A) Molar mass distributions determined by sedimentation velocity, showing the PCSAMonte Carlo distributions for HARS WT (black), HARS R137Q (red). A minor fraction
of monomer is apparent (< 5%) in the R137Q preparation. Molar masses are in excellent
agreement with a dimer of each species. B. Frictional ratio anisotropies for HARS WT
(black), HARS R137Q (red), HARS, as a function of the sedimentation coefficient.
Pseudo-3D plots derived from PCSA-Monte Carlo analyses of sedimentation velocity
experiments. The right vertical axis indicates the partial concentration in terms of color
density. These two samples show remarkable similarity.
3.3 PC12 cells as a model for axonal defects caused by HARS CMT variants
3.3.1 Results and discussion of PC12 cell neurite analysis and cellular localization
of HARS
PC12 cells were transfected with four HARS CMT variants, V155G, S356N,
Y330C, and R137Q. After differentiation with NGF for two days the cells were fixed to 24
well plates and imaged at a 20X magnification using an epifluorescent microscope.
Multiple images from each well and multiple wells transfected with the same HARS CMT
variant were collected and GFP positive cells were analyzed and neurites were measured
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(Figure 3.16A). Additionally, the number of cells bearing neurites is not different across
the experiment (Figure 3.16B). A preliminary analysis of the length of the all the neurites
counted indicated that the average neurite length for all the HARS CMT variants tested
was lower relative to WT. From the neurite data analysis there is no difference in the
percent of cells that undergo differentiation (having at least one neurite twice the length of
the average cell body diameter) (Figure 3.16C). However, the number of neurites greater
than 30 microns per cell are lower for CMT HARS variants relative to WT (Figure 3.16D).
This would suggest that while all the HARS CMT variants do not affect initial neurite
outgrowth or the number of neurites that the cell can form, the ability to form long neurites
is affected, and this variable is likely the component driving down the average neurite
length.
Furthermore, with transfected PC12 cells the cellular localization of HARS CMT
variants were evaluated. PC12 cells were transfected with C-terminally GFP-tagged HARS
CMT variants and differentiated for two days on coverslips. Antibodies against GFP and
other cytoskeletal markers (beta tubulin 3) were used in these assays. What was clear and
consistently observed for WT and all HARS CMT variants was the appearance of GFPtagged HARS proteins to the most distal regions of neurites.
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Figure 3.16. CMT variants reduce the average neurite length of differentaited
PC12 cells
Quantification of differentiated PC12 cell neurites were analyzed. Number of cells
counted for each CMT vatiant (WT = 216, Y330C = 122, R137Q = 227, V155G =117,
S356N = 106).
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Figure 3.17. Localization of GFP HARS to neurites.
Localization of WT and CMT-associated HARS variants in differentiated PC12 cells.
GFP-tagged HARS enzymes were transfected in PC12 cells and visualized with anti-GFP
antibody and co-stained with Dapi and neuronal beta tublin III.
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3.4 Conclusions
The detailed characterization of these mutants showed that they all displayed losses
in catalytic activity when assessed in vivo and in vitro. Notably, the extent of decrease in
catalytic activity was well correlated with the loss of ability to support yeast growth. The
most active of the three mutants (V155G HARS) was the only one of the three mutants that
retained some ability to support yeast growth when studied in the HARS open-reading
frame. In contrast to most of the previous work analyzing aaRS mutants linked to CMT,
each of the HARS mutants was fully characterized with respect to defects associated with
recognition of each substrate. The novel finding emerging from this analysis is that all three
mutants Y330C, S356N, and V155G displayed substantially elevated Michaelis constants
for ATP, and two of the three (Y330C and V155G) displayed an elevated KM for histidine.
Notably, none of the three exhibited an altered KM for tRNA. While the full kinetic analysis
has not been performed for R137Q, preliminary DSF and amino activation experiments are
indicative of catalytic defects. Thus, for these families, like HARS, the linkage to CMT
appears to be associated with a loss of aminoacylation function.
The work reported here on HARS suggests that, in the absence of detailed studies
where substrate dependence is examined in detail, conclusions about the functional impact
of mutations should be taken cum grano salis. Collectively, these mutants represent some
of the best characterized examples where a loss of aminoacylation is linked to CMT.
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3.5 Supplemental Methods
Clinical and Genetic analysis of patients with peripheral neuropathy
Family 1: We applied whole-exome sequencing in a cohort of index patients from
82 families with genetically undefined distal hereditary motor neuropathy, mutations in the
known pathogenic genes had previously been excluded. The Ethical Review Boards of the
participating institutions approved this study. All patients or their legal representatives
signed informed consent prior to enrolment. Blood sampling and DNA extraction was
performed according to standard methods. The Nextera Rapid Capture Expanded Exome
kit (62Mb) (Illumina) was used for exome enrichment. Subsequently, the libraries were
sequenced on a HiSeq 2500 platform (Illumina). The Burrows-Wheeler Aligner (BWA)
tool was used to perform the sequence alignment to the reference genome (hg19, UCSC
Genome Browser). Variant calling was done with Genome Analysis Toolkit (GATK)
Unified Genotyper. For the annotation and filtering we used the Clinical Sequence
Analyzer and Miner (Wuxi NextCODE). For further filtering of the data, the following
criteria were applied: no occurrence or a frequency ≤ 0.5% of the variants in public exome
variant repositories (Exome Aggregation Consortium, 1000 Genomes Project, Exome
Variant Server, in-house data); variants with impact on the encoded protein (missense,
nonsense, frame shift, inframe indels and splice site variants); read depth ≥ 7; minimal
heterozygous call percentage ≥ 20%, minimal homozygous call percentage ≥ 66%. In
addition, all data were imported and re-annotated into the GENESIS (gem.app) platform,
a

web-based

tool

for

next

generation

sequencing

data

analysis

(http://thegenesisprojectfoundation.org/) [45]. Patients were evaluated by clinical
examination in combination with nerve conduction studies according to standard methods.
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Family 2: All family members were studied at Bellvitge’s University Hospital.
Detailed neurological evaluation was performed on patients and unaffected subjects.
Electrophysiological studies were performed using standard methods in all subjects. We
classified the severity of neuropathy symptoms according to the CMT neuropathy score
(CMTNS). Blood samples were obtained from all family members once informed consent
had been given. Genomic DNA was extracted from peripheral blood leukocytes. PMP22,
MPZ, MFN and GJB1 mutations were previously excluded in index case.
Family 3: The family was evaluated in the University of Iowa CMT Clinic.
Informed consent was obtained from all individuals and the study has been approved by
the Institutional Review Board at the University of Iowa. Neurological examination and
neurophysiological studies were performed. The second version of the CMT Neuropathy
Score (CMTNSv2) and CMT Exam Score (CMTESv2) [1] were employed to evaluate
neuropathy. The SureSelect Human All Exon 50 MB Kit (Agilent) was used for in-solution
enrichment, and the HiSeq 2500 instrument (Illumina) was used to produce 100 bp pairedend sequence reads. The Burrows-Wheeler aligner, Picard, and the Genome Analysis Toolkit were used to align sequence reads and call variants. These data were imported into
GENESIS (GEM.app) [45]for further analysis and filtering of variants.
Yeast complementation assays
Yeast complementation assays to study the functional consequences of HARS
mutations were generated and performed as previously described (Vester et al. 2013). Each
indicated missense variant was modeled in the yeast HARS ortholog HTS1 or in the human
HARS open-reading frame (primers available upon request). After mutagenesis, wild-type
or mutant HARS or HTS1 were cloned into pRS316 or pYY1, respectively, using the
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QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene). Resulting expression
clones were purified and fully sequenced to confirm successful mutagenesis and rule out
PCR-induced errors. A haploid ΔHTS1 strain (harboring a maintenance vector to express
wild-type HTS1 and URA3) was transformed with an empty vector (‘Empty’ in Fig. 2A
and B) or the appropriate wild-type or mutant HTS1 or HARS in a LEU2-bearing vector
and selected on medium lacking uracil and leucine (Teknova). For each transformation, at
least two independent plasmid preparations were used and at least two colonies from each
plasmid were selected for additional analysis and grown to saturation for 2 days at 37°C in
liquid media lacking uracil and leucine. A 10 µl aliquot of each culture was spotted
undiluted or diluted 1:10 or 1:100 in H2O onto plates containing 0.1% 5-FOA (Teknova)
or medium lacking uracil and leucine and incubated at 30°C for 48-72 hours. Survival was
determined by visual inspection of growth.
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CHAPTER 4: CHARACTERIZATION OF A RECESSIVE HARS MUTATION
ASSOCIATED WITH USHER SYNDROME IIIB
4.1 Introduction
4.1.1 Usher Syndrome
Usher syndrome is the most common recessively inherited neurological disorder
that results in deafness and vision loss. Charles Usher, a Scottish ophthalmologist, first
described this inherited neurological disorder in 1914. He noted characteristic symptoms
of this disease included sensory impairment of the audio, vestibular, and visual systems.
The onset of blindness in Usher patients is caused by retinitis pigmentosa (RP), a
progressive degradation of photoreceptors in the retina. RP symptoms include peripheral
vision loss, night blindness, visual field constriction, and abnormal retinal pigmentation[1].
Usher syndrome is divided into three clinical categories, USH1, USH2, and USH3,
which are differentiated by the severity and progression of hearing loss and by the degree
of vestibular dysfunction although, visual impairment caused by RP is common to all three
subtypes [2]. USH1 is the most severe form as patients are either born completely deaf or
experience hearing impairment within the first year of life and usually do not develop
speech [1]. Vestibular dysfunction is evident from birth as children experience a delay in
sitting independently and walking later than usual. Evidence of retinitis pigmentosa occurs
during childhood, presenting as progressive constriction of the visual field and impaired
visual acuity followed by complete blindness. USH2 patients usually develop retinitis
pigmentosa symptoms later compared to their USH1 counterparts. Hearing impairment
with USH2 is congenital and usually detected at later stages when it hinders
communication. Hearing impairment increases from moderate to low frequencies to severe
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in high frequencies [1]. Curiously, vestibular function in USH2 patients appears not to be
affected. The onset of RP symptoms is variable for USH3 patients and usually occurs by
the second decade of life. Sensorineural hearing loss is progressive and can appear between
the first and third decade of life [1]. Initially hearing loss symptoms are similar to that of
USH2 patients, with a major hearing impairment seen in high frequencies. The rate of
hearing loss in USH3 patients is variable but in most cases becomes profound. However,
during the first stages of development hearing is good enough to permit development of
speech. Vestibular dysfunction is also variable, with 50% of cases experiencing impairment
[1].
Usher syndrome is an inherited polygenetic disorder and encompasses a group of
autosomal recessive genes. Interestingly, Usher syndrome is more common in regions with
small isolated, often consangious populations such as in Israel (Samarthians), Pakistan
(Hutterities), France (Poitou-Charentes region), Northern Sweden, Finland and the
Accadian population of Louisiana, United States [2]. Presently, twelve loci have been
linked to Usher syndrome, nine of which have an identified protein product (Table 1).
Seven loci have been mapped for clinical type I Usher syndrome and five causative Usher
genes have been cloned: MYO7a, USH1C, CDH23, PCDH15, and USH1G, implicated in
USH1B, USH1C, USH1D, USH1F, and USH1G, respectively [1]. Three loci are
associated with clinical type II Usher syndrome; and these genes have been identified as:
USH2A, GPR98 (USH2C), and DFNB31 (USH2D). Usher type III is the least common
type of the syndromes and thus far only one USH3A gene has been described [1].
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4.1.2 Molecular components of Usher syndrome.
The inner ear contains a spiral shaped structure called the cochlea, which is
responsible for auditory transduction of sound. The cochlea contains a specialized unit
termed the organ of Corti that contains highly specialized neurosensory cells. These
neurosensory cells are the inner and outer cochlear hair cells that consist of ciliary
structures, stereocilia and kinoclilium. Stereocilia are tethered together by fibrous
connections along their length and highly organized into bundles. The unique structure of
stereocilia is supported by the internal cytoskeleton composed of F-actin. Deflection of
stereocilia results in mechanical opening of potassium channels allowing for influx of
potassium ions, which consequently leads to the depolarization of the membrane and
release of neurotransmitters. The mechanosensory channels are connected via proteinprotein interactions with the actin filaments.
Many genes responsible for Usher syndrome affect molecular components that are
present in both the inner ear and retina (Table 4.1). The main site of colocalization for
Usher proteins are in the stereocilia of hair cells. Additionally, occurrences of many of the
Usher proteins in the synapse of hair cells suggest that they also play a functional role in
the neurotransmission and likely the reason they contribute to the pathological
development of sensorineural hearing loss. Usher proteins, such as cadherin 23, are
involved in the proper development and cohesion of hair cell bundles in the organ of Corti.
Cadherin 23 and protocadherin 15 as well as transmembrane proteins usherin and VLGR1
are part of inter-stereocilia fibrous links that are essential in hair cell cohesion. These
proteins are anchored to the intracellular scaffolding proteins harmonin and/or whirlin,
which connect, via myosin VIIa and possibly other proteins, to the actin core of stereocilia
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[2]. Of note, unconventional myosins are motor molecules with structurally conserved
heads, which move along actin filaments using their actin-activated ATPase activity [3].
Mutations in the gene encoding an unconventional myosin involved in Usher syndrome
type I, myosin VIIA, are located at the N-terminal motor domain of the protein [3].
Table 4.1. Genetic classifications of Usher syndrome.
Clinical subtype/locus

Gene/protein

Function/Inner ear and/or retina

USH1B/DFNB2/DFNA1
USH1C/DFNB18

MYO7A/myosin VIIA
USH1C/harmonin

USH1D/DFNB12

CDH23/cadherin 23

USH1E

Unknown
PCDH15/protocadherin
15

Transport –inner ear and retina
Scaffolding-inner ear and retina
Tip link formation in inner ear and
pre-ciliary maintenance in retina
Unknown
Tip link formation in inner ear and
pre-ciliary maintenance in retina
Scaffolding and protein trafficking –
inner ear and retina
Unknown
Formation of ankle links and
cochlear development for inner ear
and pre-ciliary maintenance in retina
Scaffolding –inner ear and retina
Probably role in synaptic transportinner ear and retina

USH1F
USH1G

USH1G/SANS

USH1H
USH2A

Unknown
USH2A/usherin

USH2C

GRP98/VLGR1

USH2D

DFNB31/whirlin

USH3A

USH3A/clarin-1

USH3B

HARS/histidyl-tRNA
synthetase

Protein translation - unknown

Genes and proteins identified are listed with corresponding proteins and protein function.

Usher proteins, cadherins, constitute a superfamily of glycosylated transmembrane
proteins, that mediate cell-cell adhesion, compaction and cellular rearrangement during
development [4]. Octocadherin or cadherin 23 (Cdh23 and USH1D) and protocadherin 15
(pcdh15 and USH1F) are cadherin related proteins (Table 4.1). Cdh23 expression is
restricted to inner and outer hair cells. Hair cells of a mouse model for USH1D
demonstrated that mutations in Cdh23 cause stereocilia to be disorganized rather than in a
crescent shape [4]. Stereocilia disorganization appears to be the primary defect and thus
identifies otocadherin as a critical component for proper hair bundle formation [4].
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Harmonin as an usher protein is thought to act as a scaffold protein in both the
retina and cochlea that integrates all known USH1 molecules in an USH1-protein network
[5]. In the retinal photoreceptor cells, harmonin co-localizes with other USH1 proteins
(myosin VIIa, cadherin 23, and pcdh15) at the synaptic terminals, whereas in the inner ear,
the harmonin organized USH1-protein network is found in the stereocilia of hair cells [6].
Binding studies indicate that usher proteins Usherin (USH2A) and very large G-coupled
protein receptor (VLGR1) bind to harmonin’s PDZ1 domain [2]. The “Goliath” usher
syndrome molecule VLGR1 is a cell surface receptor and similar to cadherins function in
cell adhesion of synaptic membranes and therefore participates in cell adhesion of inner
ear hair cells [2],[6]. Harmonin is the first molecular link between USH types, USH1 and
USH2, via its functions as a potent scaffold protein [6].
Pathogenic mutations in the SANS gene are associated with USH1G. SANS was
identified from an analysis of 39 sporadic and familial USH1G cases from Germany,
France, Israel, Iran and Morocco that had no mutations in myosin VIIA or in the gene
encoding harmonin. Two patients with a frame shift deletions in the SANS gene were
identified and predicted to form a truncated version of the SANS protein. It has been shown
that SANS interacts with harmonin by binding to the first PDZ domain [3]. SANS produced
in sensory hair cells, may be connected to the actin cytoskeleton via its interaction with
harmonin b, an isoform largely restricted to the inner ear [3]. Being that harmonin interacts
with myosin VIIa and cadherin 23 these results suggest that SANS is involved in the
functional network that is required for cohesion of the growing hair bundle [7].
Finally, the DFNB31 gene encodes whirlin, a PDZ scaffold protein with expression
in both hair cell stereocilia and retinal photoreceptors cells. Whirlin represents an excellent
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candidate for USH2 because it co-localizes and binds to usherin (USH2A) and VLGR1b
(USH2C), in both hair cell stereocilia and retinal photoreceptor cells [8]. Both whirlin and
myosin-15a, play a crucial role for the development and differential elongation of hair cell
stereocilia [8]. There is evidence that harmonin and whirlin can bind other components of
the USH network, including CDH23, PCDH15, Usherin, VLGR1 and myosin VIIa [2].
4.1.3 Usher Syndrome IIIB mutation in the gene for histidyl-tRNA synthetase.
The genetic mutation in human HARS linked to Usher Syndrome IIIB was
identified in children of an Old Order Amish population in Lancaster, Pennsylvania [9].
Autozygosity mapping indicated that a large homozygous block on chromosome 5q31 was
shared in three patients and exome data from two patients revealed 80 homozygous variants
within the mapped interval. Only one variant, HARS c.1361A.C (p.Tyr454Ser) (Figure
1A), was novel. Three carriers among 203 Old Order Amish controls (1.5%) were detected
[9]. Further evidence for pathogenicity was provided by an Old Order Amish patient who
was from an unrelated deme in Ontario, Canada. This Amish settlement arose from a
separate migration event from Europe than the Lancaster County settlement. The patient
had an identical phenotype to patients in PA and was homozygous for the HARS
c.1361A.C variant.
The Y454S HARS substitution associated with USH3B (OMIM #614504)
represents a striking example of a simple Mendelian trait encoding a single missense
substitution that presents as a complex human disorder [9]. Patients with USH3B exhibit
normal growth during infancy, but experience progressive loss of hearing and sight in the
first and second decades of life, respectively. For most patients, acute viral infections of
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febrile illness induce vivid hallucinations. USH3B patients also exhibit mild truncal ataxia,
wide based gait, and delayed motor development. No difference in either intracellular
levels of expression or cytoplasmic distribution was observed between the wild type (WT)
and the Y454S HARS enzyme [9]. While this disorder is rare in Lancaster County it is
common in the Amish Community of Northern Ontario with 12 afflicted individuals.
Typically, cochlear implants are done early and language development is essentialy
normal. Our recent communications with clinicians at the Children’s Health Research
Institute Ontario, Canada have divulged that several affected children from this population
have died with acute pulmonary edema during illnesses and the pathology of the lungs is
that of Adult Respiratory Distress Syndrome (ARDS). It was originally thought these were
cardiac deaths but autopsies showed that the severe pulmonary pathology was consistent
with ARDS.
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Figure 4.1. Y454S mutation disrupts hydrogen bonding interaction with E439.
A) The Y454S mutation is located in the anticodon binding domain beneath the floor of
the catalytic domain of the opposing monomer. B) Modeling the serine at Y454 position
in the anticodon binding domain creates a 6 Å gap between E439 and S454.
Previously, we collaborated with the clinic for Special Children in Lancaster PA to
study the catalytic defects of the Y454S HARS mutation found in the Amish community,
Y454S. Conclusions drawn from this study reported less than a two-fold difference in
aminoacylation function observed using murine WT and Y454S enzymes with whole
tRNA isolated from human placenta as a substrate [9]. Furthermore, no difference in either
intracellular levels of expression or cytoplasmic distribution was observed between the
wild type (WT) and the Y454S HARS enzyme [9].
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These current studies were undertaken to comprehensively examine the chemical
steps in catalysis for human WT HARS as a reference point in understanding in Y454S
mutation. We carried out kinetic studies of the human WT and Y454S HARS enzymes to
expand upon our earlier work analyzing not only multiple turnover kinetics for tRNAHis
but also for histidine. Furthermore, we measured the half reactions for amino acid
activation and aminoacylation of WT and Y454S HARS. Additionally, we explored the
hypothesis that WT and Y454S HARS differ with respect to thermal stability and
dimerization.
We carried out these studies to critically evaluate whether the USH3B phenotype
could be ascribed to a loss in the canonical aminoacylation function. The impact of the
Y454S USH3B substitution may not be a simple loss of aminoacylation function, but a
pathophysiological consequence of thermal instability linked to HARS protein
destabilization.
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4.2 Results
4.2.1 Purified wild type and Y454S enzymes prepared from human cell culture are
active.

Figure 4.2: Purification yields FLAG-tagged HARS.
Lysates (3ug total protein) from HEK293 cells transfected with FLAG-tagged WT HARS
or Y454S HARS were separated by 12% SDS-PAGE. HARS purified by FLAG resin and
ion exchange (0.1ug) was run adjacent. The gels were western-blotted using anti-FLAG
antibody (A) or anti-HARS antibody (B). Two different MW markers were run on each
gel.
In order to compare the kinetics of WT and Y454S HARS, we expressed and
purified human FLAG-tagged WT and Y454S HARS from human embryonic kidney
(HEK293) cells. The successful purification sequence included affinity and ion exchange
chromatography. A Western blot analysis showed that FLAG-HARS constituted 93% of
the purified protein, and less than 7% represented the endogenous untagged WT HARS
(Figure 4.2). On the basis of active site titration (described in Experimental Procedures),
purified enzymes contain at least 75% active protein on the basis of the maximum
amplitudes, a concentration of 3.4 µM and 4 µM AMP formation per active site was
determined for both the WT and Y454S enzyme preparations (Figure 4.3) .
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Figure 4.3. Monitoring AMP formation to determine human WT and Y454S
HARS activity
Rapid chemical quench was used to evaluate enzyme active sites. 5uM of WT HARS (A)
or Y454S (B) enzymes was mixed with 100 uM ATP in the presence of saturating
histidine (10 mM).
4.2.2 Wild type and Y454S HARS bind tRNA with comparable affinities.
Within the protein structure the USH3B Y454S substitution is located on helix 15
on the surface of the anticodon-binding domain, which is located proximal to the dimer
surface of the catalytic domain of the opposing monomer. Based on structure 4G85 [10],
Tyr454 hydrogen bonds with Glu439, a residue in a nearby β-sheet that forms a salt bridge
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with K148 across the interdomain interface to the catalytic domain of the opposing
monomer (Figure 4.1A). While the hydrogen bond may be disrupted by the substitution of
serine for Tyr454 (Figure 4.1B) the change in hydrophobic character of the position is also
lost. Y454 is conserved among eukaryotic species extending from the human to
Caenorhabditis elegans and the Trypanosoma (Figure 4.4A) [11]. In bacterial species (such
as Escherichia coli, Thermus thermophilus, and Staphylococcus aureus) however, the 454
position is occupied by a charged residue (Figure 4.4A). We tested this hypothesis by the
use of an EMSA to measure the tRNAHis binding of the Y454S mutant relative to WT.
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Figure 4.4. tRNAHis and total tRNA binding are unaffected by Y454S.
(A)Alignment and modeling of Thermus Thermophilius HARS bound to tRNA with
human HARS. tTHARS E372 and hsHARS Y454 do not mediate the same interactions
but both may impact tRNAHis binding and discrimination by the anti-codon binding
domain. Y454 (red) and E372 (dark blue) mediate different interactions in the anti-codon
binding domain. Y454 forms a hydrogen bond with E439 across the anticodon binding
domain akin to the salt bridge interaction between R376 (dark blue) and E358 (dark
blue).
(B) Y454S and HARS tRNAHis binding forward curve. HARS (circles) and Y454S
(triangles) varied from 0.1 to 30 µM. 32P-tRNAHis concentration was 30 nM. (C)
Competition Plot where transcribed tRNAHis bound to either HARS or Y454S was
competed by increasing concentrations of total tRNA purified from human placenta. 32PtRNAHis concentration was 30 nM, enzyme (HARS (circles) and Y454S (triangles)) was
5 µM and placental tRNA varied from 0 to 100 µM. Values reported are the mean ±
standard error of two independent experiments.
Binding reactions were conducted under conditions of excess protein with the
tRNA at a limiting concentration. Under the conditions reported, WT and Y454S HARS
exhibited identical apparent Kds of 7.9 ± 1.1 µM (Figure 4.4B). These apparent Kds were
dependent on assay conditions, most notably the percent of acrylamide gel used in the
electrophoresis (data not shown). Therefore, we can use this method only to determine an
upper limit of the Kd, and to compare the Kd of enzymes analyzed similarly.
In the cell, each ARS must select its correct tRNA from a pool including high
concentrations of non-cognate tRNAs. In addition, tRNAHis produced in vivo is modified
by conversion of the first guanosine in the anticodon to queuosine, relative to transcribed
tRNAHis [12]. In order to test whether WT and Y454S differ with respect to non-cognate
tRNAs, we carried out a binding competition experiment using

32

P-labeled tRNAHis

transcript as the primary ligand and total human placental tRNA as competitor. (A caveat
in the design of this experiment is that total tRNA contains ~1.4% native tRNAHis [9].) As
shown in Figure 4C, WT and Y454S responded in an identical fashion to the presence of
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increasing concentrations of unlabeled competitor tRNA. Thus, under the conditions
explored, differences in tRNA binding or tRNA binding specificity that could account for
the phenotype of Y454S were not observed.

4.2.3 Multiple turnover kinetics indicates the Y454S HARS mutant has
comparable kinetic parameters with wild type HARS.
The binding experiments suggested that the Y454S substitution does not
significantly affect tRNA recognition at the binding step. To more fully investigate the
effect of the substitution on aminoacylation function directly, steady state kinetic
parameters were determined for the tRNAHis transcript and histidine substrates. Under
steady state conditions where tRNA was the variable substrate, we observed that WT and
Y454S HARS had essentially equivalent Km values (WT, 1.2 ± 0.5 µM vs. Y454S, 0.9 ±
0.2 µM) and kcat values (WT, 3.9 ± 0.5 s-1 vs. Y454S, 4.4 ± 0.3 s-1) (Table 1). When histidine
was titrated as the variable substrate, the value of Km for Y454S was 1.7-fold decreased
relative to WT, and the value of kcat for Y454S was 1.4-fold greater than WT (Table 4.1).
In the previous comparison of mouse WT and Y454S enzymes with bulk human tRNA,
the ratio of relative kcat/Km for WT and Y454S HARS was approximately 1.5. Here, with
purified human enzymes and substrates, the ratios of kcat/Km for tRNA and for histidine
were larger for Y454S than WT, by factors of 1.6 and 2.4 respectively.
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Table 4.2. Steady state aminoacylation kinetics of tRNAHis by human and
bacterial histidyl-tRNA synthetases
Variable Substrate
tRNA

histidine

Enzyme

Km (μM)

kcat (s-1)

kcat/Km
(μM-1 s-1)

Km (μM)

kcat (s-1)

kcat/Km
(μM-1 s-1)

WT
HARS

1.2 ± 0.5

3.9 ± 0.6

3.2 ± 1.0

8.0 ± 4.0

4.1 ± 0.4a

0.5 ± 0.4

Y454S
HARS

0.9 ± 0.2

4.4 ± 0.3

5.1 ± 1.0

4.7 ± 2.5

5.9 ± 0.5a

1.2 ± 0.4

E. coli
HisRS

0.34 ± 0.05

1.71 ± 0.06

5.0

35 ± 4b

133 ± 2b

3.8b

Values reported are the mean ± standard error of three independent experiments.
a
Significantly different (extra sum-of-squares F test) p<0.05. bData are for histidine in the
pyrophosphate exchange reaction.
4.2.4 The Y454S variant has similar rates of amino acid activation and aminoacyl
transfer relative to wild type.
While not large, these differences prompted us to examine the adenylation and
aminoacylation half reactions separately. First, we examined the production of AMP under
pre-steady state conditions where ATP was the limiting substrate, but still in excess over
enzyme. As seen in Figure 4.3A and 4.3B, WT and Y454S HARS produced 3.4 µM ± 0.2
and 3.6 µM± 0.1 of AMP respectively in the first five seconds of the reaction. Based on a
concentration of 2.5 µM HARS dimers or 5 µM monomers in these reactions, this suggests
a product stoichiometry of 0.75 molecules of AMP formed per active site. At the end of
five seconds, the slopes of the progress curves approached zero suggesting that further
production of AMP had ceased. Prior to this plateau period, the rates of product formation
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were derived by fitting the progress curves in the first 500-800 milliseconds to a single
exponential followed by a linear phase. (Other equations, such as an isolated single
exponential or a double exponential, produced substantially poorer fits.) These fits
provided rates of 18.9 ± 15 s-1 and 18.2 ± 6 s-1, in the exponential phases for WT and Y454S
respectively, followed by rates of 2.8 ± 1.2 s-1 and 2.9 ± 0.7 s-1 for the respective linear
phases (Table 4.2). The values of the exponential phases for WT and Y454S were
essentially equivalent to the kobs1 for the first exponential for the rate of adenylate formed
by the E.coli enzyme under pre-steady state conditions [13]. This value is thought to
represent the rate of activation in the first subunit of the dimer, with the second
considerably slower. Consistent with the conclusions from the steady state analysis, these
measurements confirm that WT and Y454S catalyze the activation of histidine in the
absence of tRNA at the same rate. In the presence of tRNA, the rates of the exponential
and linear phases are increased by 2.5 -3 fold for WT and 1.2 -2.6 fold for Y454 (Figure
4.5A and 4.5B and Table 4.2).
Owing to the fact that the experiments were performed under conditions where the
ATP concentration (100 µM) was below Km, the rates reported are unlikely to represent the
maximal rate of amino acid activation. Values for the Km for ATP in aminoacylation
reactions previously reported in the literature include a value of 380 µM for rat HARS[14]
and 80 µM for rabbit HARS[15]. As the HARS sequence has high identity across
mammalian species, we expect these values to be a good estimate for human HARS.
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Accordingly, the maximal possible rates of amino acid activation catalyzed by both the
WT and the mutant are likely to be higher than reported here[13].
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Figure 4.5. Amino acid activation and the rate of histidine transfer is unaffected
by the Y454S mutation even in the presence of tRNAHis.
Amino acid activation (WT: panel A; Y454S: panel B) was monitored by mixing 5 µM
monomer HARS enzyme (WT: filled circles; Y454S: filled triangles) with 100 µM ATP
and saturating histidine. tRNAHis (25 µM) addition (empty circles and empty triangles,
insets: note 0.5 s time scale) increased the rate of amino acid activation, which was
determined by linear fit within the first turnover.
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Table 4.3: Pre-steady state rate for amino acid activation
Rate of amino acid activation
Reactants
WT HARS (n=3)

Rate of exponential phase
(s-1)
19 ± 15

Rate of linear phase k1
(s-1)
a
3±1

WT HARS + tRNAHis (n=2)

47 ± 21

9.1 ± 0.7a

Y454S (n=2)

18 ± 6

2.8 ± 0.7b

Y454S HARS + tRNAHis (n=2)

21 ± 5

6.4 ± 0.6b

Values reported are the mean ± standard error of n independent experiments. a
Significantly different at p<0.05. b Significantly different at p<0.01 (extra sum-ofsquares F test).
In order to address whether the WT and mutant enzymes differ with respect to the
rate of aminoacyl transfer, a single turnover experiment was performed. As described in
Methods, WT and Y454S HARS were each pre-incubated with ATP and histidine to preform the enzyme-adenylate complex in situ. Using rapid chemical quench techniques, rates
of 30 ± 6 s-1 and 30 ± 4 s-1 were determined (Table 4.3, Figure 4.6A and 4.3B). Notably,
the single turnover rates of both human enzymes were essentially equivalent, further
supporting the kinetic equivalence of WT and Y454S HARS. It is also potentially of
interest that these rates were both considerably faster than the 18.1 s-1 previously reported
for E. coli HisRS[16, 17]. In summary, the small increase in Y454S steady state kcat is not
accounted for by differences in either isolated pre-steady state amino acid activation or
aminoacyl transfer partial reactions.
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Figure 4.6. Aminoacyl transfer of WT and Y454S
The rate constant for histidine transfer ktrans (WT: panel A Y454S: panel B) was
determined by single turnover with 2 µM enzyme, preformed with histidyl-adenylate, and
mixed with 100 nM tRNAHis. ktrans was determined by fit to a single exponential. The
number of experiments is reported in Tables 2 and 3.
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Table 4.4. ktrans for Y454S and WT HARS
Single turnover aminoacyl transfer
Enzyme

ktrans (s-1)

References

WT HARS (n=4)

30 ± 6

This work

Y454S (n=6)

30 ± 4

This work

E.coli HARS

18.8 ± 2.5

[16]

Values reported are the mean ± standard error of n independent experiments. No
difference by extra sum-of-squares F test.
4.2.5 The Y454S substitution reduces the thermal stability of HARS but not
dimerization.
The observations reported above suggested that the Y454S substitution has minimal
consequences for HARS function as determined in the standard assays for aminoacylation.
Inspection of the human HARS structure leaves open the possibility that the substitution
nevertheless influences protein stability by weakening inter-domain dimeric interactions.
To further assess the dimer stability of Y454S HARS, we performed sedimentation velocity
experiments (SV) and compared the results to those obtained from WT. As an additional
comparison, we also evaluated the SV of a temperature sensitive (ts) version of HARS
originally isolated in BHK21 cells (tsBN250) that encodes an R362H substitution[18]. We
hypothesized that if a mutant dimer were less stable than the WT, it would exhibit an
increased Kd concentration and display a shift in the sedimentation coefficient distribution
when it more readily dissociates into monomer. This effect would be enhanced at low
concentration. Therefore, we measured the SV experiments at 230 nm where the extinction
coefficient is significantly higher compared to the standard 280 nm absorbance, which
allowed us to monitor at lower concentration. Data quality at 230 nm is also higher due to
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the high light emission intensity of the Xenon lamp used in the ultracentrifuge.

Figure 4.7. Molar mass distributions determined by sedimentation velocity.
Showing the PCSA-Monte Carlo distributions for HARS WT (black), HARS Y454S
(red), and HARS R362H (blue). Molar masses are in excellent agreement with a dimer of
each species. B. Frictional ratio anisotropies for HARS WT (black), HARS Y454S (red),
and HARS R362H (blue) as a function of the sedimentation coefficient. Pseudo-3D plots
derived from PCSA-Monte Carlo analyses of sedimentation velocity experiments. The
right vertical axis indicates the partial concentration in terms of color density.
Molar mass distributions from HARS mutants and WT are shown in Table 4.4,
demonstrating remarkable similarity between WT and HARS mutants. The molar mass of
the major species observed for each sample is in excellent agreement with the dimer form
of HARS (Figure 4.7A). Detailed integration results for the Monte Carlo analysis are
reported in Table 4.4. Pseudo-3D overlays of the anisotropy vs. sedimentation coefficient
for each species are shown in Figure 4.7B. These results conclusively show that the mutant
forms of HARS are equally stable under the conditions used for the SV experiments as
HARS WT.
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Table 4.5. PSCA- Monte Carlo results (straight-line parameterization) from
HARS sedimentation velocity experiment.

Values in parenthesis are 95% confidence intervals from the Monte Carlo analysis. The theoretical molar
mass of HARS WT dimer is 114.9 kDa, indicating the observed species is a dimer. The residual mean
square deviation (RMSD) of the fit is shown in units of absorbance at 230 nm.

The work described thus far suggests that the Y454S substitution has minimal effect
on substrate recognition (when assessed kinetically) and overall dimer formation.
However, these prior analyses might not be able to detect subtler structural effects, such as
those associated with localized protein unfolding. To test this hypothesis, we used
differential scanning fluorimetry (DSF) to measure the transition temperature for molten
globular formation, which will be referred to herein as Tm. Melting profiles were initially
performed in the absence of substrates, yielding Tm’s of 50.7 ± 0.4 °C and 45.5 ± 0.7 °C for
WT and Y454S HARS, respectively (Figure 4.8B, summarized in Table 4.5). The 5 °C
temperature decrease observed with the mutant relative to WT provided the first evidence
in temperature instability for Y454S. The unliganded melting profile for Y454S was only
2°C higher than the value determined for ts R362H (44.1 ± 0.2 °C), a bonafide temperature
sensitive mutant in HARS described earlier[18]. The close Tm values for Y454S and
R362H support the conclusion that the Y454S substitution destabilizes the HARS enzyme
structure in a manner similar to R362H and in fact confers temperature sensitivity.
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Figure 4.8. Y454S mutation is thermally less stable relative to WT HARS.
10 µM enzyme (WT black circles, Y454S red triangles and R362H blue squares) was
incubated with Sypro Orange dye in the absence (filled symbols) of substrate, or presence
of 5 mM histidine (empty symbols). A) Wild type ± histidine. B) Wild type vs. Y454S. C)
Y454S ± histidine. D) R362H ± histidine. Thermal shift results are from two preparations
of WT and Y454S enzymes each measured in triplicate.
Previously, it has been shown that histidine is a stabilizing substrate for HARS[19].
We therefore evaluated the effect of all three HARS substrates on the apparent melting
transition of the enzymes. Consistent with the conclusions that histidine stabilizes the
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HARS active site, the addition of 5 mM histidine increased the Tm for all three enzymes by
6.3 - 8 °C. By contrast, ATP and tRNAHis showed less pronounced stabilizing effects on
Tm, providing increases in the Tm in the range of 1 - 2 °C for both WT and Y454S mutant
enzymes. Interestingly, the R362H substitution exhibited larger stabilizing effects for these
substrates, corresponding to 4.1 and 7.2 °C for ATP and tRNA, respectively. In summary,
both Y454S and R362H HARS displayed significant decreases in thermal stability relative
to the WT protein, in the presence and absence of substrates. While both substitutions could
be described as conferring temperature sensitivity, the two mutations were distinguished
by different responses to individual substrates, with R362H exhibiting substantially
increased stability with binding all three substrates, and Y454S responding only to histidine
(Table 4.5 and Figure 4.8C).
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Table 4.6: Thermal stability of HARS enzymes with substrates
Enzyme

Tm °C

Δ Tm °Ca

Δ Tm °Cb

WT

51.7 ± 0.4c

WT + histidine

58.8 ± 0.4

7.0

-

WT + ATP

53.8 ± 0.2

2.0

-

WT + tRNAHis

53.4 ± 0.4

1.7

-

Y454S

46.3 ± 0.7c

-

-5.4

Y454S + histidine

54.4 ± 0.5

8.1

-4.4

Y454 + ATP

47.0 ± 0.5

0.7

-6.8

Y454S + tRNAHis

48.5 ± 0.4

2.2

-4.9

R362H

44.1 ± 0.2c

-

-7.7

R362H + histidine

50.4 ± 0.4

6.3

-8.4

R362H + ATP

48.2 ± 0.5

4.1

-5.6

R362H + tRNAHis

51.3 ± 0.3

7.2

-2.1

-

a

Relative to the apo form of the same enzyme. bRelative to the same form of WT HARS enzyme. Values
reported are the mean ± standard error of 2 independent experiments in triplicate (1 experiment in triplicate
for R362H). cValues that are significantly different WT to Y454S or R362H, p<0.0001 (extra sum-of-squares
F test). #Concentaration of tRNAHis tested was 10 uM *Concentration of tRNAHis tested was 20uM.

4.2.6 Elevated temperature results in lowered de novo protein synthesis in patient
fibroblasts.
The observed reduced thermal stability of the Y454S substituted HARS and the
clinical association of acute illnesses including hallucinations and interstitial lung disease
with febrile events in USH3B patients prompted us to assess the incorporation of 3H–
histidine into total protein, a measure of cellular protein translation, in cultured WT and
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Y454S human primary fibroblasts. WT and Y454S fibroblasts incorporated 3H–histidine
into cultured fibroblasts at the same rate at 37 °C. However, when the fibroblasts were
cultured at 43 °C, the incorporation of 3H –histidine into total cellular protein in the WT
fibroblasts was about 7 –fold greater than in the Y454S fibroblasts. (Figure 4.9). Thus, the
temperature sensitivity of Y454S detected in vitro has consequences for protein synthesis
in vivo.

Figure 4.9. Human fibroblasts from patients with the Y454S mutation
demonstrate less de novo protein synthesis at elevated temperatures than wild type
cells.
Scatter plot showing 3H-histidine incorporation into total cellular protein (values
normalized to cellular DNA), Y454S cells (circles) and wild type cells (squares). Values
shown include three replicates each for three Y454S cell lines and three replicates each
for six wild type cell lines (culture temperature 37 °C solid symbols, 43 °C open
symbols). Bars indicate the mean +/- SEM. Statistical significances were determined by
Welch’s t-test.
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4.3 DISCUSSION
In this study, we critically evaluated the hypotheses that USH3B results from a
decrease in canonical HARS catalyzed aminoacylation function. Rates were determined
for both partial reactions, including the amino acid activation and aminoacyl transfer steps,
and the overall rate of aminoacylation. The main conclusion from these studies is that,
under the conditions examined, no significant differences in aminoacylation could be
observed in a comparison of WT and Y454S. At the gross structural level, sedimentation
velocity experiments revealed no difference in the strength of dimer formation. By contrast,
the DSF assay indicated that the two proteins exhibited significant differences in the Tm.
In addition, translation was significantly impaired in USH3B patient fibroblasts at elevated
temperatures. These results provide a new context to rationalize the linkage of the Y454S
HARS mutant to USH3B.
4.3.1 Structural context of the Y454S substitution, and its apparent minimal effect
on aminoacylation.
The USH3B Y454S substitution is located on helix 15 on the surface of the
anticodon-binding domain, which is located proximal to the dimer surface of the catalytic
domain of the opposing monomer [10]. The substitution of serine for Tyr454 (Figure 4.1B)
changes the hydrophobic character of this position, while also removing a likely hydrogen
bond with Glu 439. Tyr454 is conserved among eukaryotic species extending from the
human to yeast (Saccharomyces) [19]. In bacterial species (such as Escherichia coli and
Staphylococcus aureus) however, the residue corresponding to Y454 positions is a charged
residue, and in the case of Thermus thermophilus, hydrophobic. The helix harboring the
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Y454S substitution in the anticodon-binding domain is predicted to make direct or indirect
contacts to the phosphodiester backbone of the tRNA anticodon arm[20]. While initial
expectations were that the mutation might affect binding affinity to tRNA, our results
indicate that tRNA binding specificity of Y454S was not disrupted (Figure 4.4). Previously,
an Escherichia coli HisRS mutant with the double substitution of G96D and R104H was
uncovered in a genetic selection for altered tRNA binding specificity[21]. Kinetic
characterization of the mutant protein showed that it exhibits reduced discrimination for
the specific sequence of the tRNAHis anticodon [21]. While the similar location of R104
and Y454 in the catalytic:anticodon-binding domain interface encourages one to speculate
about similar functional effects, the E. coli mutant enzyme with the single R104H mutation
remains to be characterized. Modeling studies of the human HARS:tRNAHis complex (not
shown) suggest that Y454 is likely to have at most only an indirect effect on tRNA binding
through perturbations of contacts to the phosphodiester backbone, which is in agreement
with our results.
A detailed analysis of human HARS kinetics showed that with respect to the
individual half reactions of amionacylation and with respect to all parameters examined,
WT and Y454S were virtually equivalent. Key parameters that were essentially equivalent
for the two enzymes included the Km for tRNA and the overall kcat for aminoacylation when
tRNA was the variable substrate. When histidine was the variable substrate in the presence
of saturating tRNA Y454S HARS was slightly more active, as reflected in a higher kcat and
slightly lower Km.
The discrepancy in values of kcat between conditions where tRNA was saturating
and conditions where histidine was saturating could arise from several sources. One
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possibility is that there is a discrepancy in the calculation of active sites for different
preparations, which would affect the values of kcat. Alternatively, the Y454S mutant could
have a bona fide differential interaction with tRNA, leading to either an increased
percentage of correctly folded protein in the presence of saturating tRNA, or a faster
dissociation of aminoacylated product. Either scenario highlights the fact that kcat measures
the limiting rate in the overall catalytic cycle, and incorporates all elementary steps
including product release. Clearly, not all of these features nor the full catalytic
contribution of the dimeric structure (e.g. potential alternating catalysis in the two active
sites of the dimer [17] are captured in the pre-steady state experiments. In any event, the
increase in kcat seen with Y454S HARS is relatively slight, and supports the conclusion that
the effect of the mutant in Usher syndrome is unlikely to be due to a loss in catalytic
efficiency, as measured in a purified system.
These findings support the conclusions of an earlier study that reported less than a
two-fold difference in aminoacylation functions of the WT and Y454S enzymes [9].
Notably, the values of Km for tRNAHis determined in the two studies were virtually
identical, despite the fact that the earlier study employed murine enzyme preparations and
total human tRNA as substrate.
Adenylation kinetics determined in the presence of tRNA highlighted a potential
difference from the E. coli enzyme. In the E.coli enzyme, the progress curve for the
formation of AMP in the absence of tRNA is best described as a double exponential
followed by a linear rate [13]. In the presence of tRNA, these complex kinetics reduce to a
linear progress curve over multiple turnovers [16]. This was interpreted to suggest that the
presence of tRNA inhibits the rate of amino acid activation in the first subunit of the dimer,
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while increasing the same rate in the second subunit. The equalization of rates is thought
to reflect the coupling of activities of the two active sites in the dimer and the linkage of
dissociation of product from subunit one to formation of product in subunit two [13]. The
rate of adenylation in the human HARS enzyme did not show the same attenuation by the
presence of tRNA, suggesting a potential mechanistic difference between these structurally
similar enzymes. This difference remains to be explored further in additional experiments.
4.3.2 The Y454S substitution is less thermally stable compared to wild type HARS.
While the results of standard aminoacylation assays argue strongly against the
model that the USH3B phenotype arises from an aminoacylation defect, the potential
structural changes (Figure 4.1B) suggest a possible decrease in protein stability by virtue
of the weakening intra- or inter-domain interactions. Here, we used sedimentation velocity
analysis to assess the dimer status of the mutant, and saw no apparent weakening of dimeric
structure (Figure 4.7). SV experiments characterize the solution behavior of
macromolecules and report on the sedimentation and diffusion behavior of all species in a
mixture. Information is also provided about the partial concentrations of various species,
buoyant molar masses, and anisotropies. Even at low concentrations, HARS and the
temperature sensitive mutants maintained their dimeric structure, indicating the mutation
alone does not alter enzyme dimerization, consistent with the binding and kinetic analyses.
Originally developed as a high throughput method for quantitatively assessing the
strength of small molecule protein interactions, the DSF assay has proven useful in other
contexts, such as profiling protein constructs for their suitability in crystallographic studies.
Here, DSF assays were used to indirectly compare the Tm of WT and Y454S HARS, and
the effects of substrates on protein stability. The clear result was that the Y454S
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substitution decreases the Tm for HARS in the range of 5-6 °C. Moreover, as evidenced by
the gain in Tm, each of the three canonical substrates (His, ATP and tRNAHis) provided the
same enhancement of protein stability as seen with WT HARS. This supports the earlier
conclusion that Y45S has minimal effect on the recognition of any of individual substrates,
versus overall stability. By contrast, the R362H mutant showed increased Tm in the
presence of ATP and tRNA relative to the other proteins, suggesting a greater propensity
to stabilization by these substrates. It will be of interest to determine whether this signature
holds true for other bona fide temperature sensitive mutants.
The inability of fibroblast cultures from patients with the HARS Y454S mutation
to incorporate [3H]-histidine into total cellular protein at elevated temperature, when
compared to control fibroblasts, is a key finding. Notably, there was no difference in
incorporation at 37 °C, but only when the cell was stressed at 43 °C. Although the
temperature used in the cell culture experiments cannot be directly compared with febrile
conditions in patients or with the DSF results, this finding comports with the clinical
observation that febrile illnesses evoke the USH3B phenotype [9],
These observations and the qualitatively similar results obtained with R362H
HARS strongly suggest that decreased temperature stability underlies the molecular basis
of the USH3B syndrome. This interpretation is supported by the direct experimental
comparison of Y454S HARS to the R362H substitution (Figure 4.8D). The latter mutant
was derived from the tsBN250 BHK cell line, which was isolated in an unbiased screen for
cell cycle arrest mutants [18, 22]. Consistent with a temperature sensitive phenotype,
tsBN250 cells exhibited decreased cell growth and increased apoptosis at elevated
temperatures. In both the tsBN250 and related tsBN269 BHK cells (which carry a ts LysRS
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allele), cell cycle arrest was attributed to decreased cyclin D1 production, which resulted
from decreased 3H incorporation into the total protein pool. Growth defects could be
overcome by supplementation of high concentrations of histidine or inducing expression
of cyclin D1[18]. Given that Y454S and R362H HARS are accompanied by similar
decreases in protein stability, we can hypothesize that elevated temperatures (or other
physiological stresses) might cause reduced protein synthesis in the mutant cells, leading
to cell cycle arrest and apoptosis. In a specific G296D ValRS mutant isolated in C. elegans,
altered editing domain function is predicted to reduce global translation by inappropriately
deacylating Val-tRNAVal at high temperatures. The reduction in aminoacylated ValtRNAVal subsequently results in mitotic cell arrest of stem cells within the organism[23].
This hypothesis might at first glance appear to contradict some observed features
of Y454S HARS, including the lack of an apparent effect on intracellular protein levels[9]
and a lack of an effect on primary aminoacylation function (this work). Of note, the
intracellular protein levels were determined in unstressed cells cultured at normal
temperature [9]. Again, the comparison with R362H HARS is instructive. Notably, no
apparent degradation of the R362H enzyme was observed in tsBN250 BHK at increased
temperatures[18, 22]. Further, thermal sensitive aminoacyl-tRNA synthetase mutations
were originally described as mutations that disrupt normal cellular growth and division,
and sensitivity to increased temperature in CHO cell lines with ARS defects could be
alleviated by high concentrations of cognate amino acid[24]. These CHO cell lines are His1, with a temperature sensitive mutation in HisRS, and Arg-1, with a temperature and
arginine-sensitive mutation in arginyl-tRNA synthetase[24]. Curiously, while His-1 and
Arg-1 CHO cell lines showed decreased 3H incorporation into the total protein pool, there
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was not a clear impairment of aminoacylation activity in vivo[24]. Accordingly, our
inability to detect decreased aminoacylation function with Y454S HARS under specified
in vitro conditions may not rule out the possibility of decreased function in vivo,
particularly at elevated temperatures. Along these lines, it should prove instructive to
conduct a kinetic characterization of the R362H enzyme, and determine whether or not it
too exhibits relatively robust aminoacylation function in vitro.
4.3.3 Comparison to other ARS linked diseases.
Our study adds to a growing body of literature in which mutations encoding
missense substitutions in aminoacyl-tRNA synthetases have been linked to a variety of
neurological disorders, most notably CMT syndrome [25, 26]. Among the tRNA
synthetases implicated in this way are GlyRS[26-28], AlaRS[29, 30], GlnRS[31],
LysRS[32], and TyrRS[33]. While for many of these examples a significant loss in
aminoacylation function has been documented[26-28], there are also a few notable reports
where retention of aminoacylation activity has been claimed[34, 35]. These latter examples
raise the possibility that, at least for some ARS-linked diseases, the molecular basis of
pathophysiology may arise from features that are distinct from a loss of primary function
under normal physiological conditions.
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4.3.5 CONCLUSIONS
Here, we have shown that perturbation of the primary aminoacylation function is
unlikely to fully account for the basis of disease for the Y454S mutation, as compared to
other ARS mutants linked to CMT that exhibit a clear loss of aminoacylation function when
measured in vitro[28]. Further work will be necessary to determine how the thermal
instability of the Y454S HARS enzyme plays a role in USH3B disease progression in the
context of the cellular environment. A multi-factorial approach will be required, with
investigations into the role of Y454S in the cellular stress response and Y454S HARS
interactions with other proteins, which may entail HARS secondary functions, yet to be
identified.

164

References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.

Millan, J.M., et al., An update on the genetics of usher syndrome. J Ophthalmol,
2011. 2011: p. 417217.
Yan, D. and X.Z. Liu, Genetics and pathological mechanisms of Usher syndrome.
J Hum Genet, 2010. 55(6): p. 327-35.
Weil, D., et al., Usher syndrome type I G (USH1G) is caused by mutations in the
gene encoding SANS, a protein that associates with the USH1C protein, harmonin.
Hum Mol Genet, 2003. 12(5): p. 463-71.
Di Palma, F., et al., Mutations in Cdh23, encoding a new type of cadherin, cause
stereocilia disorganization in waltzer, the mouse model for Usher syndrome type
1D. Nat Genet, 2001. 27(1): p. 103-7.
Reiners, J., et al., Molecular basis of human Usher syndrome: deciphering the
meshes of the Usher protein network provides insights into the pathomechanisms
of the Usher disease. Exp Eye Res, 2006. 83(1): p. 97-119.
Reiners, J. and U. Wolfrum, Molecular analysis of the supramolecular usher
protein complex in the retina. Harmonin as the key protein of the Usher syndrome.
Adv Exp Med Biol, 2006. 572: p. 349-53.
Weil, D., et al., Defective myosin VIIA gene responsible for Usher syndrome type
1B. Nature, 1995. 374(6517): p. 60-1.
Ebermann, I., et al., A novel gene for Usher syndrome type 2: mutations in the long
isoform of whirlin are associated with retinitis pigmentosa and sensorineural
hearing loss. Hum Genet, 2007. 121(2): p. 203-11.
Puffenberger, E.G., et al., Genetic mapping and exome sequencing identify variants
associated with five novel diseases. PLoS One, 2012. 7(1): p. e28936.
Xu, Z., et al., Internally deleted human tRNA synthetase suggests evolutionary
pressure for repurposing. Structure, 2012. 20(9): p. 1470-7.
Koh, C.Y., et al., Comparison of histidine recognition in human and
trypanosomatid histidyl-tRNA synthetases. Biochimie, 2014. 106: p. 111-20.
Katze, J.R. and W.R. Farkas, A factor in serum and amniotic fluid is a substrate for
the tRNA-modifying enzyme tRNA-guanine transferase. Proc Natl Acad Sci U S A,
1979. 76(7): p. 3271-5.
Guth, E., et al., Asymmetric amino acid activation by class II histidyl-tRNA
synthetase from Escherichia coli. J. Biol. Chem., 2009. 284(31): p. 20753-62.
Fahoum, S.K. and D.C. Yang, Purification of mammalian histidyl-tRNA synthetase
and its interaction with myositis-specific anti-Jo-1 antibodies. Biochemistry, 1987.
26(18): p. 5871-7.
Kane, S.M., et al., Purification and some properties of the histidyl-tRNA synthetase
from the cytosol of rabbit reticulocytes. Biochemistry, 1978. 17(8): p. 1509-14.
Guth, E., et al., A substrate-assisted concerted mechanism for aminoacylation by a
class II aminoacyl-tRNA synthetase. Biochemistry, 2005. 44(10): p. 3785-94.

165

17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.

Guth, E.C. and C.S. Francklyn, Kinetic discrimination of tRNA identity by the
conserved motif 2 loop of a class II aminoacyl-tRNA synthetase. Mol Cell, 2007.
25(4): p. 531-42.
Motomura, S., et al., A hamster temperature-sensitive G1 mutant, tsBN250 has a
single point mutation in histidyl-tRNA synthetase that inhibits an accumulation of
cyclin D1. Genes Cells, 1996. 1(12): p. 1101-12.
Koh, C.Y., et al., Comparison of histidine recognition in human and
trypanosomatid histidyl-tRNA synthetases. Biochimie, 2014. 106C: p. 111-120.
Tian, Q., et al., Structural basis for recognition of G-1-containing tRNA by histidyltRNA synthetase. Nucleic Acids Res, 2015.
Yan, W., J. Augustine, and C. Francklyn, A tRNA identity switch mediated by the
binding interaction between a tRNA anticodon and the accessory domain of a class
II aminoacyl-tRNA synthetase. Biochemistry, 1996. 35(21): p. 6559-6568.
Fukushima, K., et al., A single point mutation of hamster aminoacyl-tRNA
synthetase causes apoptosis by deprivation of cognate amino acid residue. Genes
Cells, 1996. 1(12): p. 1087-99.
Rastogi, S., et al., Caenorhabditis elegans glp-4 Encodes a Valyl Aminoacyl tRNA
Synthetase. G3 (Bethesda), 2015. 5(12): p. 2719-28.
Thompson, L.H., D.J. Lofgren, and G.M. Adair, CHO cell mutants for arginyl-,
asparagyl-, glutaminyl-, histidyl- and methionyl-transfer RNA synthetases:
identification and initial characterization. Cell, 1977. 11(1): p. 157-68.
Sivakumar, K., et al., Phenotypic spectrum of disorders associated with glycyltRNA synthetase mutations. Brain, 2005. 128(Pt 10): p. 2304-14.
Antonellis, A., et al., Functional analyses of glycyl-tRNA synthetase mutations
suggest a key role for tRNA-charging enzymes in peripheral axons. J Neurosci,
2006. 26(41): p. 10397-406.
Deng, X., et al., Large Conformational Changes of Insertion 3 in Human GlycyltRNA Synthetase (hGlyRS) during Catalysis. J Biol Chem, 2016. 291(11): p. 574052.
Griffin, L.B., et al., Impaired function is a common feature of neuropathyassociated glycyl-tRNA synthetase mutations. Hum Mutat, 2014. 35(11): p. 136371.
Simons, C., et al., Loss-of-function alanyl-tRNA synthetase mutations cause an
autosomal-recessive early-onset epileptic encephalopathy with persistent
myelination defect. Am J Hum Genet, 2015. 96(4): p. 675-81.
McLaughlin, H.M., et al., A recurrent loss-of-function alanyl-tRNA synthetase
(AARS) mutation in patients with Charcot-Marie-Tooth disease type 2N (CMT2N).
Hum Mutat, 2012. 33(1): p. 244-53.
Zhang, X., et al., Mutations in QARS, encoding glutaminyl-tRNA synthetase, cause
progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures.
Am J Hum Genet, 2014. 94(4): p. 547-58.
McLaughlin, H.M., et al., Compound heterozygosity for loss-of-function lysyl-tRNA
synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet,
2010. 87(4): p. 560-6.
166

33.
34.
35.

Jordanova, A., et al., Disrupted function and axonal distribution of mutant tyrosyltRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat
Genet, 2006. 38(2): p. 197-202.
Froelich, C.A. and E.A. First, Dominant Intermediate Charcot-Marie-Tooth
disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase. Biochemistry,
2011. 50(33): p. 7132-45.
van Berge, L., et al., Pathogenic mutations causing LBSL affect mitochondrial
aspartyl-tRNA synthetase in diverse ways. Biochem J, 2013. 450(2): p. 345-50.

167

5.0 DISCUSSION AND FUTURE DIRECTIONS
The HARS system represents a notable example in which two different complex
human diseases arise from distinct mutations in the same parent gene. Results from kinetic
assays described demonstrated that all of the HARS CMT variants have catalytic defects.
From these studies the structural integrity of only two mutations were compromised
V155G and R137Q. However, all CMT variants can form stable dimers. Additionally,
assays utilizing neuronal PC12 cells have established that CMT variants can reduce the
average neurite length. Furthermore, CMT HARS variants were localized out to the distal
most end of processes in PC12 cells.
By contrast, the recessive HARS USH3B variant, Y454S, was shown to be
kinetically indistinguishable from WT for the independent catalytic steps as well as for the
overall aminoacylation reaction. Interestingly, the Y454S variant also formed stable dimers
but is thermally unstable. This single biochemical characteristic reduces aminoacylation at
elevated temperatures, and likely accounts for the pathogenicity of Y454S. Data in this
thesis emphasizes that while some dominant variants have catalytic defects, one cannot
always assume that variants are going to be a clear loss of aminoacylation function.

5.1 The structural locations of pathogenic variants
In the case of HARS, the different disease variants are restricted to different
domains – CMT variants are localized to the catalytic domain, while the USH3B and
R362H variants are restricted to the anticodon binding domain. Previously, four additional
HARS variants identified in patients with peripheral neuropathy [1], were found to also
168

localize to the catalytic domain (Figure 1) [2]. These four variants (T132I, D175E, P134H,
and D365Y) can be found in motifs that have essential functions in the amino acylation
reaction. T132I is found in a histidine binding motif ‘TXE’ within the catalytic domain,
P134H is located in the same helix as R137Q (although it does not mediate cross dimer
interactions), D175E is localized to motif loop 2 and D364Y is found in the HARS family
conserved His B motif (Figure 5.1). While two of these substitutions do not apparently
alter direct contacts with substrate, they may indirectly alter enzyme structure and perturb
aminoacylation activity, as was the case for V155G. To date, all known HARS CMT
mutations are located in the catalytic domain.
By comparison, the 12 GARS variants that have been associated with CMT disease
are distributed over all major domains of the protein, including the WHEP domain,
catalytic domain, anticodon binding domain, and in the relatively unstructured insertion
loops [2]. Initial attempts to map many of the original GARS CMT variants to an
unliganded structure of GARS led to the proposal that, instead of loss of aminoacylation,
linkage to CMT is more strongly correlated with altered dimer stability [3].
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Figure 5.1. Four additional HARS CMT variants that are localized to the catalytic
domain.
Variants are shown as red sticks with histidine bound and shown as green sticks.
For at least some of the variants, this hypothesis was supported by the results of
sedimentation equilibrium experiments, which indicated that several (e.g, L129P, G240R)
displayed increased Kd for dimer dissociation, and two (G526R and G598A) exhibited
reduced dissociation constants for dimerization. The recent X-ray structure of the GARStRNAGly complex provides an opportunity to re-examine the question of how GARS CMT
variants might exert their effects on GARS structure and function [4]. The results of that
re-examination suggest that CMT-associated GARS variants proteins can be broken into
three groups: (1) those variants that specifically disrupt the dimeric interface (L129P,
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G240R, and potentially H418R); (2) those mutants that likely disrupt interactions with ATP
or tRNA (P244L, I280F, G526R, and G598A); and (3) those variants which are located
away from substrate binding regions, or are located in loop regions not defined in the
existing structures (A57V, E71G, D146N, C157R, D500N). Of note, the variants that lack
aminoacylation function fall into Groups 1+2, while the partially active mutants fall into
Group 3. Hence, in GARS, as in other aaRSs, loss of aminoacylation appears to correlate
with disruption of either interaction with substrates and/or the opposing monomer.
Conversely, variants (e.g., E71G and D500N) that do not appear to affect aminoacylation
(i.e., based on the in vitro assays used) are either distal to interactions with substrates or
are located in unstructured regions of the enzyme.
As earlier studies attributed disruptions in dimerization as the pathogenic variable
for many of the GARS mutations this is clearly not the case for HARS. Hence,
perturbations to the dimeric nature of aaRS enzymes are unlikely to completely satisfy the
requirement for pathogenesis. However, a notable characteristic that many aaRS variants
share is their high level of evolutionary conservation [2]. Hence, it is likely that either
variants perturb aminoacylation activity or disrupt structure and leads to disease
progression [2].

5.2 Pathology is linked to a reduction in protein synthesis
As aaRS enzymes are essential for protein synthesis, it raises the question as to how
perturbations in protein synthesis contribute to disease without conferring lethality. Results
of the enzyme assays described in this thesis emphasize that CMT HARS variants localized
to the catalytic domain do disrupt the process of aminoacylation to varying extents. The
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four HARS mutations linked to CMT described here have defects in aminoacylation
activity. While HARS CMT variants clearly have catalytic defects, similar observations
have been made previously for other CMT-associated aaRS enzymes. Notably, GARS
CMT variants have been characterized with respect to aminoacylation at varying degrees
of completeness. Some have been characterized with respect to Michaelis–Menten
parameters as a function of tRNA concentration [5] while others have only been
characterized as either single end-point assays or a single-product progress curve at one
concentration of enzyme and substrates [3]. Further, KARS [6], AARS, HARS [1], and
MARS [7] biochemical analysis suggests that the CMT-linked mutations in each case
confer at least a partial loss of aminoacylation function.
While GARS and YARS enzymes also contain multiple CMT-linked variants,
many of which have defective aminoacylation, there are some that appear to retain
significant activity. In the case of YARS, the G41R and 153-156DVKQV variants are
reported to have significantly reduced activity [8] but the E196K variant appears to be
much more active, or even unaffected [9]. However, the E196K variant and another CMTassociated variant at the same codon (E196Q) were unable to fully support yeast cell
growth in complementation studies [8, 10]. Studies employing a D. melanogaster model
of CMT showed that, despite its near wild type activity in vitro, the E196K YARS variant
leads to decreased protein synthesis rates in flies [11]. In the Drosophila system, overexpression of selected GARS and YARS variants (E71G and E196K, respectively) led to
defects in motor neuron performance, shortened lifespan, and were highly correlated with
reduced protein synthesis. Notably, the variants exhibited aminoacylation activity in vitro
and produced high levels of aminoacylated tRNA in vivo. Based on these results, the
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authors concluded that the variants exhibit a dominant negative effect on protein synthesis
that could not be reversed by over expression of the wild type protein. The mechanism that
leads to the cellular inhibition of protein translation was not determined.
In our studies of Type IIIB Usher Syndrome, we have also observed that, despite
the essentially wild type levels of aminoacylation activity in vivo, patient fibroblasts
homozygous for the mutation exhibit reduced protein synthesis at the an elevated
temperature [12]. Increasing the temperature for in vitro aminoacylation assays did not
reduce the enzyme activity of either WT or Y454S HARS (Figure 5.2). Again, in vitro
aminoacylation assays fail to recapitulate the observations from the patient cells. By
contrast, the temperature sensitive R362H HARS variant did not appear to have activity
equivalent to WT under these conditions. Preliminary multiple turnover kinetics titrating
tRNAHis as the variable substrate indicated that R362H has activity comparable to WT
HARS when measure at 37℃ (Figure 5.3). However, definitive conclusions regarding the
catalytic activity of R362H HARS awaits further replicates and additional assays with
varying histidine and ATP concentrations. When this information is in hand, a more
accurate comparison to the USH3B and CMT variants of HARS will be possible.
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Figure 5.2. Aminoacylation as a function of increasing temperature.
Time course of aminoacylation activity for 1 nM WT (black circles) and Y454S (red
triangles) HARS at 40℃ with low histidine (2𝜇𝑀) with saturating ATP (10 mM) and
1𝜇𝑀 tRNAHis (n=3) (B) Aminoacylation as a function of increasing temperature
(37℃, 40℃, 41℃ ) with saturating histidine and ATP (10 mM) and 5 𝜇𝑀 tRNAHis for 5
nM WT (black circles), Y454S (red triangles) and R362H (blue squares) (n=3).
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Figure 5.3. R362H multiple turnover aminoacylation kinetics.
Aminoacylation by R362H (10nM) with tRNAHis as the variable substrate (n=3)
The observations that patient fibroblasts display significantly reduced incorporation
of histidine into the total protein pool raises questions regarding in vitro conditions and the
link between the mutant protein activtity with the phenotype. This observation could
indicate that the enzyme activity within the context of the cell is reduced. An additional
control using a different amino acid, such as

14

C-Thr or

14

C-Leu, might help indicate if

under heat shock conditions the reduction in translation is global, rather than being specific
to histidine and HARS activity. Additionally, detection of reduced aminoacylated tRNAHis
from patient cell lysates could also indicate if reduced histidine incorporation is specifically
linked to reduced HARS aminoacylation activity. Interestingly, this type of global
reduction in translation activity has been described in a GARS Drosophila model of CMT,
utilizing click-chemistry to visualize protein translation [11]. Similar methods to visualize
global translation of USH3B patient cells during heat shock could be informative, and
validate our initial observations.
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One plausible mechanism for reduced protein translation by Y454S during heat
shock involves the structural instability revealed by DSF. While in vitro aminoacylation
reactions have demonstrated that the enzyme can aminoacylate tRNAHis even at elevated
temperature although these assays do not truly reflect translational events occurring in the
cellular environment. After aminoacylation of tRNAHis, elongation factor 1 alpha (eEf1a)
is responsible for the transportation of aminoacylated tRNA to the ribosome. Previously, it
was demonstrated that, as eEf1a is a GTPase, increasing GTP levels can directly increase
HARS activity. The addition of an antibody against eEF1a in these assays dampened the
affect [13]. If during heat shock Y454S is structurally altered such that it disrupts the handoff of aminoacylated tRNAHis to eEF1a, then a reduction in histidine incorporation might
be apparent. This point reiterates the need to address protein synthesis in the context of the
cell from patient cells in response to heat shock conditions.
A key question that emanates from these analyses is how the translational defects
we observe preferentially affect certain tissues. The peripheral nerves and the sciatic nerve
in particular, is the largest and has the longest axonal processes in the body. Localized
translation in remodeling the synaptic proteome and along axons has become increasingly
recognized as an important process for neuronal homeostasis [14]. How aaRS enzymes and
other essential components of the protein translational machinery in these distal regions of
neurons are regulated remain to be investigated. Given that the average neurite length of
CMT transfected PC12 cells was observed to be shorter, experiments utilizing Clickchemistry might be useful to address the issues of whether or not localized protein synthesis
is disrupted along the axon and/or at the synapse. The concept that reduction in translation
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can lead to tissue specific pathology is supported by a recent mouse model which revealed
that reduction of a brain specific tRNAArg molecule, increased ribosomal stalling, leading
to neurodegeneration of the cerebellum. This phenotype is exacerbated by the absence of
GTP binding protein 2 (Gtpbp2) protein that aids in resolving ribosomal stalling [15].
A systematic characterization for each CMT variant utilizing the biochemical
studies described in this thesis are instrumental in determining the extent to which
aminoacylation activity is affected. However, in light of the points discussed here new
methods should be used to connect the loss of aminoacylation function to the cellular
biology of disease.
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5.3 ER stress as the pathological mechanism
As noted above, a key observation is that under elevated temperatures,
incorporation of histidine into total proteins was reduced. Accordingly, we suspect that ER
stress may be activated. If histidine incorporation into the total protein pool is significantly
reduced, then ribosomal stalling would likely increase, and lead to an increase of misfolded
proteins. Misfolded proteins in the ER would then activate the unfolded protein response
(UPR). UPR is mediated by three resident ER proteins; PRKR-like ER kinase (PREK),
activating transcription factor 6α (AFT6a) and inositol-requiring protein 1α (IRE1a)
signaling branches. When unfolded proteins build up in the ER, chaperone Binding
immunoglobulin protein (Bip) dissociates from ATF6a. ATF6a then subsequently gets
processed in the Golgi to short ATF6 (sATF6). As a transcription factor, sATF6 targets ER
protein 57 (ERp57) and glucose-regulated protein (GRP) 94, proteins that serve as ER
chaperones and aid in protein folding [16]. Additionally, IRE-1a released via disruption of
Bip binding becomes phosphorylated activating its RNase activity to splice X-box binding
protein 1 (XBP1) mRNA. The spliced and translated short XBP1 (sXBP1) translocates to
the nucleus where it serves as a transcription factor and induces the expression of ER stress
chaperones and genes responsible for ER-associated protein degradation (ERAD). In the
final parallel UPR pathway, ER resident protein PERK also serves as a sensor to increased
ER stress via BIP binding. The UPR initiated by PERK dimerization and
autophosphorylation leads to phosphorylation of eukaryotic translation initiation factor 2α
(eIF2a) which directly inhibits protein translation. Furthermore, chronic induction of
apoptosis typically occurs through C/EBP homologous protein (CHOP) [16].
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A central question that emerges here is the degree to which ER stress is a direct
consequence of a loss of canonical aaRS function, or the destabilized of aaRS proteins
themselves. Preliminary qRt-PCR experiments with patient fibroblast cells, following heat
shock treatment, indicated that downstream targets of ER stress are upregulated compared
to normal fibroblasts (Figure 5.4). The DNAJB9 transcript levels are regulated by IRE1a
and is a Hsp40 family ERAD co-chaperon with protein folding chaperone Hsp70. While
HSPA5 is regulated by ATF6 and interacts with multiple ER-associated proteins required
to facilitate protein folding and degradation of misfolded proteins. Patient fibroblasts seem
to be exceptionally sensitive not only to the four-hour heat shock but also histidinol
mediated inhibition of HARS.

Figure 5.4. Monitoring ER stress of patient fibroblasts by qRT-PCR.
Data was kindly provided by Dr. Susan Robey Bond.
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As mentioned previously, if HARS activity is reduced in the USH3B patient cells
and a large pool of un-aminoacylated tRNA is present, the amino acid starvation response
would likely be activated. The amino acid starvation response is a cellular response that
converges on the unfolded response pathway through eIF2a. GCN2 kinase serves as a
sensor to amino acid starvation by detection of un-aminoacylated tRNA. High levels of unaminoacylated tRNA molecules cause the GCN2 kinase to dimerize and phosphorylate its
primary target eIF2a𝛼 which serves to down regulate translation.
In the case of the Y454S variant, another reason histidine incorporation might be
decreased in the patient cells is that levels of the enzyme itself are reduced. From DSF
experiments, Y454S is less thermally stable than WT but maintains its dimeric structure.
However, the cellular environment during heat shock may increase the structural instability
of Y454S, such as reduced chaperone binding. Therefore, Y454S maybe more sensitive or
unstable during physiologically relevant febrile temperatures of 101 º𝐹 to 104 º𝐹 or
38.3 º𝐶 to 40 º𝐶.
Previously, experiments involving treatment of HEK293 cells expressing either
HARS WT, with proteasome inhibitor (MG132), failed to show the appearance of high
molecular weight species during heat shock corresponding to increased ubiquitination.
(Figure 5.5). However, this experiment was done using a cell line not physiologically
relevant, with a plasmid that drives over expression, and only a 4-hour heat shock
treatment, for which increased proteasome processing may not be apparent. It may be
worthwhile to determine if during heat shock of USH3B patient cells, HARS levels are
reduced and trigger the observed elevated ER stress response.
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Figure 5.5. Heat shock of HEK293 cells in the presence of MG132.
Data were generously provided by Dr. Susan Robey-Bond. HEK 293 cells were exposed
to heat shock for 4 hours in the presence of MG132. Lysates were resolved by SDSPAGE and western-blotted for the presence of GFP and HARS.
ER stress continues to be identified as a critical mediator in many disease states
[17]. As the Y454S HARS variant is currently described as Usher syndrome, there are some
key clinical differences that are not typical of Usher syndrome patients. The two most
distinct presentations that make this variant as an Usher variant unique are the
hallucinations patients experience during illness and the severe pulmonary phenotype.
Other pulmonary diseases such as asthma [18] and cystic fibrosis [19, 20] can lead to
specifically increased ER stress of these tissues. These diseases represent examples of ER
stress activation in a tissue-specific nature and may explain the complexity of HARS
disease associated variants. Moreover, ER stress is elevated in demyelinating CMT [21]
and may present a common pathogenic mechanism that may be shared by the USH3B
variant and CMT variants.
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5.4 Perturbations of neuronal processes as a potential pathogenic mechanism
Previous studies examining the links between mutations in aaRS genes and CMT
have attempted to address the question of whether mutations lead to a change in the
neuronal cell localization [3]. As human peripheral nerve axons can extend more than a
meter in length, and transport of essential proteins to the cell periphery is likely to be
essential for maintaining axonal function [22]. Evidence of local protein translation along
axons and at synapses is ever increasing yet not well understood [14, 23]. It will be
important to investigate if the HARS mutations described here also lead to local reductions
in protein synthesis in vivo.
Previously, investigations into the cellular localization of GARS CMT variants
demonstrated that these variants do not localize to the synapse for local translation.
Contrary to these results, our PC12 cell data shows that unlike some GARS variants that
cannot localize the distal most regions of neurites – all of the HARS CMT variants
examined here exhibited localization in distal regions. Despite these contradictory results,
effects on local translation may not be ruled out. The absence of GARS protein would
reduce levels of translation in the same capacity as trafficking out non-functional HARS
protein. It will be interesting to evaluate with Click-chemistry and high resolution
microscopy if changes in synapse translation are reduced by the presence of non-functional
HARS proteins. In addition to our PC12 model we hope to validate the preliminary axonal
shortening, with transgenic zebrafish that highlight the peripheral nervous system GFP and
motor nervous system RFP.
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In addition to a loss-of-function mechanism, multiple gain-of-function hypotheses
have also been proposed, specifically for GARS mutations [24]. For example, a mouse
model involving the ability of mutant monomeric GARS that alters neuronal signaling via
binding to the VEGF receptor neuropilin-1 has been described [25]. As yet, this model has
not yet been tested in the context of human diseases-causing alleles in GARS or in the
genes of other ARSs linked to CMT disease. While the findings reported here do not
explicitly address the neuropilin-1 hypothesis, our characterization of HARS mutant
proteins indicates a loss of canonical catalytic function rather than weakened dimerization
(Figure 5.5). Previously it was argued that the propensity of mutant GARS to bind to
neuropilin-1 was linked to weakened dimer formation [26]. It is also striking that, despite
the linkage of over 80 loci to CMT disease, neither mutations in neuropilin-1 nor in its
ligands have been identified in patients with CMT disease.
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Table 5.1. Protein interaction partners identified from SILAC.

Experiments and data analyzed by Dr. Susan Robey-Bond.
The USH3B variant instability may be indicative that Y454S likely has localized
unfolded regions or has a somewhat structurally dissimilar anti-codon binding domain
compared to WT HARS. As described above, an altered structure may encourage the
association of new protein binding partners. Initial, stable isotope labeling with amino acids
in cell culture (SILAC) experiments coupled with mass spectrometry of Y454S and WT
transfected mouse otocyst cells (embryonic inner ear hair cells) highlight that under normal
growth conditions, some protein-interaction partners differentially bind to Y454S
compared with WT (Table 5.1). Interestingly, many of these proteins are involved in
vesicular transport. Furthermore, the Y454S variant also preferentially binds endosomal
trafficking protein Ras-related protein (Rab7) (SRB results). Curiously, mutations in Rab7
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proteins are also associated with CMT [27]. We had hoped from these proteomic
investigations, to identify Usher proteins, as potential binding partners, and the association
of HARS with vesicular trafficking proteins maybe significant. Previous studies in
zebrafish have indicated that if Usher proteins do not pre-assemble for trafficking to the
stereocilia in the ER, chronic activation of ER stress will lead to apoptosis and inner ear
hair cell death [28]. Yet again we come across another potential link between USH3B and
CMT HARS variants to ER stress.
5.5 Closing remarks
This thesis has presented data that further supports a loss-of-function molecular
pathology for CMT variants and provides key data, newly applied methods, and novel
reagents for studying the pathological mechanism of aaRS-associated human disease.
Additionally, the complex nature of the USH3B HARS variant results demonstrate that a
loss-of-function may not be apparent in vitro. However, a key feature shared by these
diseases associated variants is a reduction in activity. This thesis summarizes that ER stress
is also a plausible disease mechanism that may be shared by these two distinct disease
phenotypes and remains a focus for future investigations.
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